NZ730702B2 - N-(hetero)aryl-substituted heterocyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system - Google Patents

N-(hetero)aryl-substituted heterocyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system Download PDF

Info

Publication number
NZ730702B2
NZ730702B2 NZ730702A NZ73070215A NZ730702B2 NZ 730702 B2 NZ730702 B2 NZ 730702B2 NZ 730702 A NZ730702 A NZ 730702A NZ 73070215 A NZ73070215 A NZ 73070215A NZ 730702 B2 NZ730702 B2 NZ 730702B2
Authority
NZ
New Zealand
Prior art keywords
chan
mel
annotation
alkyl
fluorophenoxy
Prior art date
Application number
NZ730702A
Other versions
NZ730702A (en
Inventor
Susanna Cremonesi
Colin Leslie
Tim Luker
Fabrizio Micheli
Teresa Semeraro
Luca Tarsi
Original Assignee
Chronos Therapeutics Limited
Filing date
Publication date
Priority claimed from GBGB1416351.3A external-priority patent/GB201416351D0/en
Application filed by Chronos Therapeutics Limited filed Critical Chronos Therapeutics Limited
Publication of NZ730702A publication Critical patent/NZ730702A/en
Publication of NZ730702B2 publication Critical patent/NZ730702B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R9a, R9b, R9c, R9d, R9e, R9f, m, n, A, L and B are as defined herein.

Description

N-(HETERO)ARYL-SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM This invention relates to cyclic derivatives that are inhibitors of dopamine active transporter protein (DAT) and to pharmaceutical compositions containing, and the uses of, such derivatives.
Background to the Invention The yclic derivatives of the present invention are inhibitors of human dopamine active transporter protein (DAT) and have a number of therapeutic applications, particularly in the treatment of sexual dysfunction, affective disorders, anxiety, depression, chronic fatigue, Tourette syndrome, Angelman syndrome, attention deficit disorder (ADD), ion t hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorder, substance abuse (including smoking cessation), eating disorders, and impulse control disorders.
Dopamine (DA) is a neurotransmitter which has a fundamental role in cognitive, affective, motor, motivational and reward-related functions. Following evoked action potentials DA is released into the synaptic cleft and this DA signal is extinguished by ke of DA into pre-synaptic neurons by DAT and by amine diffusion and local metabolism via enzymatic ation. Dysfunction of the dopaminergic system is implicated in numerous CNS disorders and consequently DAT has been the focus of research into a number of these conditions and strong associations exist between abnormal DAT expression and/or on and disease. l marketed drugs have pharmacological activity at DAT, but none are selective and potent DAT inhibitors. Stimulants such as amphetamine and methylphenidate have le pharmacological activities including effects on synaptic levels of DA, noradrenaline (NE) and serotonin (5-HT). e their therapeutic potential in conditions such as ADHD, they also carry unwanted side effects such as abuse potential (1), cardiovascular effects (2), appetite suppression (3) and sleep disturbance (4).
Other non-selective DAT inhibitors are also used to treat CNS disorders. Bupropion which is ibed as an antidepressant and a smoking cessation aid has a icant DAT component to its pharmacological activity, although it carries an sed seizure risk. Similarly Modafinil which is prescribed as a treatment for narcolepsy, ive daytime sleepiness and shift work sleep disorder has been shown to inhibit DAT as part of its pharmacological mechanism of action. Multiple nds have been developed that target the other monoamine transporters either selectively as inhibitors of the serotonin transporter (SERT) opram, Fluoxetine) or noradrenaline transporter (NET) inhibitors 1004852697 [Annotation] Mel.Chan None set by an [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan ed set by Mel.Chan [Annotation] Mel.Chan None set by an [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan (Atomoxetine, Reboxetine) as well as dual serotonin/noradrenaline reuptake inhibitors (Venlafaxine).
Drugs that inhibit SERT and NET have been burdened with multiple e side s such as nausea (5), sexual dysfunction (6), increased suicide risk (7) for drugs that elevate 5-HT levels and elevated heart rate and blood pressure (8, 9) for drugs that increase noradrenaline levels. This makes a selective and potent DAT inhibitor, with a hemical profile distinct from that of stimulants, a highly desirable compound for the treatment of CNS disorders.
ADD and ADHD are neurodevelopmental atric, behavioural and cognitive disorders characterised by concentration deficits, inner restlessness/hyperactivity, and impulsivity. These are the most common behavioural disorders amongst children, with a prevalence of 5-10% of the general population. It is widely believed that the symptoms of these ers result from a dopaminergic and/or noradrenergic hypofunction. There is a wealth of information showing that the core ms of ADHD are influenced by changes in dopaminergic function (10) and hence a DAT inhibitor which would raise ic DA levels, should be cious. Current ents for ADD/ADHD include the stimulants amphetamine and methylphenidate. These compounds have pharmacological activity for DAT, amongst other activities, and it is believed that their efficacy is d from the elevation of ostriatal DA and NE.
These drugs are not selective DAT inhibitors however, and as such cause rapid, transient and marked release of DA from synaptic terminals which has been associated with their unwanted side effects, such as abuse potential. This hemical profile is distinct from that of a selective and potent DAT inhibitor which causes a slower se in dopamine which is sustained for a much longer duration. This different neurochemical profile has been ated with less reinforcing effects and subsequently lower abuse potential (11). In addition to the neurochemical evidence for a likely therapeutic benefit of DAT inhibitors in ADHD, several studies have shown associations between DAT polymorphisms and overexpression of DAT in ADHD (12 ). Preclinical models of ADHD symptoms have shown that like amphetamine and methylphenidate a selective DAT inhibitor will decrease impulsive behaviour in rodents (13) further supporting the potential for efficacy of DAT inhibitors. Collectively this evidence provides compelling data to believe that selective DAT inhibitors will be efficacious in ADD/ADHD and other disorders characterised by poor impulse control (such as Trichotillomania, pathological gambling, Kleptomania and disorders with comorbid impulse control such as Parkinson’s disease) or inattention.
Tourette’s syndrome is a sychiatric disorder characterised by motor and/or phonic tics. |t normally presents during childhood and is poorly treated with drugs. Studies have postulated that one aspect underlying Tourette’s is dopaminergic dysfunction whereby tonic/phasic dysfunction results in reducgnaptic DA levels and uently higher levels in axon terminals leading to increased us dependent release. Further s have shown that post-mortem tissue from Tourette’s [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] an Unmarked set by Mel.Chan [Annotation] an None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by an patients showed elevated levels of DAT in the frontal lobe (14) and that polymorphisms in DAT are associated with the occurrence of Tourette’s. This was further supported in a clinical study of drug nai've children which showed and increased specific/non-specific DAT binding ratio in those with Tourette’s (15). These findings suggest that a selective DAT tor may provide symptomatic relief for te’s patients.
Other neuropsychiatric disorders such as ive compulsive disorder (OCD), oppositional defiant disorder (ODD) and t disorder have also been associated with DAT. OCD ts have been shown to have an increased specific/non-specific DAT binding ratio (16) and this ratio was altered following treatment with SSRIs which are commonly used to treat OCD. Similarly abnormal dopamine function and/or dopamine turnover have been implicated in ODD, conduct disorder and other related behavioural disorders (17) and polymorphisms in DAT have been implicated as a risk factor for externalising behaviour in children. Studies showing that children with conduct disorder display ted reinforcement signalling and a response to reward have also suggested that modulation of synaptic dopamine levels could be a therapeutic option for these disorders presenting the opportunity to use a selective DAT tor to treat these behavioural disorders.
Sleep disorders such as narcolepsy, cataplexy, excessive daytime sleepiness and shift work sleep disorder can interfere with an individual’s normal mental and physical wellbeing. Several of these disorders are treated with drugs that have pharmacological activity at DAT. Modafinil is widely used to treat narcolepsy and its therapeutic potential has been related to occupancy of DAT). Other treatments for sleep disorders e amphetamine, methamphetamine and methylphenidate, all of which have pharmacological actions at DAT. nical studies have shown that the wake promoting effects of several of these compounds and a selective DAT inhibitor are abolished in DAT knockout mice. Together these data support the use of a selective DAT inhibitor in the treatment of sleep disorders.
Mood disorders such as major sive disorder, bipolar depression, seasonal affective disorder, melancholic depression, catatonic depression, postpartum depression and dysthymia represent a major medical and social burden on y and are amongst the most common of all CNS disorders.
Treatment for these disorders is currently uate with low levels of efficacy and poor der rates to currently available therapies. In addition many of the drugs that are the current standard of care carry unwanted side s. SPECT studies in patients suffering from major sive disorder have shown that there is an increased binding of DAT in depressed patients and that this was reversed follownuccessful antidepressant treatment (18,19). In addition to this marketed antidepressants such as Nomifensine have a significant DAT inhibitory component to their mechanism of action. Preclinical [Annotation] an None set by an [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] an MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan studies investigating the behavioural phenotype of DAT knockout mice in tests for antidepressant activity have shown that genetic removal of DAT on results in antidepressant-like behaviour. This evidence is supportive for a therapeutic benefit for DAT inhibitors in mood disorders.
A comorbid symptom of depression and an ed side effect of many commonly used antidepressants is sexual dysfunction (20). Bupropion a commonly ibed pressant with a significant DAT inhibitory component to its mechanism of action has been shown to result in fewer sexual dysfunction related side effects than other antidepressants (21). rmore Bupropion has been shown to reverse the sexual dysfunction caused by SSRIs. Preclinical studies have shown an effect of Bupropion on sexual behaviour in rats which is supported by clinical evidence that the drug is effective in treating women suffering from hypoactive sexual desire disorder. Amphetamine has also been shown to increase sexual behaviour in male and female rats and has also been shown to reverse sexual impairment in female rats. This evidence for drugs that have pharmacological activity at DAT is an indicator that a ive and potent DAT inhibitor would be a suitable therapy for antidepressant induced sexual dysfunction as well as for treating sexual dysfunction in non-depressed patients.
DAT polymorphisms have been implicated in anxiety disorders such as post traumatic stress disorder (PTSD) (22). The lective monoamine oxidase inhibitor Phenelzine which elevates dopamine levels in the brain amongst its actions has been shown to reduce the ms of PTSD. Bupropion which has a icant DAT inhibitory component to its mechanism of action is also prescribed for ts with anxiety disorders and has been shown to be efficacious in patients with panic disorder, further ting the potential of DAT tors in these conditions.
Movement disorders such as Parkinson’s disease (PD) and Restless Leg Syndrome (RLS) are common neurological disorders which have been treated with therapies that result in elevated brain dopamine.
PD is characterised by a loss of dopaminergic neurones in the nigrostriatal pathway and a subsequent loss of dopamine. Drugs such as L-DOPA which is converted to dopamine in the brain have been shown to alleviate the motor symptoms of both PD and RLS. Given that DAT inhibitors also increase dopamine levels it is able to assume that they would also provide therapeutic benefit in movement disorders which have been shown to have a dopaminergic component. Further support for this hypothesis is given by the fact that phenidate, a stimulant which has DAT inhibition amongst its pharmacological activities has shown to be clinically efficacious in PD patients, both in motor (23) and non-motor symptoms (24,25).
[Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by an [Annotation] Mel.Chan Unmarked set by an [Annotation] Mel.Chan None set by an [Annotation] Mel.Chan MigrationNone set by Mel.Chan ation] Mel.Chan Unmarked set by an Addiction and substance abuse are closely linked to dopamine and reward circuits in the brain.These substance dependencies include alcohol dependence, opioid dependence, ***e dependence, cannabis dependence, amphetamine dependence (or amphetamine-like), hallucinogen dependence, inhalant dependence, polysubstance dependence, phencyclidine (or phencyclidine-like) dependence, and nicotine dependence. Preclinical studies using the selective DAT inhibitor GBR12909 and other benztropines have shown that these compounds can block the rewarding effects of drugs of abuse, such as ***e. 09 has been shown to block the neurochemical effects of ***e (26, 27) as well as that of amphetamine. Furthermore compounds which have been demonstrated to be DAT inhibitors are effective in smoking cessation. This provides evidence that a high affinity, selective DAT inhibitor could block the rewarding effects of drugs of abuse and be an effective medication to treat addiction.
Dopamine is also known to have a role in eating ers such as Binge Eating Disorder (BED). Eating disorders such as BED are known to have multiple components including impulse l, reward circuits and cognition, all of which are under the influence of dopaminergic signalling. It has been shown that BED sufferers have abnormal brain dopamine ses, which tes motivation for food intake (28). In addition BED and obese patients show an abnormal frontostriatal dopamine signalling as compared to healthy controls (29). Preclinical models have shown that ation of the s accumbens, which receives major dopaminergic input, attenuates binge eating behaviour in rats and that this effect is blocked by dopaminergic antagonists. This indicates that increased synaptic dopamine is a potential therapeutic opportunity for eating disorders such as binge eating er. Preclinical data has shown that food intake is modulated by drugs which modulate synaptic dopamine levels and specifically by compounds with affinity at DAT (30 ). DAT has been specifically implicated in BED and other eating disorders due to polymorphisms in DAT being ated with eating disorders (31). This hypothesis is further supported by the efficacy of drugs with DAT inhibition as part of their mechanism of action in clinical trials of BED and other eating disorders (32 ). Together this is supportive for the therapeutic potential of a selective DAT inhibitor in eating disorders such as BED.
Dopamine has a well-documented role in cognition and particularly in cognitive deficits seen in patients suffering from diseases characterised by al dopaminergic signalling such as Parkinson’s disease and schizophrenia (33). This coupled with the fact that cortical dopamine D1 receptor on is linked to NMDA mediated glutamate signalling implies that cognitive ses would be expected to be enhanced by DAT inhibitors.
Chronic persistent fatigue is a symptom which is common to several diseases and can be persisting or relapsing (34). e states that are ated with fatigue include chronic fatigue syndrome, post- [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan ation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan viral fatigue syndrome, HIV, multiple sclerosis, amyotrophic l sclerosis (ALS), myasthenia gravis, sarcoidosis, cancer, chemotherapy treatment, celiac e, ble bowel syndrome, spondyloarthropathy, fibromyalgia, arthritis, infectious es, diabetes, eating disorders, Parkinson's disease, sleep disorders, stroke, mood disorders, drug and alcohol abuse. Clinical studies have shown that multiple drugs with DAT inhibition as part of their mechanism of action are effective in combating fatigue in chronically ill patients (35). Drugs such as modafinil, methylphenidate and bupropion which share DAT inhibition as a common pharmacological mechanism of action have been shown to be efficacious in fatigue associated with cancer, chemotherapy, dosis, ALS, depression, bipolar disorder, multiple sclerosis, Parkinson’s disease, HIV and chronic fatigue syndrome. This evidence is supportive of likely efficacy for a selective and potent DAT inhibitor in e associated with the diseases mentioned above.
The multiple potential applications for a selective and potent DAT inhibitor have ed in us chemical series being described in the literature. A particular issue has been pharmacological selectivity, with many previously described structural classes of DAT inhibitors suffering from significant off target pharmacology, which has limited their development. A particular issue is the affinity of DAT inhibitors described in the literature for ion channels. Vanoxerine has been shown to have significant activity at multiple ion channels resulting in a cardiovascular safety risk that has ed its development (36).
The nd showed potent functional activity at multiple sodium, calcium and potassium channels which would be an undesirable profile for a drug to treat CNS disorders. In addition to off target ion channel pharmacology DAT tors (particularly those of the opine class) have been shown to have pharmacological activity at multiple other receptors such as the serotonin receptor 5-HT2, the muscarinic receptor M1 and the histamine receptor H1 (37,38,39). These significant secondary pharmacological activities may introduce unwanted side effects to potentially therapeutically beneficial DAT tors. This makes the selectivity profile of DAT inhibitors of ular importance.
Therefore there remains a need to develop new DAT inhibitors, ally inhibitors that are selective over noradrenaline and serotonin, that will have utility to treat a wide range of disorders, in particular to treat sion, ADHD and eating disorders. red compounds will possess a good pharmacokinetic profile and in particular will be suitable as drugs for oral delivery. Particularly preferred compounds will additionally display ivity over noradrenaline and serotonin.
Summar of the Invention The prdt invention relates to a series of heterocyclic derivatives that are inhibitors of DAT. Many of these compounds demonstrate good selectivity for DAT and are ially useful in the treatment of [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by an [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan sexual dysfunction, affective disorders, anxiety, depression, te syndrome, an me, attention deficit disorder (ADD), ion deficit hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorder, substance abuse (including ***e abuse and smoking cessation), eating disorders, chronic fatigue and impulse control disorders. The invention further relates to pharmaceutical compositions of the inhibitors, to the use of the compositions as therapeutic , and to methods of treatment using these compositions.
In an aspect, the invention provides a compound ing to formula I, A is ed from phenyl and heteroaryl; B is selected from phenyl and heteroaryl; L is a linker selected from alkylene and O; R1 is selected from H, alkyl, alkoxy, S-alkyl, S(O)qalkyl, CORS, CONRSRG, COORS, CHZOH, OH, F and Cl; R2 is selected from NR7R8, CRllRlzNR7R8, 8, (CR11R12)2NR7R8 and (CR11R12)3NR7R8, wherein R1 is alkyl, alkoxy, CHZOH, CORS, CONR5R6 or COOR5 when R2 is NR7R8; R3 is selected from H, alkyl, alkoxy, NR7R8, CHZOH, OH, F and Cl; or R2 and R3 come together with the carbon atoms to which they are attached to form heterocyclyl or heteroaryl, wherein the heterocyclyl or heteroaryl ns at least one ring member selected from N and NRB; provided that when R2 and R3 come together with the carbon atoms to which they are attached to form heterocyclyl or heteroaryl, L is 0; provided that when R1 is H, either R2 and R3 come together with the carbon atoms to which they are attached to form heterocyclyl; or R3 is selected from alkyl, alkoxy, NR7R8, CHZOH, OH, F and Cl; R4, R5 and R6 are each independently selected from H and alkyl; [Annotation] Mel.Chan None set by Mel.Chan ation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan ed set by an R7 and R8 are independently ed from H, alkyl, cycloalkyl, cyclyl, and C(O)R10, wherein when R7 is C(O)R10, R8 is H or alkyl; or R7 and R8 may come together with the nitrogen atom to which they are attached to form heterocyclyl; R93, Rgb, Rgc, Rgd, R9e and R9f are independently selected from H and alkyl; R10 is selected from alkyl, aryl, heterocyclyl and heteroaryl; - - - - is absent or represents a bond, wherein when - - - - is a bond R1 and R4 are absent; m is 0, 1 or 2, wherein when m is 2, n is 0; n is 0, 1 or 2, wherein when n is 2, m is 0; qislor2; alkyl is a linear saturated hydrocarbon having up to 6 carbon atoms (C1-C6) or a branched saturated hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkyl may optionally be substituted with 1,2,3,4 or 5 substituents selected from S-alkyl, S(O)alkyl, S(O)2alkyl, cycloalkyl, heterocyclyl, alkoxy, OH, -CN, CF3, , CON R13R14, F, Cl, NR13COR14 and NR13R14; cycloalkyl is a monocyclic saturated hydrocarbon of between 3 and 7 carbon atoms ); lkyl may optionally be substituted with 1, 2, 3, 4 or 5 substituents ndently selected from S-alkyl, S(O)alkyl, S(O)2alkyl, alkyl, , OH, -CN, CF3, COOR13, CONR13R14, F, Cl, and NR13R14; phenyl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, OH, F, Cl, -CN, OCF3, CF3, NR13COR14 and NR13R14' alkylene is a bivalent C13 straight-chained alkyl radical or a bivalent C3_4 ed alkyl radical, wherein alkylene may optionally be tuted with 1 or 2 substituents selected from S-alkyl, S(O)alkyl, S(O)2alkyl, heterocyclyl, alkoxy, OH, -CN, CF3, COOR13, CONRBRM, F, Cl, NR13COR14 and NR13R14; heterocyclyl is a clic ring which is saturated or partially unsaturated, containing, where possible, 1 or 2 ring members independently selected from N, S, O and NR13 and 2 to 5 carbon atoms; heterocyclyl may optionally be substituted with 1,2 or 3 substituents independently selected from alkyl, cycloalkyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, oxo, OH, F, Cl, -CN, OCF3, CF3, NR13COR14 and NR13R14; heteroarfl is a 5 or 6 membered aromatic ring, containing, where possible, 1, 2 or 3 ring membersindep ntly selected from N, NR13, S and O; heteroaryl may be optionally substituted with 1, 2 or 3 [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan ionNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan ation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan substituents independently selected from alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, OH, F, Cl, -CN, OCF3, CF3, NR13C0R14and NRBRM; alkoxy is a linear O-linked arbon of between 1 and 6 carbon atoms (C1-C6) or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkoxy may ally be substituted with 1, 2, 3, 4 or 5 substituents independently selected from S-alkyl, S(O)alkyl, S(O)2alkyl, alkyl, OH, -CN, CF3, COOng, CONR13R14, F, Cl, NR13C0R14and NRBRM; R11, R12, R13 and R14 are independently ed from H and alkyl; and tautomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic es thereof), pharmaceutically acceptable salts and solvates thereof; wherein the compound of formula I is not: 1 NAN / Ag, \L MJ? Fi? CH3 CH3 Oi-EKLJ4 In an aspect, the invention comprises a nd of formula I, wherein when R2 and R3 come together with the carbon atoms to which they are attached to form heterocyclyl or heteroaryl, the sum of m and n is 2.
In an aspect, the invention comprises a compound of formula I, wherein: R1 is selected from alkyl, alkoxy, S-alkyl, S(O)qalkyl, CORS, CONRSRG, COORS, CHZOH, OH, F and Cl; R2 is ed from NR7R8, CONR7R8, CRllRlzNR7R8, (CR11R12)2NR7R8 and (CR11R12)3NR7R8; R3 is selected from H and alkyl; R4, R5 and R6are each ndently selected from H and alkyl; - - - - is absent.
In an aspect, the invention comprises a compound of formula I, wherein n is 1 and m is 0 or 1.
In an aspect, the ion comprises a compound of formula I, wherein R93, Rgb, Rgc, Rgd, Rge, Rgf, R11 and Rizare all H.
In an ant, the ion comprises a compound of formula I, according to formula IA, [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by an [Annotation] Mel.Chan Unmarked set by Mel.Chan A is selected from phenyl and heteroaryl; B is selected from phenyl and heteroaryl; L is a linker selected from alkylene and O; R1 is selected from CHZOH, OH, F and Cl; R7 and R8 are independently selected from H, alkyl, cycloalkyl, heterocyclyl, and C(O)R10, wherein when R7 is C(O)R10, R8 is H or alkyl; or R7 and R8 may come together with the en atom to which they are attached to form heterocyclyl; R10 is selected from alkyl, aryl, heterocyclyl and heteroaryl; m is 0 or 1; alkyl is a linear saturated hydrocarbon having up to 6 carbon atoms (C1-C6) or a branched saturated hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkyl may optionally be substituted with 1,2,3,4 or 5 substituents selected from cycloalkyl, heterocyclyl, l S(O)alkyl, S(O)2alkyl, alkoxy, OH, -CN, CF3, COOR13, CONR13R14, F, Cl, NR13COR14and 4; cycloalkyl is a monocyclic saturated hydrocarbon of between 3 and 7 carbon atoms ); cycloalkyl may optionally be substituted with 1, 2, 3, 4 or 5 substituents independently selected from S-alkyl, S(O)alkyl, lkyl, alkyl, alkoxy, OH, -CN, CF3, COOR13, CONR13R14, F, Cl, NR13COR14 and NR13R14; phenyl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, heterocyclyl, , S-alkyl, S(O)alkyl, S(O)2alkyl, OH, F, Cl, -CN, OCF3, CF3, NR13COR14and NR13R14' heterocyclyl is a monocyclic ring which is saturated or partially unsaturated, containing, where le, 1 or 2 ring members ndently selected from N, S, O and NH and 2 to 5 carbon atoms; heterocyclyl may optionally be substituted with 1, 2 or 3 substituents independently ed from alkyl, cycloalkyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, oxo, OH, F, Cl, -CN, OCF3, CF3, NR13COR14and NR13R14; heteroD is a 5 or 6 membered ic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, NR13, S and O; heteroaryl may be optionally substituted with 1, 2 or 3 [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan ation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan ation] Mel.Chan Unmarked set by Mel.Chan substituents independently selected from alkyl, cycloalkyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, OH, F, Cl, -CN, OCF3, CF3, NR13COR14 and NRBRM; alkoxy is a linear O-linked arbon of between 1 and 6 carbon atoms ) or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkoxy may optionally be substituted with 1, 2, 3, 4 or 5 substituents independently selected from S-alkyl, S(O)alkyl, S(O)2alkyl, alkyl, OH, -CN, CF3, COOR13, CONR13R14, F, Cl, NR13COR14and NRBRM; R13 and R14 are independently selected from H and alkyl; and tautomers, stereoisomers (including omers, diastereoisomers and racemic and scalemic mixtures thereof), pharmaceutically acceptable salts and solvates thereof.
In an aspect, the invention comprises a nd of formula I, wherein m is 1.
In an aspect, the invention comprises a compound of a I, wherein R1 is OH.
In an aspect, the invention comprises a nd of formula I, n L is O.
In an aspect, the invention comprises a compound of formula I, wherein A is phenyl, pyridyl or pyrimidinyl, optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, lkyl, OH, F, Cl, -CN, OCF3, CF3, NR13COR14and NR13R14.
In an aspect, the invention ses a nd of formula I, wherein A is phenyl, 2-pyridyl or 1,3- pyrimidinyl, optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, F, Cl, - CN and CF3.
In an aspect, the invention comprises a compound of formula I, wherein A is selected from the group consisting of: [Annotation] Mel.Chan None set by an [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan ionNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan F CF3 L-B A/N L-B CN F A/NI L-B N L-B L-B CH3 \0 \ \ NI NI N L-B L-B N L—B CN \S N \ N \ l l LB / / N L-B’ N L-B’ F [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan ionNone set by Mel.Chan ation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by an [Annotation] Mel.Chan Unmarked set by Mel.Chan (d F W N L-B N L-B F/?:\LB F L-B L-B F F F and ((1/N L-B In an aspect, the invention comprises a compound of a I, wherein B is phenyl, optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, OH, F, Cl, -CN, OCF3, CF3, NR13C0R14and NRBRM.
In an aspect, the invention comprises a compound of a I, wherein B is selected from the group consisting of: { F, F ’E CH3 , , ’g CN and .
In an aspect, the invention comprises a compound selected from Examples 1 to 39.
[Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan ionNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan ation] Mel.Chan Unmarked set by Mel.Chan In yet another aspect the present invention provides an N-oxide of a compound of formula I as herein defined, or a prodrug or pharmaceutically acceptable salt thereof.
It will be understood that certain compounds of the present invention may exist in solvated, for example hydrated, as well as unsolvated forms. It is to be understood that the present invention encompasses all such solvated forms.
Detailed ption In an aspect, the invention comprises a subset of the compounds of formula I, as defined by formula IB, "‘V‘" "‘33. """""" L """""""53- | B wherein: A is selected from phenyl and heteroaryl; B is selected from phenyl and heteroaryl; L is a linker selected from ne and 0; either R1 is CHZOH and R2 is NR7R8; or R1 is ed from OH, F and Cl, and R2 is CHZNR7R8; R7 and R8 are independently selected from H, alkyl, cycloalkyl, heterocyclyl and C(O)R10, wherein when R7 is 0, R8 is H; or R7 and R8 may come together with the nitrogen atom to which they are attached to form heterocyclyl; R10 is selected from alkyl, aryl, heterocyclyl and heteroaryl; m is 0 or 1; alkyl is a linear saturated arbon having up to 6 carbon atoms (C1-C6) or a ed saturated hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkyl may optionally be substituted with 1,2,3,4 or 5 tuents selected from cycloalkyl, heterocyclyl, S-alkyl, kyl, S(O)2alkyl, alkoxy, OH, -CN, CF3,CCD13,CONR13R14, F, Cl, NR13C0R14and NRBRM; [Annotation] Mel.Chan None set by an [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] an MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan cycloalkyl is a monocyclic ted hydrocarbon of between 3 and 7 carbon atoms (C3-C7); cycloalkyl may optionally be substituted with 1, 2, 3, 4 or 5 substituents independently selected from S-alkyl, S(O)alkyl, S(O)2alkyl, alkyl, alkoxy, OH, -CN, CF3, COOR13, CONR13R14, F, Cl, NR13COR14 and NR13R14; phenyl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, heterocyclyl, , S-alkyl, S(O)alkyl, S(O)2alkyl, OH, F, Cl, -CN, OCF3, CF3, NR13COR14and NRBRM_ heterocyclyl is a monocyclic ring which is saturated or lly rated, containing, where possible, 1 or 2 ring members independently ed from N, S, O and NH and 2 to 5 carbon atoms; heterocyclyl may optionally be tuted with 1,2 or 3 substituents independently ed from alkyl, cycloalkyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, oxo, OH, F, Cl, NR13COR14and NR13R14; , -CN, OCF3, CF3, heteroaryl is a 5 or 6 membered aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, NR13, S and O; heteroaryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, lkyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, OH, F, Cl, -CN, OCF3, CF3, NR13COR14 and NR13R14; alkoxy is a linear O-linked hydrocarbon of n 1 and 6 carbon atoms (C1-C6) or a branched O-linked arbon of between 3 and 6 carbon atoms (C3-C6); alkoxy may optionally be substituted with 1, 2, 3, 4 or 5 substituents independently selected from S-alkyl, S(O)alkyl, lkyl, alkyl, OH, -CN, CF3, COOR13, CONR13R14, F, Cl, NR13COR14and NR13R14; R13 and R14 are independently selected from H and alkyl; and tautomers, stereoisomers (including enantiomers, diastereoisomers and racemic and ic mixtures thereof), pharmaceutically acceptable salts and es thereof.
The present invention also comprises the following aspects and combinations thereof.
In an aspect A is selected from phenyl, pyrazinyl, pyridyl and pyrimidinyl, optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, alkoxy, S-alkyl, OH, F, Cl, -CN, OCF3, CF3 and NR13R14.
In an ?t A is selected from phenyl, pyridyl and pyrimidinyl, optionally substituted with 1, 2 or 3 su ents independently selected from alkyl, cycloalkyl, alkoxy, S-alkyl, F, -CN and CF3.
[Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan ionNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan In an aspect A is selected from phenyl, 2-pyridyl and 1,3-pyrimidinyl, ally substituted with 1, 2 or 3 substituents independently ed from alkyl, cycloalkyl, alkoxy, S-alkyl, F, -CN and CF3.
In an aspect A is phenyl or pyrimidinyl, optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, lkyl, alkoxy, S-alkyl, F, -CN and CF3.
In an aspect B is phenyl or pyridyl, optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, alkoxy, S-alkyl, OH, F, Cl, -CN, OCF3, CF3 and NR13R14.
In an aspect B is phenyl, optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, F, Cl, -CN, OCF3, and CF3.
In an aspect B is selected from unsubstituted phenyl or phenyl substituted with 1 or 2 groups selected from F, -CN and CH3.
In an aspect B is phenyl substituted with one F substituent. In an aspect B is meta-fluoro-phenyl.
In an aspect: R1 is ed from H, alkyl, alkoxy, CHZOH, OH, F and Cl; R2 is selected from NR7R8,CR11R12NR7R8, (CR11R12)2NR7R8 and (CR11R12)3NR7R8, and R3 is selected from H and alkyl; or R2 and R3 come er with the carbon atoms to which they are attached to form cyclyl or heteroaryl, wherein the heterocyclyl or heteroaryl contains at least one ring member selected from N and NR13; provided that when R2 and R3 come together with the carbon atoms to which they are attached to form heterocyclyl or heteroaryl, L is O and provided that when R1 is H, R2 and R3 come together with the atoms to which they are attached to form heterocyclyl.
In an aspect: R1 is selected from alkyl, , CHZOH, OH, F and Cl; R2 is ed from NR7R8,CR11R12NR7R8, (CR11R12)2NR7R8 and (CR11R12)3NR7R8; R3 is selected from H and alkyl; R4, R5 and R6are each ndently selected from H and alkyl; - - - - is absent.
In an aspect R1 is selected from H, alkyl, alkoxy, CHZOH, OH, F and Cl.
In an aspect R1 is selected from CHZOH, OH, F and Cl.
In an as ect R1 is selected from OH, F and Cl.
In an a?t R1 is OH or F.
In an aspect R1 is OH.
[Annotation] Mel.Chan None set by an [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan In an aspect R2 is selected from NR7R8, CRllRlzNR7R8, (CR11R12)2NR7R8 and 12)3NR7R8 wherein R1 is alkyl orCHZOH when R2 is NR7R8.
In an aspect R2 is NR7R8 or CHZNR7R8.
In an aspect R2 is CHZNR7R8. In an aspect R2 is CHZNHZ.
In an aspect L is methylene, ne or O.
In an aspect L is methylene or O.
In an aspect L is O.
In an aspect R are all H. In an aspect R13 is H. In an aspect R14 is H.
In an aspect m is 0 or 1 and n is 0 or 1.
In an aspect n is 1 and m is 0 or 1. In an aspect n is 1 and m is 1.
In an aspect R3 and R4 are independently selected from H and alkyl.
In an aspect R3 and R4 are H.
In an aspect R7 and R8 are independently selected from H, alkyl, cycloalkyl, cyclyl, and C(O)R1°, wherein when R7 is C(O)R1°, R8 is H; or R7 and R8 may come together with the nitrogen atom to which they are attached to form heterocyclyl.
In an aspect q is 2.
[Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan ionNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan ionNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] an Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan In an aspect, the invention comprises a subset of the nds of formula I selected from: N /A-L-B N \A-L-B and N In an aspect A-L-B is selected from: R15 R15 R15 R15 R15 R15 R15 R15 R15 L—B R15 L—B R15 R15 [Annotation] an None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] an Unmarked set by Mel.Chan wherein, each R15 is independently selected from H and R17, and 0, 1, 2 or 3 R15 are R"; each R16 is ndently selected from H and R17, and 0, 1, 2 or 3 R16are R17; and each R17 is independently selected from alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, OH, F, Cl, -CN, OCFg, CF31 NR13C0R14 and NRBRM.
In an aspect A is selected from: F NC L-B L-B L-B L-B : L-B L-B L-B 'g L-B L-B L-B F F , , [Annotation] an None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan ation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan ation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan ation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan In an aspect BIS selected from: MOQV«0 @«0:00» D99DFD [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by an [Annotation] Mel.Chan ed set by Mel.Chan Pg; F/ / F grep p???p\ In an aspect A-L-B is selected from: (m?o F(b) : Ni NC Aw Kl £0DN 0 F(d) O [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan ionNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] an Unmarked set by Mel.Chan (k) F [Annotation] Mel.Chan None set by an [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] an None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by an [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan ionNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan (dd) F (ee) F F F : (ff) g 0 F O F (gg) { NC N / / N O F 0 F (hh) (m CF3 CF3 N/ klQ O F N/ O (kk) (II) \ NI N 0 N O (mm) (nn) F [Annotation] Mel.Chan None set by Mel.Chan [Annotation] an MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] an MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by an [Annotation] an MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by an (ddd) (hhh) F (HD F Preferably A-L-B is selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (j), (k), (m), (n), (s), (XL(vllddlleel("L(nnL(pp)(SQ,(bbbllgggllhhhland(?n- More preferably A-L-B is selected from the group consisting of (a), (b), (c), (k), (n) and (dd).
In an aspect, the invention ses a compound of formula I selected from: 4-[(dimethylamino)methyl][4-(3-fluorophenoxy)—6-(trifluoromethyl)pyrimidinyl]piperidinol; 1-[4-(3-fluorophenoxy)—6-(trifluoromethyl)pyrimidinyl](pyrrolidin-l-ylmethyl)piperidinol; 4-[(cyclopropylamino)methyl][4-(3-fluorophenoxy)—6-(trifluoromethyl)pyrimidinyl]piperidinol; 4-{[cyclopropyl(methyl)amino]methyl}[4—(3-fluorophenoxy)(trifluoromethyl)pyrimidin yl]piperidinol; 1-[4-(3-fluorophenoxy)—6-(trifluoromethyl)pyrimidinyl][(methylamino)methyl]piperidinol; 4-[(3,3-difluoropyrrolidinyl)methyl][4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin yl]piperidinol; 4-(1,4-diazepanylmethyl)[4-(3-fluorophenoxy)—6-(trifluoromethyl)pyrimidinyl]piperidinol; 4-[(2,5nethylpyrrolidin-l-yl)methyl][4—(3-fluorophenoxy)(trifluoromethyl)pyrimidin yl]piperidinol; [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by an [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan 4-[(tert-butylamino)methyl][4-(3-fluorophenoxy)(trif|uoromethyl)pyrimidinyl]piperidinol; 1-({1-[4-(3-fluorophenoxy)(trif|uoromethyl)pyrimidin-Z-yl]hydroxypiperidiny|}methy|)pyrro|idin- 2-one; 4-(aminomethyl)[4-(3-fluorophenoxy)(trif|uoromethyl)pyrimidiny|]piperidinol; {4-fluoro[4-(3-fluorophenoxy)(trif|uoromethy|)pyrimidin-Z-yl]piperidiny|}methanamine; 4-(aminomethyl)[3-fluoro(3-fluorophenoxy)phenyl]piperidinol; 4-(aminomethyl)[2,5-dif|uoro(3-fluorophenoxy)phenyl]piperidinol; 4-(aminomethyl)(2-fluorophenoxyphenyl)piperidinol; 4-(aminomethyl)[2-fluoro(3-fluorophenoxy)phenyl]piperidinol; 4-(aminomethyl)[2,3-dif|uoro-S-(3-fluorophenoxy)phenyl]piperidinol; 4-(aminomethyl)[3,4-dif|uoro-S-(3-fluorophenoxy)phenyl]piperidinol; {4-amino[4-(3-fluorophenoxy)(trif|uoromethyl)pyrimidin-Z-y|]piperidiny|}methanol; [4-(3-fluorophenoxy)(trif|uoromethyl)pyrimidin-Z-yl]hydroxypiperidiny|}methy|) propanamide; 2-cyclopropyl-N-({1-[4-(3-fluorophenoxy)-6—(trif|uoromethyl)pyrimidin-Z-yl]hydroxypiperidin y|}methyl)acetamide; N-({1-[4-(3-fluorophenoxy)(trif|uoromethyl)pyrimidin-Z-yl]hydroxypiperidiny|}methy|) (propan-Z-yloxy)acetamide; N-({1-[4-(3-fluorophenoxy)(trif|uoromethyl)pyrimidin-Z-yl]hydroxypiperidin y|}methyl)acetamide; N-({1-[4-(3-fluorophenoxy)(trif|uoromethyl)pyrimidin-Z-yl]hydroxypiperidiny|}methyl)azetidine- oxamide; N-({1-[4-(3-fluorophenoxy)(trif|uoromethyl)pyrimidin-Z-yl]hydroxypiperidin y|}methy|)benzamide; N-({1-[4-(3-f|uorophenoxy)(trif|uoromethyl)pyrimidin-Z-yl]hydroxypiperidiny|}methy|)-1H- pyrazoIecarboxamide; N-({1-[4-(3-fluorophenoxy)(trif|uoromethyl)pyrimidin-Z-yl]hydroxypiperidiny|}methyl)pyrazine- 2-carboxamide; 2-amino-N-({1-[4-(3-fluorophenoxy)(trif|uoromethyl)pyrimidin-Z-yl]hydroxypiperidin y|}methyl)acetamide; 3-[(cyclopropylamino)methyl][4-(3-fluorophenoxy)(trif|uoromethyl)pyrimidin-Z-yl]pyrro|idinol; -[(cyclopropylamino)methy|][4-(3-f|uorophenoxy)(trif|uoromethy|)pyrimidin-Z-yl]pyrro|idin- 3-ol; (3R)-3Dclopropylamino)methy|]—1-[4-(3-f|uorophenoxy)(trif|uoromethyl)pyrimidin-Z-yl]pyrro|idin- 3-ol; [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan ation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan 3-(aminomethyl)[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]pyrrolidinol; N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypyrrolidinyl}methyl) methylpropanamide; [4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypyrrolidinyl}methyl)azetidine- 3-carboxamide; 4-(3-fluorophenoxy){3H,4H,5H,6H,7H-imidazo[4,5-c]pyridinyl}(trifluoromethyl)pyrimidine; 6-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]-decahydro-1,6-naphthyridine; and pharmaceutically acceptable salts and solvates thereof.
Preferably, the invention ses a compound of formula I selected from: 4-[(cyclopropylamino)methyl][4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin-Z-yl]piperidinol; 1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl][(methylamino)methyl]piperidinol; 4-(1,4-diazepanylmethyl)[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidinol; 4-[(tert-butylamino)methyl][4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidinol; 4-(aminomethyl)[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidinol; {4-fluoro[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidinyl}methanamine; 4-(aminomethyl)[3-fluoro(3-fluorophenoxy)phenyl]piperidinol; 4-(aminomethyl)[2,5-difluoro(3-fluorophenoxy)phenyl]piperidinol; nomethyl)(2-fluorophenoxyphenyl)piperidinol; 4-(aminomethyl)[2-fluoro(3-fluorophenoxy)phenyl]piperidinol; 4-(aminomethyl)[2,3-difluoro(3-fluorophenoxy)phenyl]piperidinol; 4-(aminomethyl)[3,4-difluoro(3-fluorophenoxy)phenyl]piperidinol; {4-amino[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidinyl}methanol; N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methyl) methylpropanamide; opropyl-N-({1-[4-(3-fluorophenoxy)-6—(trifluoromethyl)pyrimidinyl]hydroxypiperidin yl}methyl)acetamide; N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methyl) (propanyloxy)acetamide; N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidin hyl)acetamide; N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methyl)azetidine- 3-carboxamide; yl}metN-({1-[afluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidin [Annotation] Mel.Chan None set by Mel.Chan ation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by an ation] Mel.Chan None set by Mel.Chan ation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methyl)-1H- pyrazolecarboxamide; N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methyl)pyrazine- 2-carboxamide; 2-amino-N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidin yl}methyl)acetamide; 3-[(cyclopropylamino)methyl][4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]pyrrolidinol; (35)[(cyclopropylamino)methyl][4-(3-fluorophenoxy)(trifluoromethy|)pyrimidinyl]pyrrolidin- 3-ol; (3R)[(cyclopropylamino)methyl][4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]pyrrolidin- 3-ol; 3-(aminomethyl)[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]pyrrolidinol; N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypyrrolidinyl}methyl)azetidine- 3-carboxamide; 4-(3-fluorophenoxy){3H,4H,5H,6H,7H-imidazo[4,5-c]pyridinyl}(trifluoromethy|)pyrimidine; and ceutically acceptable salts and solvates thereof.
Therapeutic Applications As previously mentioned, the compounds of the present invention are potent inhibitors of dopamine transporters. They are ore useful in the treatment of disease ions for which over-activity of a dopamine transporter is a causative factor.
The compounds of the present invention are preferably selective for dopamine transporters over noradrenaline and serotonin transporters. In the present context, the word "selective" means the compound has an |C50 value that is at least d selective for the dopamine transporter than for each of the noradrenaline and serotonin transporters, preferably at least 20-fold, more preferably at least 30- fold, even more preferably 50-fold, most preferably 100-fold higher for the dopamine orter than for each of the noradrenaline and serotonin transporters.
Accordingly, the present invention provides a compound of formula I for use in therapy.
The present invention also provides for the use of a compound of a I in the manufacture of a medicament for the treatment or prevention of a condition, disease or disorder ameliorated by inhibitDJf a dopamine transporter.
[Annotation] Mel.Chan None set by Mel.Chan ation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan The present invention also provides a compound of formula I for use in the ent or prevention of a ion, disease or disorder ameliorated by inhibition of a dopamine transporter.
The present invention also provides a method of treatment of a condition, disease or disorder ameliorated by tion of a dopamine transporter comprising administration to a subject in need thereof a eutically effective amount of a compound of formula |.
In one aspect, the ion, disease or disorder ameliorated by inhibition of a dopamine transporter es sexual dysfunction, affective disorders, anxiety, depression, Tourette syndrome, Angelman syndrome, attention deficit disorder (ADD), attention t hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorder, substance abuse (including g cessation), eating disorders, chronic fatigue and e control disorders.
In a particular aspect, the condition, disease or disorder is selected from ADD, ADHD and binge eating disorder.
In the context of the present ion, references herein to "treatment" include references to curative, palliative and lactic treatment.
The term "therapeutically effective amount" as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or nal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated. ation Therapy When combination therapy is employed, the compounds of the present invention and said ation agents may exist in the same or different pharmaceutical compositions, and may be administered separately, sequentially or simultaneously.
The compounds of the invention may be administered as a combination with at least one other active pharmaceutical ingredient for the treatment of mood disorders, ers such as depression, refractory depression, bipolar depression, and tic depression. Such a pharmaceutical combination may be in the foer a unit dosage form or it may be in the form of a package comprising the at least two active components separately. In a further , the invention relates to such pharmaceutical combinations. ation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan In a further , the invention therefore relates to a pharmaceutical combination comprising a therapeutically effective amount of an compound of the invention and a second active nce, for aneous or sequential administration.
In an aspect the invention relates to a compound of the invention in combination with another therapeutic agent n the other therapeutic agent is selected from: a lic antidepressant (Amitriptyline, Clomipramine, Doxepin, |mipramine, Trimipramine Desipramine, Nortriptyline, Protriptyline), tetracyclic antidepressant (Amoxapine, Maprotiline, Mazindol, rin, Mirtazapine, Setiptiline) , selective nin reuptake inhibitor (Citalopram, Escitalopram, Paroxetine, Fluoxetine, Fluvoxamine, line) , serotonin antagonist and reuptake inhibitors (Etoperidone, done, Trazodone), selective norepinephrine reuptake inhibitor (Atomoxetine, Reboxetine, Viloxazine) , serotonin and norepinephrine reuptake inhibitor (Desvenlafaxine, Duloxetine, Milnacipran, Venlafaxine), monoamine oxidase inhibitor (Isocarboxazid, Phenelzine, Selegiline, Tranylcypromine, emide, Pirlindole), mood stabilisers (Lithium, ic Acid, Lamotrigine, Carbamazepine, Oxcarbazepine) and/or antipsychotics (Clozapine, Olanzapine, idone, Quetiapine, Ziprasidone, Amisulpride, ine, Paliperidone, ||operidone, Zotepine, Sertindole, Lurasidone, Aripiprazole, Haloperidol, idol, Chlorpromazine, Fluphenazine Perphenazine, Prochlorperazine, Thioridazine, Trifluoperazine, Mesoridazine, Periciazine, Promazine, promazine, Levomepromazine, Promethazine, Pimozide, Cyamemazine, Chlorprothixene, Clopenthixol, Flupenthixol, Thiothixene, Zuclopenthixol).
In addition to treating the primary disease symptoms or the therapeutic lag phase, DAT inhibitors may be used adjunctively to treat medication induced sedation, common in diseases such as bipolar depression as well as sexual dysfunction which is a common side effect of antidepressant treatment, particularly SSRIs.
The compounds of the invention may be administered as a combination with at least one other active pharmaceutical ingredient for the ent of smoking cessation and mitigation of nicotine withdrawal and weight gain. Such a pharmaceutical combination may be in the form of a unit dosage form or it may be in the form of a package comprising the at least two active components separately. In a further n ion relates to such pharmaceutical combinations. ation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan ionNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan ionNone set by Mel.Chan [Annotation] Mel.Chan ed set by Mel.Chan In a r aspect, the invention therefore relates to a pharmaceutical combination comprising a therapeutically effective amount of an compound of the invention and a second active substance, for simultaneous or sequential administration.
In an aspect, the invention relates to a compound of the ion in combination with r therapeutic agent wherein the other therapeutic agent is selected from: Nicotine replacement therapies (nicotine patches, nicotine gum, ne sprays, nicotine sublingual tablets, nicotine lozenges and nicotine inhalers), nicotinic full/partial agonists (Nicotine, Varenicline, Lobeline), opioid antagonists/inverse agonists (Naloxone, Naltrexone, Buprenorphine).
The compounds of the invention may be administered as a combination with at least one other active pharmaceutical ingredient for the treatment of ADHD. Such a ceutical combination may be in the form of a unit dosage form or it may be in the form of a package comprising the at least two active components separately. In a further aspect, the invention relates to such pharmaceutical combinations.
In a further aspect, the invention therefore relates to a ceutical combination comprising a therapeutically effective amount of an compound of the invention and a second active substance, for simultaneous or sequential administration.
In an aspect, the invention relates to a compound of the invention in combination with another therapeutic agent wherein the other therapeutic agent is selected from: Norepinephrine ke inhibitors (Atomoxetine, Reboxetine, Viloxazine), adrenoceptor ts (Guanfacine, Clonidine).
The compounds of the invention may be administered as a combination with at least one other active pharmaceutical ingredient for the treatment of movement disorders such as Parkinson’s disease and Restless Leg Syndrome. Such a pharmaceutical combination may be in the form of a unit dosage form or it may be in the form of a package comprising the at least two active components separately. In a further aspect, the invention relates to such pharmaceutical combinations.
In a further , the ion therefore relates to a pharmaceutical combination comprising a therapeutically effective amount of an compound of the invention and a second active substance, for simultnus or sequential administration.
[Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by an [Annotation] Mel.Chan Unmarked set by Mel.Chan In an aspect, the invention relates to a compound of the invention in combination with another therapeutic agent wherein the other therapeutic agent is selected from: A dopamine precursor (L-dopa) a dopaminergic agent opa-carbidopa, Levodopa-benzerazide), a dopaminergic and anti-cholinergic agent (amantadine), an anti-cholinergic agent (trihexyphenidyl, benztropine, ethoproprazine, or procyclidine), a dopamine t rphine, bromocriptine, oline, |isuride, pergo|ide, pramipexole, or ropinirole), a MAO-B (monoamine oxidase B) inhibitor (selegiline, rasage|ine or le, a COMT (catechol O-methyltransferase) inhibitor (tolcapone or entacapone.
Definitions "Alkyl" is as defined above and includes saturated hydrocarbon residues including: - linear groups of up to 6 carbon atoms (C1-C6), or of up to 4 carbon atoms (C1-C4). Examples of such alkyl groups include, but are not limited, to C1 - methyl, C2 - ethyl, C3 - propyl and C4- n-butyl. - branched groups of n 3 and 6 carbon atoms (C3-C6), or of up to 4 carbon atoms (C3-C4).
Examples of such alkyl groups include, but are not limited to, C3 - iso-propyl, C4 - sec-butyl, C4 - iso- butyl, C4 - tert-butyl and C5 - neo-pentyl. each optionally substituted as stated above.
"Cycloalkyl" is as d above and includes monocyclic saturated hydrocarbon of between 3 and 7 carbon atoms, or from 3 to 6 carbon atoms, or from 3 to 5 carbon atoms, or from 3 to 4 carbon atoms.
Examples of le monocyclic cycloalkyl groups include ropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Cycloalkyl is optionally substituted as stated above.
"Alkylene" is a bivalent C13 straight-chained alkyl radical, such as -(CH2)-, -(CH2)2-, 3- or a bivalent C34 branched alkyl l such as -CH(CH3)CH, CHZCH(CH3)-, -CH(CH3)CH(CH3)-. Alkylene is optionally substituted as stated above.
"Alkoxy" is as defined above and includes O-linked hydrocarbon residues including: - linear groups of between 1 and 6 carbon atoms (C1-C6), or of between 1 and 4 carbon atoms (C1-C4).
Examples of such alkoxy groups include, but are not limited to, C1 - methoxy, C2 - ethoxy, C3 - n- propoxy and C4 - n-butoxy. - branched groups of between 3 and 6 carbon atoms (C3-C6) or of n 3 and 4 carbon atoms (C3- C4). Examples of such alkoxy groups include, but are not limited to, C3 - opoxy, and C4 - sec- buu and tert-butoxy. each optionally substituted as stated above.
[Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan "Heteroaryl" is as defined above. Examples of suitable heteroaryl groups include thienyl, furanyl, pyrrolyl, lyl, imidazoyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl (optionally substituted as stated above).
Preferably heteroaryl is selected from pyridyl, pyrazinyl, pyrimidinyl and 1,2,4-triazinyl optionally substituted as stated above. Unless otherwise stated pyrimidinyl refers to 1,3-pyrimidinyl. Unless otherwise stated (e.g. by a chemical a) when A is pyrimidinyl it is attached to the heterocyclic backbone at the 2-position. Unless other stated when B is pyrimidinyl it is attached to L at the 2- position.
"Heterocyclyl" is defined above. Examples of suitable heterocyclyl groups include aziridinyl, azetidinyl, pyrrolidinyl, olidinyl, olyl, morpholine, rpholine pyrazolidinyl, piperidinyl and piperazinyl (optionally substituted as stated above).
The term "O-linked", such as in "O-linked hydrocarbon residue", means that the hydrocarbon residue is joined to the remainder of the molecule via an oxygen atom.
In groups such as —CN and -CH2CH(CH3)-, "-" denotes the point of attachment of the substituent group to the remainder of the molecule.
"Pharmaceutically acceptable salt" means a logically or toxicologically tolerable salt and includes, when appropriate, ceutically acceptable base addition salts and pharmaceutically acceptable acid addition salts. For example (i) where a compound of the invention contains one or more acidic groups, for example carboxy groups, pharmaceutically acceptable base addition salts that can be formed e , ium, calcium, magnesium and ammonium salts, or salts with organic amines, such as, diethylamine, N-methyl-glucamine, diethanolamine or amino acids (e.g. lysine) and the like; (ii) where a compound of the invention contains a basic group, such as an amino group, pharmaceutically acceptable acid addition salts that can be formed include hydrochlorides, romides, es, phosphates, acetates, citrates, lactates, tartrates, mesylates, succinates, oxalates, phosphates, esylates, tes, benzenesulfonates, naphthalenedisulphonates, maleates, adipates, fumarates, hippurates, rates, xinafoates, p-acetamidobenzoates, dihydroxybenzoates, hydroxynaphthoates, ates, ascorbates, oleates, ates and the like.
Hemisalts of acids and bases can also be formed, for example, lfate and hemicalcium salts.
[Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] an None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan For a review of suitable salts, see "Handbook of Pharmaceutical Salts: Properties, Selection and Use" by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002). ug" refers to a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis, reduction or ion) to a compound of the ion. le groups for forming pro-drugs are described in ’The Practice of Medicinal Chemistry, 2nd Ed. 585 (2003) and in F. J. Leinweber, Drug Metab. Res., 1987, 18, 379. .
The compounds of the ion can exist in both unsolvated and solvated forms. The term 'solvate' is used herein to describe a molecular complex comprising the compound of the invention and a iometric amount of one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term 'hydrate' is employed when the solvent is water.
Compounds of the invention may exist in one or more geometrical, l, omeric, diastereomeric, conformational and tautomeric forms, including but not limited to cis- and trans-forms, E— and Z—forms, R-, $— and meso-forms, keto- and enol-forms, and conformers. Unless otherwise stated a reference to a particular compound includes all such isomeric forms, including racemic and other mixtures thereof. Where appropriate such isomers can be separated from their mixtures by the application or adaptation of known s (e.g. chromatographic techniques and recrystallisation techniques). Where appropriate such isomers can be prepared by the application or adaptation of known methods (e.g. asymmetric synthesis).
An example of a compound of the invention that exhibits optical isomerism is 3- [(cyclopropylamino)methyl][4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]pyrrolidinol.
The present invention therefore encompasses the enantiomeric forms of this compound, as illustrated below.
HO A A N HO/I//,, N H H N N N O F N O F N \ N \ CF3 CF3 [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by an [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan Preferably, wherein the compound is present as an enantiomer, the enantiomer is present at an enantiomeric excess of greater than or equal to about 80%, more preferably, at an enantiomeric excess of greater than or equal to about 90%, more preferably still, at an enantiomeric excess of greater than or equal to about 95%, more preferably still, at an enantiomeric excess of greater than or equal to about 98%, most preferably, at an omeric excess of greater than or equal to about 99%. Similarly, wherein the compound is present as a diastereomer, the diastereomer is t at an diastereomeric excess of greater than or equal to about 80%, more preferably, at an diastereomeric excess of greater than or equal to about 90%, more preferably still, at an diastereomeric excess of greater than or equal to about 95%, more preferably still, at an diastereomeric excess of greater than or equal to about 98%, most preferably, at an diastereomeric excess of greater than or equal to about 99%.
General Methods The compounds of formula I should be assessed for their biopharmaceutical ties, such as solubility and on stability (across pH), permeability, etc., in order to select the most appropriate dosage form and route of administration for treatment of the proposed tion. They may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs (or as any combination f). Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable excipients.
The term ’excipient’ is used herein to describe any ingredient other than the nd(s) of the invention which may impart either a onal (i.e., drug release rate controlling) and/or a non- functional (i.e., processing aid or diluent) characteristic to the ations. The choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
Compounds of the invention intended for pharmaceutical use may be administered as a solid or liquid, such as a tablet, e or solution. Pharmaceutical compositions le for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in Remington’s ceutical Sciences, 19th Edition (Mack Publishing y, 1995).
Accordingly, the present invention es a pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable r, diluent or excipient.
The co?unds of the invention may also be administered directly into the blood stream, into subcutaneous tissue, into muscle, or into an internal organ. Suitable means for parenteral [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] an MigrationNone set by Mel.Chan [Annotation] an Unmarked set by Mel.Chan stration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, ternal, intracranial, intramuscular, intrasynovial and subcutaneous. Suitable devices for parenteral administration e needle (including microneedle) injectors, needle-free injectors and infusion techniques.
Parenteral formulations are typically aqueous or oily solutions. Where the solution is aqueous, excipients such as sugars (including but not restricted to glucose, manitol, sorbitol, etc.), salts, carbohydrates and buffering agents rably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as e, pyrogen-free water. eral formulations may include ts derived from degradable polymers such as polyesters (i.e., polylactic acid, ctide, polylactide-co-glycolide, polycapro-lactone, polyhydroxybutyrate), polyorthoesters and polyanhydrides. These formulations may be administered via surgical incision into the subcutaneous tissue, muscular tissue or directly into specific organs.
The preparation of parenteral formulations under sterile conditions, for e, by lisation, may readily be accomplished using standard pharmaceutical techniques well known to those d in the The solubility of compounds of formula I used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of co-solvents and/or solubility-enhancing agents such as surfactants, micelle structures and cyclodextrins.
In one aspect, the compounds of the invention may be administered orally. Oral stration may involve wing, so that the compound enters the gastrointestinal tract, and/or buccal, lingual, or gual administration by which the compound enters the blood stream directly from the mouth.
Formulations suitable for oral administration include solid plugs, solid microparticulates, semi-solid and liquid (including multiple phases or dispersed systems) such as tablets; soft or hard capsules containing multi- or nano-particulates, liquids, emulsions or powders; lozenges (including liquid-filled); chews; gels; fast dispersing dosage forms; films; ovules; sprays; and /mucoadhesive patches.
Formuuns suitable for oral administration may also be designed to deliver the compounds of the invention in an immediate release manner or in a rate-sustaining manner, wherein the release profile [Annotation] an None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by an ation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan can be delayed, pulsed, controlled, sustained, or delayed and sustained or modified in such a manner which optimises the therapeutic efficacy of the said compounds. Means to deliver compounds in a rate- sustaining manner are known in the art and include slow release polymers that can be formulated with the said compounds to l their release.
Examples of rate-sustaining polymers include degradable and non-degradable polymers that can be used to release the said compounds by diffusion or a combination of diffusion and r erosion.
Examples of rate-sustaining polymers include hydroxypropyl methylcellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, sodium ymethyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone, xanthum gum, polymethacrylates, polyethylene oxide and polyethylene glycol.
Liquid (including multiple phases and dispersed s) formulations include emulsions, solutions, syrups and elixirs. Such formulations may be presented as fillers in soft or hard capsules (made, for example, from gelatin or ypropylmethylcellulose) and typically comprise a carrier, for example, water, ethanol, hylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the titution of a solid, for example, from a sachet.
The compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Liang and Chen, Expert Opinion in Therapeutic Patents, 2001, 11 (6), 981-986.
The formulation of tablets is discussed in Pharmaceutical Dosage Forms: Tablets, Vol. 1, by H. Lieberman and L. Lachman (Marcel Dekker, New York, 1980).
For stration to human patients, the total daily dose of the compounds of the invention is lly in the range 0.01 mg and 1000 mg, or between 0.1 mg and 250 mg, or between 1 mg and 50 mg depending, of course, on the mode of stration.
The total dose may be stered in single or divided doses and may, at the physician's discretion, fall outside of the typical range given herein. These dosages are based on an average human subject having a weight of about 60kg to 70kg. The physician will readily be able to determine doses for subjects whose weight falls outside this range, such as infants and the elderly.
Synthn/lethods [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan ation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by an [Annotation] Mel.Chan Unmarked set by Mel.Chan The compounds of the present invention can be ed according to the procedures of the following schemes and examples, using appropriate materials, and are further exemplified by the specific examples ed herein below. Moreover, by utilising the procedures described herein, one of ordinary skill in the art can readily prepare additional compounds that fall within the scope of the present invention claimed herein. The compounds illustrated in the examples are not, however, to be construed as forming the only genus that is considered as the invention. The examples further illustrate details for the preparation of the compounds of the present ion. Those skilled in the art will y tand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds.
The compounds of the invention may be isolated in the form of their ceutically acceptable salts, such as those described previously herein above.
It may be necessary to protect reactive functional groups (e.g. hydroxy, amino, thio or carboxy) in intermediates used in the preparation of compounds of the invention to avoid their unwanted participation in a reaction leading to the formation of the compounds. tional protecting groups, for example those described by T. W. Greene and P. G. M. Wuts in "Protective groups in organic chemistry" John Wiley and Sons, 4th n, 2006, may be used. For example, a common amino protecting group suitable for use herein is tert-butoxy carbonyl (Boc), which is readily removed by treatment with an acid such as trifluoroacetic acid or hydrogen chloride in an organic solvent such as dichloromethane. Alternatively the amino protecting group may be a benzyloxycarbonyl (2) group which can be removed by enation with a palladium st under a hydrogen atmosphere or 9- fluorenylmethyloxycarbonyl (Fmoc) group which can be removed by ons of secondary organic amines such as diethylamine or piperidine in an organic t. Carboxyl groups are lly protected as esters such as , ethyl, benzyl or tert-butyl which can all be removed by hydrolysis in the presence of bases such as lithium or sodium hydroxide. Benzyl protecting groups can also be removed by hydrogenation with a palladium catalyst under a hydrogen atmosphere whilst tert-butyl groups can also be removed by trifluoroacetic acid. Alternatively a trichloroethyl ester protecting group is removed with zinc in acetic acid. A common hydroxy protecting group suitable for use herein is a methyl ether, deprotection conditions comprise refluxing in 48% s HBr for 1-24 hours, or by stirring with borane tribromide in dichloromethane for 1-24 hours. Alternatively where a hydroxy group is protected as a benzyl ether, deprotection conditions comprise hydrogenation with a palladium catalyst under a hydroien atmosphere.
[Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] an None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] an Unmarked set by Mel.Chan The compounds according to general a I can be prepared using conventional synthetic methods for example, but not limited to, the routes outlined in the schemes below. i S nthesis of heteroc clics stems SchemeA N’R2 OH OH R2 R2 ( Step" N" n=o,1 F'a ( Step12 ( l.‘ n=o,1 "=01 R1 N R1 _> mm N X—aryl N H alryl HNR1R2' (XIII) Step10 O O 6%) Step1 ) n=0,1 . n=0,1 N N (DKQ (IDKQ H2NR1J Step2 OH OH ,BOC OH OH IN" OH I I _ I n—o,1 We IE" H R1 Step3 n—0,1_ R1 ( I Step4 ( n=o,1 n=0,1 é Step5 R1 Step6 n=o,1 R1 N X aryl | | H aryl aryl (III) (IV) (V) (VI) (VII) Step 81 step 71 RZCOOH F F OH NH , JL ( I Step9 ( l\|l ( N R2 "01= R1 <— n=0y1 R1 n=o,1 R1 I I I aryl aryl aryl (X) (IX) (VIII) Step 1 Compound of a Il may be obtained by Corey-Chaykovsky epoxidation of compound I (commercially available from Sigma-Aldrich) using trimethylsulfoxonium iodide and a inorganic base, e. g. NaH, carrying out the reaction in a le solvent, such as DMSO, at room temperature. The reaction takes about 1 to about 2 hours to te.
Step 2 Compound of a "I may be obtained by epoxide opening of compound II using primary amines , such as methylamine, carrying out the reaction in a mixture of MeOH/water, at room temperature. The reactiIDkes from about 1 to about 16 hours to complete.
Step 3 [Annotation] Mel.Chan None set by Mel.Chan [Annotation] an MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] an Unmarked set by Mel.Chan Compound of a IV may be obtained by N-protection of compound III under standard literature conditions such as by reaction with Di-tert—butyl dicarbonate, with or without the presence of a suitable base such as triethy|amine, carrying out the reaction in a suitable solvent, e.g. DCM, lly at room temperature. The reaction takes about 1 to about 16 hours to complete.
Step 4 Compound of formula V may be ed from compound IV by removing the benzyl group by hydrogenolysis, e. g. using ammonium formate and palladium on carbon, in a suitable solvent such as methanol under reflux. The reaction takes about 1 hour.
Step 5 Compound VI can be obtained from compound V by SnAr substitution with the appropriate aryl halide in a suitable aprotic solvent, e. g. DMSO, in presence of an inorganic base, such as K2C03. The reaction ds in a temperature range of about 25 to about 100 °C and takes about 1 to about 12 hours. atively the compound VI can be obtained from Buchwald reaction with the appropriate aryl halide in the presence of suitable transition metal catalyst, e. g. Pd2(dba)3, a suitable ligand such as DavePhos, a suitable base, such as K3P04 and like, in a suitable solvent, e. g. DM E. The reaction is carrying out at a temperature from about 100 °C to about 110 °C and takes about 12 hours.
Step 6 Compound VII can be obtained from compound VI by removing the Boc group under acidic ions, e. g. TFA in dichloromethane solution at room temperature. The on takes about 1 hour. , typically Step 7 Compound VIII can be obtained from compound VII by coupling with the appropriate ylic acid (such as isobutyric acid) in the presence of coupling agents such EDC HCI and HOBt and an organic base, e. g. TEA. The reaction is carrying out in a suitable solvent such as dichloromethane, typically at room temperature. The reaction takes from about 3 hours to about 12 hours.
Step 8 Compound IX can be obtained treating compound VI with a nated agent, such as Deoxofluor®, in a suitable solvent, such as dichloromethane, typically at 0 °C. The reaction takes about 1 hour.
Step 9 nd IX can be obtained from compound X by removing the Boc group under acidic conditions, e. g. TFA in dichloromethane solution, typically at room temperature. The reaction takes about 1 hour.
Step 10 Compound of formula XI may be obtained by epoxide opening of compound II using secondary amines, such idine, ng out the reaction in a mixture of MeOH/water, at room temperature. The reacti kes from about 2 to about 16 hours to complete.
[Annotation] an None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan Step 11 Compound of formula XII may be obtained from compound X by removing the benzyl group by enolysis, e. g. using ammonium formate and palladium on carbon, in a suitable solvent such as methanol under reflux. The reaction takes about 1 hour.
Step 12 nd XIII can be obtained from compound XII by SnAr substitution with the appropriate aryl halide in a le aprotic solvent, e. g. DMSO, in presence of an inorganic base, such as K2C03. The reaction proceeds in a temperature range of about 45 °C to about 100 °C and takes about 1 to about 12 hours.
Scheme B H2N$OH Step B , OH 00 ?OH 1 c’ oc?OH Step5 Step 3 I}I HZE€OH Step2 0C X-aryl H26€OH Bn B"IB aryl aryl (I) (II) (III) (IV) (v) (VI) Step 1 Compound of formula II may be obtained by reduction of compound I (commercially available from Activate Scientific) using a suitable reducing agent, e. g. LiAlH4, ng out the on in a suitable solvent, such as THF under reflux. The reaction takes about 2 hours to complete.
Step 2 Compound of formula III may be obtained by N-protection of compound II under standard literature conditions such as by reaction with Di-tert—butyl dicarbonate, with the presence of a suitable base such as triethylamine, carrying out the reaction in a suitable solvent, e.g. DCM, typically at room temperature. The reaction takes about 2 hours to complete.
Step 3 Compound of formula IV may be obtained from compound III by ng the benzyl group by hydrogenolysis, e. g. using ammonium formate and palladium on carbon, in a le solvent such as methanol under reflux. The reaction takes about 1 hour.
Step 4 Compound V can be obtained from compound IV by SnAr tution with the riate aryl halide in a suitable aprotic solvent, e. g. DMSO, in presence of an inorganic base, such as K2C03. The reaction proceeds in a temperature of about 60 °C and takes about 1 hour.
Step 5 Comptgl VI can be ed from compound V by ng the Boc group under acidic conditions, e. g. TFA in dichloromethane solution, typically at room temperature. The reaction takes about 1 hour.
[Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan ii S nthesis of A-L-B s stems Scheme 1 Step 1 3.0 O a," (I) (II) Step 1 Compound of formula II can be obtained by reduction of compound I, (3- bromophenyl)(phenyl)methanone, rcially available from Sigma-Aldrich) with a suitable reducing , such as NaBH4 in presence of TFA, carrying out the reaction in a suitable solvent, e. g. romethane, typically at room temperature. The reaction takes about 12 hours to complete.
Scheme2 StepZ Hal—?x HO|\ + —R1 Hl'\OI\R3T _ ’ 1 (III) (IV) (V) Step2 Compound V can be obtained by Ullmann condensation between compounds "I, the d di-halogen benzene, such as bromo-4,5-difluorobenzene, and compound IV, the appropriate phenol, such as 3-fluorophenol, (both commercially available from Alfa-Aesar and Sigma-Aldrich respectively) in presence of a suitable catalyst, such as Cu, and a suitable base, e. g. KOH, typically at high temperature, from about 100 to about 150 °C. The reaction takes about 14 hours to te. Alternatively compound V may be obtained by SnAr reaction n compounds I" and IV in presence of an inorganic base, such as K2C03, a suitable solvent, e. g. DMSO, at a temperature between 25 °C and about 160 °C, the reaction takes from about 20 to around 12 hours to complete.
[Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan Scheme3 HO Step3 o / B\OH \ \ \ Hal— | —> + | —R1 HaIT | —R1 \,\ / \X / R R (VI) (VII) (VIII) 1Step5 9H + BF4' \ B‘OH I \ Step4 I HO \ \ R1—: + I 7% —R1 R—!1 I _R1 + l —Hal / / / / / (IX) (X) (XI) (XII) Step3 Compound of formula VIII may be obtained via Chan-Lam coupling between compound VI, the desired boronic acid, such as phenyl boronic acid, and compound VII, the appropriate phenol, e. g. 3-bromo phenol (both commercially available from Sigma-Aldrich and Zentek respectively), in presence of a suitable catalyst, such as Cu(OAc)2, a suitable base, e. g. ylamine, typically at room temperature.
The reaction takes about 16 hours to complete.
Step 4 Compound XI can be ed by reaction between nd IX, the desired boronic acid, e. g. phenyl boronic acid, and compound X, the appropriate benzene iodide, such as iodobenzene, (both commercially available from Aldrich), in presence of a le t, such as m-CPBA, and BFgEtzO, carrying out the reaction in a suitable solvent, such as romethane. The reaction proceeds at a temperature between 0 °C and room temperature and takes about 45 minutes to complete.
Step 5 Compound VIII may be obtained from nd XI by on with compound XII, a suitable phenol such as 3-fluorophenol, in presence of a suitable base, such as tBuOK, in a suitable solvent, usually THF, at a temperature between 0 °C and 40 °C. The reaction takes about 1 hour.
Scheme4 CF3 CF3 Step6 l"? —* f o N 0 CI N/ CI (XIII) (XIV) [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan ed set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan Step 6 Compound XIV can be obtained by chlorination of the commercially available (from Sigma-Aldrich) compound XIII, 6-(Trifluoromethyl)uracil, by treatment with a suitable chlorinating agent, such as SOCIZ in a le solvent, e. g. DMF, carrying out the reaction usually at 80 °C for about 4 hours.
Scheme5 S/ 3/ b Step? / Ii CI N CIAN/ CI (XV) (XVI) Step7 nd of formula XVI can be obtained by chlorination of compound XV, 2-chloro (methylthio)pyrimidine (commercially available from Sigma-Aldrich), with N- chlorosuccinimide in presence of 6-Tetramethylpiperidinylmagnesium chloride m chloride complex solution in luene, in a suitable solvent, such as THF, typically at room temperature. The reaction takes 4 hours to complete.
Scheme6 R R R Ste 8 R1 p R1 N \ N \ R1 A / —> A / and/or l R2 //J\ R CI N CI CI N o’ o’ 2 CI N (XVIII) (XIX) (XVII) Step8 Compounds of structure XVIII and XIX can be obtained via SnAr reaction n compound XVII, e. g. 2,4-dichloromethylpyrimidine (commercially available from Sigma-Aldrich), or ad hoc prepared, and a suitable partner such as 3-fluorophenol (commercially available from Sigma-Aldrich), the reaction typically proceeds in aprotic solvent, such as DMSO, in presence of a le base, such as K2C03, at a ature between 25 °C and 110 °C. The reaction takes from about 20 min to about 12 hours to complete.
Scheme 7 R R R \ R1 Step9 \ R1 / R1 \ —> | :—R2 and/or | / / \ CI CI CI N o CI N/ oGR2 (XXI) (XXII) [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by an [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan Step 9 Compounds of structure XXI and XXII can be obtained via SnAr reaction between compound XX, e. g. 2,6- dichloropyridine (commercially available from Sigma-Aldrich), and a suitable phenol, such as 3- fluorophenol (commercially available from Sigma-Aldrich). The reaction lly proceeds in aprotic solvent, such as DMSO, in presence of a suitable base, such as K2C03, at a temperature between 25 °C and 103 °C. The reaction takes from about 2 hours to about 48 hours to te.
Scheme8 Step 10 11 C1113 Step 10 Compound of structure XXIV can be obtained via SnAr reaction between compound XXIII, cially available from Sigma-Aldrich, and a suitable , such as 3-fluorophenol (commercially available from Sigma-Aldrich), the reaction typically proceeds in aprotic solvent, such as DMF, in presence of a suitable base, such as tBuOK, at a temperature of about 90 °C. The reaction takes about 2 hours to complete.
Scheme 9 Cl 0 _p.Ste 11 L.Ste 12 N \ + CIMg NI \ )L CIAN/ /l\ / / CI N CI N CI (XXV) (XXVI) (XXVI I) (XXVIII) Step 11 Compound XXVII may be ed by reaction between compound XXV, 2,4,6-trichloropyrimidine (commercially available from Sigma-Aldrich), and a rd reagent XXVI, such as benzylmagnesiumchloride, (both commercially available from Sigma-Aldrich). The reaction proceeds at a temperature between -78 °C and 20 °C, and takes about 3 hours to te.
Step 12 Compound XXVIII can be obtained by treatment of compound XXVII with MeONa, freshly obtained in situ by adding NaH in MeOH. The reaction is carried out in MeOH, typically at room temperature and takes at 1 hour to complete.
[Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by an [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan ed set by Mel.Chan Scheme 10 St 13 _, T / / \ CI CI CI o (XXX) (XXIX) Step 13 Compound of structure XXX can be obtained via SnAr reaction between compound XXIX, commercially ble from Sigma-Aldrich, and a suitable phenol, such as 3-fluorophenol (commercially available from Sigma-Aldrich), the reaction typically proceeds in aprotic solvent, such as DMF, in presence of a suitable base, such as cesium ate, at a ature of around 80 °C. The reaction takes about 48 hours to complete.
Examples The invention is further illustrated by the following non-limiting examples.
In the ures that follow, after each starting material, reference to a Preparation or Example by number is lly provided. This is provided merely for assistance to the skilled chemist. The starting material may not necessarily have been prepared from the batch referred to.
Where reference is made to the use of a "similar or analogous" procedure, as will be appreciated by those skilled in the art, such ure may involve minor variation, for example reaction temperature, reagent/solvent amount, reaction time, work-up conditions or chromatographic purification conditions.
All temperatures refer to °C.
Proton Magnetic Resonance (NMR) spectra may be typically recorded either on Varian instruments at 400 or 500 MHz, or on a Bruker ment at 400 MHz. al shifts are expressed in parts of million (ppm, 6 units). Chemical shifts are reported in ppm eld (6) from Me4Si, used as internal standard, and are typically assigned as singlets (s), broad singlets (br.s.), doublets (d), doublets of doublets (dd), doublets of doublets of doublets (ddd), doublets of triplets (dt), triplets (t), ts of doublets (td), quartets (q), or multiplets (m).
LCMS may be recorded under the following conditions: DAD chromatographic traces, mass chromatograms and mass spectra may be taken on UPLC/PDA/MS AcquityTM system coupled with Micromass ZQTM or Waters SQD single quadrupole mass spectrometer operated in ve and/or negative ES ionisation mode. The QC methods used were two, one operated under low pH conditions and another one operated under high pH conditions. Details of the method operatDinder low pH conditions were: column, Acquity BEH C18, 1.7 pm, 2.1 x 50 mm or Acquity CSH C18, 1.7 pm, 2.1 x 50 mm, the temperature column was 40 °C; mobile phase solvent A was milliQ water + [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan ed set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan 0.1% HCOOH, mobile phase solvent B MeCN + 0.1% HCOOH. The flow rate was 1 ml/min. The gradient table was t= 0 min 97% A — 3% B, t= 1.5 min 0.1% A— 99.9% B, t= 1.9 min 0.1% A— 99.9% B and t= 2 min 97% A — 3% B. The UV detection range was 210 — 350 nm and the ES+/ES' range was 100 — 1000 amu.
Details of the method operated under high pH conditions were the same of those listed above for the low pH method apart from: column Acquity BEH C18, 1.7 pm, 2.1 x 50 mm; mobile phase solvent A was mM acqueous solution of NH4HC03 adjusted to pH= 10 with ammonia, mobile phase solvent B MeCN. eparative mass directed autopurifications (MDAP) were carried out using Waters FractionlynxTM systems operated under low or high pH chromatographic conditions. The stationary phases used were, XTerra C18, XBridge C18, Sunfire C18, XSelect C18, Gemini AXIA C18. The length of the columns was 5, or 15 cm, while the internal er was 19, 21 or 30 mm. The particle size of the stationary phases was 5 or 10 pm. The purifications were carried out using low pH or high pH tographic conditions.
The mobile phase solvent ition was the same used for QC analysis. The combinations stationary/mobile phases used were: XTerra, XBridge, Sunfire, XSelect — low pH mobile phases and XTerra, XBridge, Gemini AXIA — high pH mobile phases. All the purifications were d out with the column kept at room T. The flow rate used was 17 or 20 ml/min for columns of internal diameter 19 or 21 mm and 40 or 43 ml/min for columns of al diameter 30 mm. The trigger for the collection of the target species was the presence of the target m/z ratio value in the TIC MS signal. The gradient timetable was customised on the Rt behaviour of the target species.
Purification may also be performed using Biotage® |so|era or Biotage® SP1 flash chromatography systems, these instruments work with Biotage® KP-SIL cartridges and Biotage® KP-NH cartidges.
Unless otherwise stated, all reactions are typically performed under inert atmosphere (for example under Nitrogen).
The following abbreviations are used in the text: EtOAc, AcOEt, EA = ethyl e, EtZO = diethyl ether, MeOH = methanol; THF = ydrofuran, Tlc refers to thin layer chromatography on silica plates, and dried refers to a solution dried over anhydrous sodium te, r.t. (RT) refers to room temperature, DMSO = dimethyl ide; DMF = N,N’-dimethylformamide, DCM = dichloromethane, EtOH = l, DCE = dichloroethane, DME = methoxyethane, Cy, cHex = cyclohexane, TEA = triethylamine, DIPEA = N,N-Diisopropylethylamine, Boc20 = Di-tert—butyl dicarbonate; TFA = trifluoroacetic acid, Pd2(dba)3 = Tris(dibenzylideneacetone)dipalladium(0), EDC HCl = N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride, HOBt = 1-Hydroxybenzotriazole hydrate, SCX Cartridge = Strong Cation Exchange Cartrip [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] an None set by an [Annotation] an MigrationNone set by Mel.Chan ation] Mel.Chan Unmarked set by Mel.Chan Preparation 1: 2,4-dichloro(trifluoromethyl)pyrimidine (P1) A mixture of 6-(Trifluoromethyl)uracil (3 g, 16.66 mmol), SOCIZ (8 mL) and DMF (1 mL) was stirred at 80 °C for 4 hrs, then cooled to 0 °C. Hexane and crushed ice were added to the resulting mixture, followed by careful addition of NaHC03 until C02 had stopped evolving. The organic layer was separated, dried and carefully concentrated at reduced pressure with bath temperature below 35 °C, giving 2,4-dichloro- 6-(trifluoromethyl)pyrimidine (P1, 3.2 g, y= 88%) as pale yellow oil used in the next stage without additional purification. 1H NMR (CHLOROFORM-d): 5 ppm 7.67 (s, 1H) Preparation 2: 2-chloro(3-fluorophenoxy)(trifluoromethyl)pyrimidine (P2) A e of 2,4-dichloro(trifluoromethyl)pyrimidine (P1, 2 g, 9.2 mmol), rophenol (0.75 mL, 8.2 mmol) and K2C03 (1.66 g, 12 mmol) in DMSO (2 mL) was heated at 60 °C for 20 min. After cooling at RT, EtOAc and water were added and phases were separated. The organic phase was dried and evaporated; the crude material was purified by FC on silica gel (eluent: Cy to Cy/AcOEt 9/1) affording 2-chloro(3- fluorophenoxy)(trifluoromethyl)pyrimidine (P2, 2.26 g, y= 94%) as pale yellow oil. 1H NMR (CHLOROFORM-d): 6 ppm 7.47 (td1H), 7.22 (s, 1H), 7.09 (td, 1H), 7.03- 6.93 (m, 2H) Preparation 3: 1-bromofluoro(3-fluorophenoxy)benzene (P3) F o F ; : 3-fluorophenol (0.178 mL, 1.97 mmol) and KOH (110 mg, 1.97 mmol) were d at 50 °C for 30 min beforeD addition of 1,3-dibromofluorobenzene (500 mg, 1.97 mmol) and Cu powder (125 mg, 1.97 mmol). The reaction mixture was heated to 150 ° for 2 hrs and then at 100 °C overnight. The crude ation] an None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan ation] Mel.Chan Unmarked set by Mel.Chan t was purified by FC on silica gel (eluent: Cy), giving 1-bromofluoro(3- fluorophenoxy)benzene (P3, 834 mg, y= 22%) as oil. (dd, 1H), 6.79 (dt, 1H), 6.70 (dt, 1H) ation 4: mixture of o-2,3-difluoro(3-fluorophenoxy)benzene and 5-bromo-1,2- difluoro(3-fluorophenoxy)benzene (P4) 0 ; :1 UOQF F F F F F 3-fluorophenol (0.117 mL, 1.29 mmol) and KOH (73 mg, 1.29 mmol) were stirred at 50 °C for 30 min before the addition of 1,5-dibromo-2,3-difluorobenzene (350 mg, 1.29 mmol) and Cu powder (82 mg, 1.29 mmol). The reaction mixture was heated to 150 °C for 2 hrs and then at 100 °C overnight. The crude material was purified by FC on silica gel (eluent: Cy) giving a mixture "1:1 of 1-bromo-2,3-difluoro(3- fluorophenoxy)benzene and 5-bromo-1,2-difluoro(3-fluorophenoxy)benzene (P4, 68 mg, y= 17%) as 1H NMR (CHLOROFORM-d): 6 ppm 7.35 (q, 2 H), 7.16 - 7.23 (m, 1 H), 6.97 - 7.04 (m, 2 H), 6.87 - 6.95 (m, 2 H), 6.84 - 6.87 (m, 1 H), 6.79 - 6.84 (m, 2 H), 6.76 (ddt, 2 H).
Preparation 5: 1-bromo-2,5-difluoro(3-fluorophenoxy)benzene (P5) Br 0 F 3-fluorophenol (0.099 mL, 1.1 mmol) and KOH (62 mg, 1.1 mmol) were stirred at 50 °C for 30 min before the addition of 1,3-dibromo-2,5-difluorobenzene (300 mg, 1.1 mmol) and Cu powder (70 mg, 1.1 mmol).
The reaction mixture was heated to 100 °C overnight. The crude material was purified by FC on silica gel (eluent: Cy), giving 1-bromo-2,5-difluoro(3-fluorophenoxy)benzene (P5, 61 mg, y= 18%) as oil. 2H) D [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan ation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] an Unmarked set by Mel.Chan Preparation 6: 1-bromofluorophenoxybenzene (P6) Br 0 Method A: TEA (2.66 mL, 19.1 mmol) was added to a mixture of 3-bromofluorophenol (730 mg, 3.82 mmol), phenyl boronic acid (932 mg, 7.64 mmol), Cu(OAc)2 (1.04 mg, 5.73 mmol), molecular sieves and DCM (35 mL). The mixture was stirred at RT ght and ed through a pad of Celite g with DCM. The filtrate was concentrated and the crude material was purified by FC on silica gel (eluent: Cy) to afford 1- bromofluorophenoxybenzene (P6, 40 mg, y= 4%) as colourless oil.
Method B: Step at 3-chloroperbenzoic acid (640 mg, 3 mmol) was dissolved in DCM (10 mL). To the solution nzene (0.31 mL, 2.7 mmol) was added followed by slow addition of BFgOEtZ (0.850 mL, 6.8 mmol) at RT. The ing yellow solution was stirred at RT for 30 min, cooled down to 0 °C and then phenyl boronic acid (370 mg, 3 mmol) was added in one portion. After 15 min at RT, the crude reaction mixture was charged on a silica cartridge (6 g) and eluted with DCM (60 mL) followed by OH 20/1 (120 mL). The latter solution was concentrated and EtZO was added to precipitate the product which was further triturated with EtZO. After decantation the white off solid was dried to afford diphenyliodonium tetrafluoroborate (1 g).
Step b To a suspension of t-BuOK (43 mg, 0.37 mmol) in THF (1.5 mL) ofluorophenol (65 mg, 0.34 mmol) was added at 0 °C and the reaction mixture was left stirring for 15 min. Diphenyliodonium tetrafluoroborate (from step a, 145 mg, 0.4 mmol) was added in one portion and the reaction was stirred at 40 °C for 1 h. The reaction was quenched with H20 and the product was extracted with DCM.
Organic phase was evaporated and crude material purified by FC on silica gel (eluent: pentane) to afford 1-bromofluorophenoxybenzene (P6, 69 mg, y= 76%) 1H NMR (CHLOROFORM-d): 6 ppm 7.42-7.31 (m, 3H), 7.19-7.12 (m, 1H), 7.06 -6.94 (m, 4H) [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan ation] Mel.Chan Unmarked set by Mel.Chan Preparation 7: 1-bromofluoro(3-fluorophenoxy)benzene (P7) Br 0 F Method A 3-fluorophenol (0.107 mL, 1.18 mmol) and KOH (66 mg, 1.18 mmol) were stirred at 50 °C for 30 min before the addition of 1,3-dibromofluorobenzene (300 mg, 1.18 mmol) and Cu powder (75 mg, 1.18 mmol). The reaction mixture was heated to 100 °C overnight. The crude material was purified by FC on silica gel (eluent: Cy), giving 1-bromofluoro(3-fluorophenoxy)benzene (P7, 12 mg, y= 3.5%) as oil.
Method B Step at 3-chloroperbenzoic acid (640 mg, 3 mmol) was dissolved in DCM (10 mL). To the solution was added 3- fluoro-iodobenzene (0.317 mL, 2.7 mmol) ed by slow addition of BFgOEtZ (0.850 mL, 6.8 mmol) at RT. The resulting yellow solution was stirred at RT for 30 min, then cooled at 0 °C and 3-fluoro- phenylboronic acid (420 mg, 3 mmol) was added in one portion. After 15 min at RT, the crude reaction mixture was charged on a silica cartridge (6 g) and eluted with DCM (60 mL) followed by DCM/MeOH /1 (120 mL). The latter solution was concentrated and EtZO was added to triturate the product. After decantation the pale yellow solid was dried to afford Fluoro-phenyl)iodonium tetrafluoroborate (820 mg).
Step b To a suspension of t-BuOK (97 mg, 1.1 eq) in THF (3.5 mL), 3-bromofluorophenol (150 mg, 0.785 mmol) was added at 0 °C and the reaction was left stirring for 15min at that temperature. Bis(3-fluoro- )iodonium luoroborate (from step a, 381 mg, 0.942 mmol) was added in one n and the reaction was stirred at 40 °C for 1 h. The reaction was ed with H20 and the product was extracted with DCM. Organic phase was evaporated and the crude material was purified by FC on silica gel (eluent: pentane) affording 1-bromofluoro(3-fluorophenoxy)benzene (P7, 160 mg, y= 71%). 1H NMR (DMSO-ds): 5 ppm 7.59 (td, 1H), 7.49-7.40 (m, 1H), 7.30-7.19 (m, 2H), 7.07 -6.94 (m, 2H), 6.86 (dd, 1H) ation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan ed set by Mel.Chan ation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan Preparation 8: 6-benzyloxaazaspiro[2.5]octane (P8) To an ice-cooled mixture of NaH (60% dispersion in mineral oil, 2.75 g, 68.69 mmol) and trimethylsulfoxonium iodide (12.79 g, 58.12 mmol) DMSO (50 mL) was added keeping the mixture at 10 °C. The mixture was stirred for 10 min at 10 °C then it was allowed to reach RT and left stirring at that temperature for 1 h. A solution of 1-benzylpiperidinone (9.79 mL, 52.84 mmol) in DMSO (30 mL) was added via syringe. The mixture was stirred for 1.5 h at RT, diluted with EtZO and ed by the addition of saturated aqueous NH4CI. Phases were separated and aqueous one was back-extracted with EtZO. Combined organics were dried, filtered and concentrated under reduced pressure affording 6- benzyloxaazaspiro[2.5]octane (P8, 11.3 g, y= quant.) that was used as such in the next step.
MS (ES) (m/z): 204.05 .
Preparation 9: 1-benzyl[(dimethylamino)methyl]piperidinol (P9) To a stirred solution of 6-benzyloxaazaspiro[2.5]octane (P8, 0.5 g, 2.46 mmol) in ater (2/4 mL), at 0 °C, dimethylamine 40% water solution (0.62 mL, 4.92 mmol) was added dropwise. Once the addition was complete, the th was removed and the resulting reaction mixture was stirred at RT for 2 hrs. Solvent was removed under reduced re and the residue was partitioned between DCM and NaOH 1M aq. Organic phase was dried and concentrated under reduced pressure affording 1- benzyl[(dimethylamino)methyl]piperidinol (P9, 612 mg, y= quant) used as such in next step.
MS (ES) (m/z): 249.12 [M+H]+.
[Annotation] an None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan ed set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan ionNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by an Example 1: 4-[(dimethylamino)methyl][4-(3-fluorophenoxy)-6(trifluoromethyl)pyrimidin yl]piperidinol (E1) N N o F Step a To a solution of 1-benzyl[(dimethylamino)methyl]piperidinol (P9, 200 mg, 0.8 mmol) in MeOH (5 mL) ammonium formate (305 mg, 4.83 mmol) and 10% Pd/C (12 mg) were added at RT then the mixture was stirred under reflux for 1 h. The e was cooled down to RT and filtered through a pad of celite washing with MeOH. Solvent was eliminated under reduced pressure affording 4- [(dimethylamino)methyl]piperidinol (259 mg) as formate salt. Used as such in next step Step b To a solution of 4-[(dimethylamino)methyl]piperidinol (from step a, 75 mg, 0.22 mmol) in DMSO (2 mL) 2-ch|oro(3-fluorophenoxy)(trifluoromethyl)pyrimidine (P2, 66 mg, 0.22 mmol) and K2C03 (92 mg, 0.66 mmol) were added at RT then the mixture was shaken at 50 °C for 1 h. The mixture was cooled down, diluted with AcOEt and washed with water. Organic phase was dried and concentrated; the crude material was purified by FC on silica gel (eluent: DCM to DCM/MeOH 8:2) then further purified by FC on NH column (eluent: Cy to Cy/AcOEt 7:3) affording 4-[(dimethylamino)methyl][4-(3-fluorophenoxy)- 6(trifluoromethy|)pyrimidinyl]piperidin-4—ol (E1, 28 mg).
MS (ES) (m/z): 415.05 [M+H]+. 1H NMR (CHLOROFORM-d): 6 ppm 7.45-7.35 (m, 1H), 7.07- 6.91 (m, 3H), 6.33 (s, 1H), 4.52 (br. s., 1H), 4.23 (br. s., 1H), 3.32 (br. s., 2H), 2.43 (s, 6H), 2.34 (br. s., 2H), 1.45 (d, 4H) [Annotation] Mel.Chan None set by Mel.Chan ation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan ed set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan Preparation 10: yl(pyrrolidinylmethyl)piperidinol (P10) To a stirred solution of 6-benzyloxaazaspiro[2.5]octane (P8, 0.2 g, 0.98 mmol) in MeOH/water (1/2 mL), idine (0.164 mL, 1.96 mmol) was added dropwise. Once the on was complete the resulting reaction e was shaken at RT for 2 hrs. Solvent was removed under reduced pressure and the residue was partitioned between DCM and NaOH 1M aq. Organic phase was dried and concentrated under reduced pressure affording yl(pyrrolidinylmethyl)piperidinol (P10, 280 mg, y= quant.) used as such in next step.
MS (ES) (m/z): 275.20 [M+H]+ Example 2: 1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl](pyrrolidin ylmethyl)piperidinol (E2) N N o F Step 0: To a solution of 1-benzyl(pyrrolidiny|methyl)piperidinol (P10, 280 mg, 1.02 mmol) in MeOH (5 mL) ammonium formate (386 mg, 6.12 mmol) and 10% Pd/C (30 mg) were added at RT, then the mixture was stirred under reflux for 1h. The mixture was cooled down to RT and filtered through a pad of celite washing with MeOH. Solvent was eliminated under reduced pressure affording 4-(pyrrolidin ylmethyl)piperidinol (280 mg).
Step b: To a ernn of 1-benzyl(pyrrolidinylmethyl)piperidinol (from step a, 80 mg, 0.43 mmol) in DMSO (2 mL) 2-chloro(3-fluorophenoxy)(trifluoromethyl)pyrimidine (P2, 102 mg, 0.35 mmol) and [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan ed set by Mel.Chan [Annotation] an None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan K2C03 (178 mg, 1.29 mmol) were added at RT then the mixture was shaken at 60 °C for 2 hrs. The mixture was cooled down, diluted with DCM and washed with water. Organic phase was dried and concentrated and the crude material was purified by FC on NH column (eluent: Cy to Et 1:1) affording 1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]—4-(pyrrolidinylmethyl)piperidin ol (E2, 42 mg, y= 22%) MS (ES) (m/z): 441.19 [M+H]+. 1H NMR (CHLOROFORM-d): 6 ppm .34 (m, 1H), 7.04— 6.88 (m, 3H), 6.37 -6.29 (m, 1H), 4.54 (br. s., 1H), 4.16 (br. s., 1H), 3.32 (br. s., 2H), 2.74 (br. s., 3H), 2.55 (br. s., 2H), 1.83 (br. s., 5H), 1.45 (br. s., Preparation 11: 1-benzyl[(cyclopropylamino)methyl]piperidinol (P11) To a stirred solution of 6-benzyloxaazaspiro[2.5]octane (P8, 0.2 g, 0.98 mmol) in MeOH/water (1/2 mL), at 0 °C, cyclopropylamine (0.136 mL, 1.97 mmol) was added dropwise. Once the addition was complete, the th was removed and the resulting reaction mixture was stirred at RT for 2 hrs.
Solvent was removed under reduced pressure and the residue was partitioned between DCM and NaOH 1M aq. c phase was dried and concentrated under reduced pressure affording 1-benzyl [(cyclopropylamino)methyl]piperidinol (P11, 260 mg, y= quant.) used as such in next step.
MS (ES) (m/z): 261.13 [M+H]+.
[Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by an [Annotation] Mel.Chan ionNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan Preparation 12: tert-butyl N-[(1-benzylhydroxypiperidinyl)methyl]-N-cyclopropylcarbamate (P12) To a solution of 1-benzyl[(cyclopropylamino)methyl]piperidinol (P8, 260 mg, 1 mmol) in DCM 5 mL, Boczo (218 mg, 1 mmol) was added and the mixture was stirred at RT for 2 hrs, then solvent was eliminated under reduced pressure affording tert—butyl N-[(1-benzylhydroxypiperidinyl)methyl]—N- cyclopropylcarbamate (P12, 391 mg, crude material) used as such.
MS (ES) (m/z): 361.1 .
Preparation 13: tert-butyl N-cyclopropyl-N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin yl]hydroxypiperidinyl}methyl)carbamate (P13) To a solution of tert-butyl N-[(1-benzylhydroxypiperidinyl)methyl]-N-cyclopropylcarbamate (P12, 391 mg, 1.08 mmol) in MeOH (5 mL) um formate (408 mg, 6.48 mmol) and 10% Pd/C (30 mg) were added at RT then the mixture was stirred under reflux for 3 hrs. The e was then cooled down to RT and filtered through a pad of celite washing with MeOH. Solvent was eliminated under reduced pressure affording utyl N-cyclopropyl-N-[(4-hydroxypiperidinyl)methyl]carbamate (425 [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan ionNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by an [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan Step b: 2-chloro(3-fluorophenoxy)(trifluoromethyl)pyrimidine (P2, 65 mg, 0.222 mmol), tert—butyl N- cyclopropyl-N-[(4-hydroxypiperidinyl)methyl]carbamate (from step a, 100 mg, 0.222 mmol) and K2C03 (40 mg, 0.289 mmol) were mixed in dry DMSO (1 mL) and the mixture was shaken at 60 °C for 1 hr. Then the mixture was diluted with EtOAC and water. The organic phase was washed several times with brine, dried, filtered and evaporated. Crude material was purified by FC on NH column t: Cy to Cy Ac10). affording tert—butyl N-cyclopropyl-N-({1-[4-(3-fluorophenoxy) (trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methyl)carbamate (P13, 50 mg).
MS (ES) (m/z): 527.19 [M+H]+.
Example 3: 4-[(cyclopropylamino)methyl][4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin yl]piperidinol (E3) Au??i? TFA (0.5 mL) was added to a solution of tert—butyl opropyl-N-({1-[4-(3-fluorophenoxy) (trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methyl)carbamate (P13, 50 mg, 0.095 mmol) in 3 mL of DCM. The mixture was stirred at RT for 1 h, and then the solvent was removed under reduced pressure. The residue was charged on SCX cartridge washing with MeOH and eluting with 1M NH3 in MeOH to afford 4-[(cyclopropylamino)methyl][4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin eridinol (E3, 40 mg, y= 98%).
MS (ES) (m/z): 427.18 [M+H]+ 1H NMR (CHLOROFORM-d): 6 ppm 7.46-7.33 (m, 1H), 7.07 -6.85 (m, 3H), 6.34 (s, 1H), 4.47 (br. s., 1H), 4.22 (br. s., 1H), 3.40-3.17 (m, 2H), 2.70 (s, 2H), 2.31-2.20 (m, 1H), 1.64-1.50 (m, 2H), 1.44 (br. s., 2H), 0.57-0.47 (m, 2H), 0.40 (br. s., 2H) [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan ation] Mel.Chan Unmarked set by Mel.Chan Example: clopropyl(methyl)amino]methyl}[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin- iperidinol (E4) A ii? To a solution of 4-[(cyclopropylamino)methyl][4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin yl]piperidinol (E3, 20 mg, 0.047 mmol) in DCM (2 mL), formaldehyde (0.035 mL, 0.47 mmol) was added and the e was stirred at RT for 15 min. NaBH(OAc)3 (38 mg, 0.180 mmol) was added and the mixture was stirred at RT overnight. Water was added and phases were ted. The organic phase was washed with brine, dried, filtered and evaporated to afford 4- {[cyclopropyl(methyl)amino]methyl}[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidin- 4-ol (E4, 15 mg, y= 72%).
MS (ES) (m/z): 441.21 [M+H]+ 1H NMR (CHLOROFORM-d): 6 ppm 7.44-7.35 (m, 1H), 7.07- 6.90 (m, 3H), 6.33 (s, 1H), 4.47 (br. s., 1H), 4.21 (br. s., 1H), 3.29 (br. s., 2H), 3.10 (br. s., 1H), 2.58 (s, 2H), 2.48 (s, 3H), 1.96 (br. s., 1H), 1.56 (br. s., 2H), 1.44 (br. s., 2H), 0.59-0.39 (m, 4H) Preparation 14: 1-benzyl[(methylamino)methyl]piperidinol (P14) To a stirred solution of 6-benzyloxaazaspiro[2.5]octane (P8, 0.2 g, 0.98 mmol) in MeOH/water (1/2 mL), at 0 °C, methylamine 33% ethanol solution (0.244 mL, 1.97 mmol) was added dropwise. Once the addition was complete, the th was removed and the resulting reaction mixture was stirred at RT for 2 hrs. Solvent was removed under reduced pressure and the residue was partitioned between DCM and NbenzyRmethylamino)methy|]piperidin-4—ol1M aq. Organic phase was dried and concentrated under d pressure affording 1- (P14, 222 mg, y= 97 %) used as such in next step.
[Annotation] Mel.Chan None set by Mel.Chan [Annotation] an ionNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan MS (ES) (m/z): 235.09 .
Preparation 15: tert-butyl N-[(1-benzylhydroxypiperidinyl)methy|]-N-methylcarbamate (P15) 1-benzyl[(methylamino)methyl]piperidinol (P14, 220 mg, 0.939 mmol) was dissolved in DCM (2 mL), TEA (0.2 mL, 1.41 mmol) was added followed by a solution of Boczo (247 mg, 1.13 mmol) in DCM (2 mL).The ing solution was stirred at RT for 2 hrs. NH4C| was added, the organic phase was separated, dried and concentrated. The crude material was purified by FC on silica gel (eluent: EtOAc to EtOAc/MeOH 90/10) affording tert—butyl N-[(1-benzylhydroxypiperidinyl)methyl]—N- methylcarbamate (P15, 240 mg, y= 76%) as colourless oil.
MS (ES) (m/z): 335.22 [M+H]+.
Preparation 16: tert-butyl N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin-Z-yl] hydroxypiperidinyl}methyl)-N-methylcarbamate (P16) Step 0: To a on of tert—butyl N-[(1-benzylhydroxypiperidinyl)methyl]-N-methylcarbamate (P15, 240 mg, 0.718 mmol) in MeOH (6 mL) ammonium formate (272 mg, 4.31 mmol) and 10% Pd/C (72 mg) were added at RT then the mixture was stirred under reflux for 1 h. The e was then cooled down to RT and fil through a pad of celite washing with MeOH. Solvent was eliminated under reduced pressure affording tert—butyl N-[(4-hydroxypiperidinyl)methyl]—N-methylcarbamate (150 mg) as colourless oil. ation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan ation] an Unmarked set by Mel.Chan ation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan Step b: 2-chloro(3-fluorophenoxy)(trifluoromethyl)pyrimidine (P2, 60 mg, 0.205 mmol), tert—butyl N-[(4- hydroxypiperidinyl)methyl]-N-methylcarbamate (from step a, 50 mg, 0.205 mmol) and K2C03 (37 mg, 0.267 mmol) were mixed in dry DMSO (1 mL) and the mixture was shaken at 60 °C for 1 hr. The e was diluted with EtOAC and water. The organic phase was washed several times with brine, dried, filtered and evaporated; crude material was purified by FC on NH column (eluent: Cy to Cy85/EtOAc15) affording tert—butyl N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidin y|}methy|)-N-methylcarbamate (P16, 40 mg).
MS (ES) (m/z): 501.18 [M+H]+.
Example 5: 3-fluorophenoxy)(trifluoromethyl)pyrimidin-Z-yl] [(methylamino)methyl]piperidinol (E5) \ N)\\NN21 £1o F TFA (0.5 mL) was added to a solution of tert—butyl N-({1-[4-(3-fluorophenoxy) (trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methyl)-N-methylcarbamate (P16, 40 mg, 0.080 mmol) in DCM (3mL). The mixture was stirred at RT for 1h, and then the solvent was removed under reduced pressure. The residue was charged on SCX cartridge washing with MeOH and eluting with 1M NH3 in MeOH to afford 1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl] [(methylamino)methyl]piperidinol (E5, 30 mg, y= 94%).
MS (ES) (m/z): 401.15 [M+H]+ 1H NMR (CHLOROFORM-d): 6 ppm 7.43-7.33 (m, 1H), 7.06- 6.88 (m, 3H), 6.37-6.30 (m, 1H), 4.55 (br. s., 1H), 4.19 (br. s., 1H), 3.30 (br.s., 2H), 2.56 (s, 2H), 2.53 (s, 3H), 1.59 (br. s., 2H), 1.46 (br. s., 2H) [Annotation] Mel.Chan None set by an [Annotation] Mel.Chan MigrationNone set by an [Annotation] Mel.Chan ed set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan Preparation 17: 1-benzyl[(3,3-difluoropyrrolidinyl)methy|]piperidinol (P17) To a stirred solution of 6-benzyloxaazaspiro[2.5]octane (P8, 0.2 g, 0.98 mmol) in MeOH (1 mL), a solution of 3,3-Difluoropyrrolidine hydrochloride (282 mg, 1.96 mmol) and TEA (0.272 mL, 1.96 mmol) in H20 (2 mL) was added dropwise. Once the on was complete the resulting reaction mixture was shaken at RT overnight. Solvent was removed under reduced pressure and the residue was partitioned between DCM and NaOH 1M aq. Organic phase was dried and concentrated under reduced pressure affording 1-benzyl[(3,3-difluoropyrrolidin-l—yl)methyl]piperidinol (P17, 305 mg, y= quant.) used as such in next step.
MS (ES) (m/z): 311.16 [M+H]+.
Example 6: 4-[(3,3-difluoropyrrolidinyl)methyl][4-(3-fluorophenoxy) uoromethyl)pyrimidin-Z-yl]piperidinol (E6) N N 0 To a solution of 1-benzyl[(3,3-difluoropyrrolidinyl)methyl]piperidinol (P17, 305 mg, 0.98 mmol) in MeOH (8 mL) um formate (370 mg, 5.88 mmol) and 10% Pd/C (30 mg) were added at RT then the mixture was stirred under reflux for 3 hrs. The mixture was then cooled down to RT and filtered through a pad of celite g with MeOH. Solvent was eliminated under reduced pressure affording 4- [(3,3-difluoropyrrolidinyl)methyl]piperidinol (320 mg).
[Annotation] an None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by an [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan ation] Mel.Chan Unmarked set by Mel.Chan A mixture of 4-[(3,3-difluoropyrrolidinyl)methyl]piperidinol (from step a, 80 mg, 0.195 mmol), 2- chloro(3-fluorophenoxy)(trifluoromethyl)pyrimidine (P2, 44 mg, 0.195 mmol) and K2C03 (35 mg, 0.253 mmol) in DMSO (0.5 mL) was heated at 100 °C for 1 h. After cooling to RT, EtOAc and water were added and phases were separated. The c phase was dried and evaporated, the residue was ed by FC on NH column (eluent: cHex to cHex 80/ EtOAc 20) affording 4-[(3,3-difluoropyrrolidin yl)methyl][4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidinol (E6, 27 mg,) as colourless oil.
MS (ES) (m/z): 477.01 [M+H]+. 1H NMR (CHLOROFORM-d): 6ppm 7.44-7.34 (m, 1H), 7.05 -6.89 (m, 3H), 6.35 (s, 1H), 4.52 (br. s., 1H), 4.24 (br. s., 1H), 3.31 (br. s., 2H), 3.10 (t, 2H), 2.96 (t, 2H), 2.82 (br. s., 1H), 2.52 (s, 2H), 2.30 (tt, 2H), 1.60 (d, 2H), 1.46 (br. s., 2H) Preparation 18: tert-butyl 4-[(1-benzylhydroxypiperidinyl)methyl]-1,4-diazepanecarboxylate (P18) To a stirred mixture of 6-benzyloxaazaspiro[2.5]octane (P8, 300 mg, 1.48 mmol) in MeOH (1.5 mL) and water (2 mL), a solution of tert—butyl 1,4-diazepanecarboxylate (0.58 mL, 2.95 mmol) in MeOH (0.5 mL) was added and the resulting reaction e was shaken overnight at RT. The mixture was concentrated under reduced pressure, the residue was taken up with DCM and saturated sodium bicarbonate, the organic phase was washed with water, dried and trated under vacuum. The residue was purified by FC on silica gel (eluent: DCM to DCM/MeOH 97/3) to give tert—butyl 4-[(1-benzyl- 4-hydroxypiperidinyl)methyl]-1,4-diazepanecarboxylate (P18, 367 mg, y= 66%) as colourless oil.
MS (ES) (m/z): 404.3 [M+H]+.
[Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan ionNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan Preparation 19: utyl 4-[(4-hydroxypiperidinyl)methyl]-1,4-diazepanecarboxylate (P19) To a solution of utyl 4-[(1-benzylhydroxypiperidinyl)methyl]-1,4-diazepane-l-carboxylate (P18, 367 mg, 0.91 mmol) in MeOH (20 mL), ammonium formate (344 mg, 5.46 mmol) and 10% Pd/C (114 mg) were added at RT then the mixture was stirred under reflux. After 2 hrs the reaction mixture was filtered through a pad of celite and the t removed under vacuum. The residue was dissolved in DCM, the organic solution washed with saturated NaHC03, dried and concentrated under reduced pressure to give tert—butyl 4-[(4-hydroxypiperidinyl)methyl]-1,4-diazepane-l—carboxylate (P19, 139 mg, y= 49%) as colourless oil.
MS (ES) (m/z): 314.2 [M+H]+. ation 19A: tert-butyl 4-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin-Z-yl] hydroxypiperidinyl}methyl)-1,4-diazepanecarboxylate (P19A) In a closed vessel a mixture of tert—butyl 4-[(4—hydroxypiperidinyl)methyl]-1,4-diazepane carboxylate (P19, 64 mg, 0.21 mmol), 2-chloro(3-fluorophenoxy)(trifluoromethyl)pyrimidine (P2, 60 mg. 0.21 mmol) and K2C03 (38 mg, 0.27 mmol) in DMSO (0.8 mL) was heated at 90 °C and shaken 2 hrs at this temperature. After cooling at RT, EA and water were added, the organic phase was washed with water, dried and evaporated. Crude product was purified by FC on NH column (eluent: Cy to Cy/EA 80/20) affording tert—butyl [4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl] hydroxypiperidinyl}methyl)-1,4-diazepane-l—carboxylate (P19A, 73 mg, y= 61%).
MS (ES) (m/z): 570.3 [M+H]+.
[Annotation] an None set by Mel.Chan ation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan Example 7: 4-(1,4-diazepanylmethyl)[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin yl]piperidinol hydrochloride (E7) Step a To a solution of tert—butyl 4-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl] hydroxypiperidinyl}methy|)-1,4-diazepane-l—carboxylate (P19A, 73 mg, 0.13 mmol) in DCM (0.6 mL), at RT, TFA (0.29 mL) was added. After 2 hrs the reaction mixture was concentrated under vacuum. The residue was taken up with DCM and concentrated sodium bicarbonate, the organic phase was dried and the solvent removed under vacuum affording 4-(1,4-diazepanylmethyl)[4-(3-fluorophenoxy) (trifluoromethyl)pyrimidinyl]piperidinol (35 mg).
Step b 4-(1,4-diazepanylmethyl)[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidinol (from step a, 35 mg, 0.075 mmol) was dissolved in DCM (0.2 mL) and 2N HCI in ether (0.037 mL) was added. The mixture was concentrated under reduced pressure, the residue was triturated with ether and dried under vacuum to give -diazepanylmethyl)[4-(3-fluorophenoxy) (trifluoromethyl)pyrimidinyl]piperidinol hydrochloride (E8, 11 mg, y= 17%).
MS (ES) (m/z): 470.25 [M+H]+ 1H NMR (DMSO-ds): 6ppm 8.84 (br. s., 2H), 7.58-7.45 (m, 1H), 7.26 (dt, 1H), .08 (m, 2H), 6.62 (s, 1H), 4.30 (br. s., 2H), 3.87 (br. s., 1H), 3.09 (s, 2H), 3.14 (s, 3H), 2.95 (br. s., 2H), 2.78 (br. s., 2H), 2.47 (br. s., 2H), 1.84 (br. s., 2H), 1.42 (br. s., 4H) ation 20: 1-benzyl[(2,5-dimethylpyrrolidinyl)methyl]piperidinol (P20) ation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] an Unmarked set by Mel.Chan To a stirred solution of 6-benzyloxaazaspiro[2.5]octane (P8, 0.2 g, 0.98 mmol) in MeOH/water (2/4 mL) 2,5-dimethylpyrrolidine (0.241 mL, 1.97 mmol) was added dropwise. Once the addition was complete the reaction mixture was shaken at RT for 2 hrs, then at 45 °C overnight. Solvent was removed under reduced pressure and the e was partitioned between DCM and NaOH 1M aq. Organic phase was dried and concentrated under reduced pressure affording 1-benzyl[(2,5-dimethylpyrrolidin yl)methyl]piperidinol (P20, 263 mg, y= 88%) used as such in next step.
MS (ES) (m/z): 303.1 [M+H]+.
Preparation 21: 5-dimethylpyrrolidinyl)methyl]piperidinol (P21) To a solution of 1-benzyl[(2,5-dimethylpyrrolidinyl)methyl]piperidinol (P20, 263 mg, 0.87 mmol) in MeOH (5 mL) ammonium formate (0.329 g, 5.21 mmol) and 10% Pd/C (20 mg) were added at RT then the mixture was stirred under reflux for 1.5 h. The mixture was then cooled down to RT and filtered through a pad of celite washing with MeOH. Solvent was eliminated under reduced pressure affording 4- [(2,5-dimethylpyrrolidinyl)methyl]piperidinol (P21, 340 mg, crude material) MS (ES) (m/z): 213.2 . e 8: 4-[(2,5-dimethylpyrrolidinyl)methyl][4-(3-fluorophenoxy) (trifluoromethyl)pyrimidin-Z-yl]piperidin-4—ol (E8) N N o F To a solution of 4-[(2,5-dimethylpyrrolidinyl)methyl]piperidinol (P21, 50 mg, 0.24 mmol) in DMSO (2 ro(3-fluorophenoxy)(trifluoromethyl)pyrimidine (69 mg, 0.24 mmol) and K2C03 (66 mg, 0.48 mmol) were added at RT then the mixture was shaken at 50 °C for 2 hrs. The mixture was ation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan cooled down to RT, diluted with DCM and washed with water. c phase was dried and concentrated and the crude material was purified by FC on Silica gel (eluent: Cy to Cy/AcOEt 1/1) then charged on a SCX cartridge g with MeOH and eluting with NH3 1M in MeOH to give 4-[(2,5- dimethylpyrrolidinyl)methyl]—1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidinol (E8, 20 mg, y: 18%) MS (ES) (m/z): 469.07 [M+H]+ 1H NMR (CHLOROFORM-d): 6 ppm 7.45-7.33 (m, 1H), 7.05- 6.87 (m, 3H), 6.31 (s, 1H), 4.60 (br. s., 1H), 4.17 (br. s., 1H), 3.29 (br. s., 2H), 2.71 (d, 2H), 2.51 (s, 2H), 1.89 (br. s., 2H), 1.45-1.28 (m, 6H), 1.12 (d, 6H) Preparation 22: 1-benzyl[(tert-butylamino)methyl]piperidinol (P22) To a stirred solution of 6-benzyloxaazaspiro[2.5]octane (P8, 0.2 g, 0.98 mmol) in MeOH/water (1/2 mL), at 0 °C, tert-butylamine (0.2 mL, 1.97 mmol) was added se. Once the addition was complete, the ice-bath was removed and the resulting reaction e was stirred at 45 °C overnight. Solvent was removed under reduced pressure and the residue was ioned between DCM and NaOH 1M aq.
Organic phase was dried and concentrated under reduced pressure affording 1-benzyl[(tert— butylamino)methyl]piperidinol (P22, 270 mg, y= quant) used as such in next step.
MS (ES) (m/z): 277.1 .
Preparation 23: 4-[(tert-butylamino)methyl]piperidinol (P23) To a solution of 1-benzyl[(tert—butylamino)methyl]piperidinol (P22, 270 mg, 0.98 mmol) in MeOH (8 mL)Dnonium formate (370 mg, 5.88 mmol) and 10% Pd/C (90 mg) were added at RT then the mixture was stirred under reflux for 1 h. The e was cooled down to RT and filtered through a pad [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by an of celite washing with MeOH. Solvent was eliminated under reduced pressure affording 4-[(tert— butylamino)methyl]piperidinol (P23, 180 mg, y= quant.), as white solid.
MS (ES) (m/z): 177.1[M+H]+.
Example 9: 4-[(tert-butylamino)methyl][4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin yl]piperidinol (E9) N N + .
A e of 2-chloro(3-fluorophenoxy)-6—(trifluoromethyl)pyrimidine (P2, 73 mg, 0.249 mmol), 4- [(tert—butylamino)methyl]piperidinol (P23, 50 mg, 0.268 mmol) and K2C03 (44 mg, 0.323 mmol) in DMSO (0.8 mL) was heated at 45 °C for 1 h.
After cooling to RT, EtOAc and water were added and the product was extracted in organic phase. The organic phase was dried and evaporated, the e was purified by FC on NH column (eluent: cHex to tOAc 80/20) affording 4-[(tert—butylamino)methyl][4-(3-fluorophenoxy) (trifluoromethyl)pyrimidinyl]piperidinol (E9, 59 mg, y= 53%) as yellowish oil.
MS (ES) (m/z): 443.20 [M+H]+. 1H NMR (DMSO-d5): 6 ppm 7.57-7.46 (m, 1H), 7.26-7.06 (m, 3H), 6.55 (s, 1H), 4.09 (br. s., 3H), 3.29 (br. s., 2H), 2.42 (s, 2H), 1.48 (br. s.,4H), 1.29 (d, 1H), 1.03 (s, 9H) ation 24: 1-[(1-benzylhydroxypiperidinyl)methyl]pyrrolidin-Z-one (P24) HO H To a mixture of pyrrolidinone (250 mg, 2.94 mmol) in DMF (10 mL) at 0 °C, NaH 60% dispersion in ominer? (125 mg, 3.2. mmol) was added and the suspension was stirred at 0 °C for 30 min, then a6-benzyloxaazaspiro[2.5]octane (P8, 200 mg, 0.98 mmol) in DMF (2 mL) was added. The [Annotation] an None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan mixture was allowed to reach RT and stirred at that temperature for 1.5 hr. The mixture was then heated to 80 °C and stirred at that ature for further 2 hrs. on e was cooled down to RT, poured into water/ice and extracted twice with AcOEt. Organic phase was dried and concentrated under reduced pressure and the e containing DMF was loaded on a SCX cartridge, washed with MeOH and eluted with NH3 1M in MeOH. Solvent was eliminated under reduced pressure affording 1- [(1-benzylhydroxypiperidinyl)methyl]pyrrolidinone (P24, 128 mg, y= 45%).
MS (ES) (m/z): 289.2 [M+H]+.
Preparation 25: 1-[(4-hydroxypiperidinyl)methyl]pyrrolidin-Z-one (P25) To a solution of 1-[(1-benzylhydroxypiperidinyl)methyl]pyrrolidinone (P24, 128 mg, 0.44 mmol) in MeOH (5 mL) ammonium formate (0.168 g, 2.66 mmol) and 10% Pd/C (15 mg) were added at RT then the mixture was stirred under reflux for 1.5 h. The mixture was cooled down to RT and filtered through a pad of celite washing with MeOH. Solvent was eliminated under reduced pressure affording 1-[(4- ypiperidinyl)methyl]pyrrolidinone (P25, 85 mg, y= 97%) MS (ES) (m/z): 199.1[M+H]+. e 10: 1-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidin yl}methyl)pyrrolidin-Z-one (E10) N N o F To a solution of 1-[(4-hydroxypiperidinyl)methyl]pyrrolidinone (P25, 82 mg, 0.35 mmol) in DMSO (2 mL)Diloro(3-fluorophenoxy)(trifluoromethyl)pyrimidine (P2, 103 mg, 0.35 mmol) and K2C03 (97 mg, 0.7 mmol) were added at RT then the mixture was shaken at 50 °C for 2 hrs. The mixture was [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] an Unmarked set by an [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan cooled down, diluted with DCM and washed with water. c phase was dried and concentrated and the crude material was purified by FC on Silica gel (eluent: Cy to AcOEt), affording 1-({1-[4-(3- fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methyl)pyrrolidinone (E10, 85 mg, y= 53%).
MS (ES) (m/z): 455.01 [M+H]+. 1H NMR (CHLOROFORM-d):6 ppm 7.47 - 7.35 (m, 1 H), 7.08 -6.89 (m, 3 H) 6.35 (s, 1 H) 4.70-4.13 (m, 2 H) 3.54 (t, 2 H) 3.45 - 3.23 (m, 4 H) 2.48 (t, 2 H) 2.20 - 2. 03 (m, 2 H) 1.64 (s, 2 H) 1.48 (s, 2H) Preparation 26: 4-(aminomethyl)benzylpiperidinol (P26) To a d solution of 6-benzyloxaazaspiro[2.5]octane (P8 ,3 g, 14.7 mmol) in MeOH (18 mL), at 0 °C, 28% aq. NH4OH (36 mL) was added. Once the addition was complete, the th was removed and the resulting reaction mixture was stirred at RT overnight. Then, reaction e was concentrated under reduced pressure, the residue was taken up with DCM and 1N NaOH, aqueous phase was back extracted with DCM, combined organics were dried and concentrated under reduced pressure. 4- (aminomethyl)benzylpiperidinol (P26, 2.9 g, y= 89%) was obtained as less oil. Used as such in next step MS (ES) (m/z): 221.10 [M+H]+.
Preparation 27: tert-butyl N-[(1-benzylhydroxypiperidinyl)methyl]carbamate (P27) "o?nAok [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan ation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan To a solution of 4-(aminomethyl)benzylpiperidinol (P26, 2.9 g, 13.18 mmol) in DCM (30 mL) a solution of Boczo (2.87 mg, 13.18 mmol) in DCM (20 mL) was added and the e was d at RT for 14 hrs. The solvent was ated under reduced pressure and crude material purified by FC on silica gel (eluent: Cy to AcOEt) affording tert—butyl N-[(1-benzylhydroxypiperidin yl)methyl]carbamate (P27, 2.9 g, y= 68.7%) as a white solid.
MS (ES) (m/z): 321.11 [M+H]+.
Preparation 28: tert-butyl N-[(4-hydroxypiperidinyl)methyl]carbamate (P28) >[\O/\Nll To a solution of tert—butyl N-[(1-benzylhydroxypiperidinyl)methyl]carbamate (P27, 2.9 g, 9.06 mmol) in MeOH (50 mL) ammonium formate (3.42 g, 54.3 mmol) and 10% Pd/C (0.3 g) were added at RT then the mixture was stirred under reflux for 1 h. The mixture was cooled down to RT and filtered h a pad of celite washing with MeOH. Solvent was eliminated under reduced pressure affording tert—butyl N-[(4-hydroxypiperidinyl)methyl]carbamate (P28, 2.2 g, y= quant. 90% weight), as clear oil.
MS (ES) (m/z): 231.0 .
Preparation 29: tert-butyl N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin-Z-yl] hydroxypiperidinyl}methyl)carbamate (P29) N N o F #0"ll To a solution of utyl N-[(4-hydroxypiperidinyl)methyl]carbamate (P28, 0.34 g, 1.36 mmol (90% weight) in DMSO (6 mL) 2-chloro(3-fluorophenoxy)(trifluoromethy|)pyrimidine (P2, 0.4 g, 1.36 mmol) and K2C03 (0.37 g, 2.72 mmol) were added at RT then the mixture was shaken at 50 °C for 2 hrs.
The mDe was cooled down, diluted with DCM and washed with water. Organic phase was dried and concentrated and the crude material purified by FC on silica gel (eluent: Cy to Cy/AcOEt 1:1) affording [Annotation] Mel.Chan None set by Mel.Chan [Annotation] an MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] an MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan utyl N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidin yl}methyl)carbamate (P29, 350 mg, y= 53%) as a white solid.
MS (ES) (m/z): 487.0 [M+H]+.
Example 11: 4-(aminomethyl)[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin-Z-yl]piperidinol (E11) N N o F TFA (0.5 mL) was added to a solution of tert—butyl N-({1-[4-(3-fluorophenoxy) (trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methyl)carbamate (P29, 150 mg, 0.308 mmol) in DCM (5 mL). The mixture was stirred at RT for 1 h, and then the t was removed under reduced pressure. The residue was charged on SCX cartridge washing with MeOH and eluting with 1M NH3 in MeOH to afford 4-(aminomethyl)[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidin ol (E11, 105 mg, y= 88%).
MS (ES) (m/z): 387.2 [M+H]+.
Example 12: 4-(aminomethyl)[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin-Z-yl]piperidinol hydrochloride (E12) N N o F 4-(aminomethyl)[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidinol (E11, 80 mg. 0.207 mmol) was ved in DCM (1 mL) and treated with HCl 2M in diethyl ether (0.109 mL, 0.217 mmol). Then the solvent was ated to give 4-(aminomethyl)[4-(3-fluorophenoxy) (trifluoromethyl)pyrimidinyl]piperidinol hydrochloride (E12, 88 mg, y= 100%) as white solid.
MS (ES) (m/z): 387.2 [M+H]+ 1H NMR (DMSO-ds): 6 ppm 7.56-7.46 (m, 1H), 7.35-7.10 (m, 5H), 6.65 (s, 1H), 5.04 (br. s., 1H), 4.22 (br. s., 1H), 3.85 (br. s., 1H), 3.21 (br. s., 2H), 2.72 (s, 2H), 1.47 (br. s., 6H) [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan ation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by an Preparation 30: tert-butyl N-({4-fluoro[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin eridinyl}methyl)carbamate (P30) N N o F >kOANll To a solution of tert-butyl N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl] hydroxypiperidinyl}methyl)carbamate (P29, 51 mg, 0.109 mmol) in DCM (2 mL) at 0 °C laminosulfur trifluoride (0.029 mL, 0.218 mmol) was added and the reaction mixture was stirred for 1 h at 0 °C under N2. NH4C| was added, the organic phase was separated, dried and solvent was evaporated. Crude al was purified by FC on silica gel (eluent: Cy to Cy/AcOEt 1:1) affording tert- butyl fluoro[4-(3-fluorophenoxy)-6—(trifluoromethyl)pyrimidinyl]piperidin yl}methyl)carbamate (P30, 28 mg, y= 52%).
MS (ES) (m/z): 489.0 [M+H]+.
Example 13: {4-fluoro[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin-Z-yl]piperidin yl}methanamine (E13) N N o F To a solution of tert—butyl N-({4-fluoro[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin yl]piperidinyl}methyl)carbamate (P30, 28 mg, 0.057 mmol) in DCM (4 mL) 0.1 mL of TFA were added and the solution stirred at RT for 1 h. The reaction mixture was diluted with DCM and treated with NaHC03 saturated solution at 0 °C. Organic phase was dried and concentrated under reduced pressure.
Crude aerial was loaded on a SCX cartridge washing with MeOH and eluting with NH3 1M in MeOH [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by an [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan affording {4-fluoro[4-(3-fluorophenoxy)-6—(trifluoromethyl)pyrimidinyl]piperidinyl}methanamine (E13, 15 mg, y= 68%).
ES)(m/2):388.99[|VI+I-Il+— 1H NMR OFORM-d): 5 ppm 7.45 - 7.35 (m, 1 H), 7.06 -6.90 (m, 3 H), 6.39 (s, 1 H), 4.44 (br. s., 2 H), 3.23 (t, 2 H), 2.86 (s, 1 H), 2.81 (s, 1 H), 2.02- 1.87 (m, 2 H), 1.65 - 1.41 (m, 2 H) Preparation 31: tert-butyl N-({1-[3-fluoro(3-fluorophenoxy)phenyl]hydroxypiperidin yl}methyl)carbamate (P31) F OQF To a stirred on of tert—butyl N-[(4-hydroxypiperidinyl)methyl]carbamate (P28, 50 mg, 0.217 mmol) and 1-bromofluoro(3-fluorophenoxy)benzene (P3, 62 mg, 0.21 mmol) in DME (2 mL) at RT, DavePhos (8.5 mg, 0.0217 mmol), Pd2(dba)3 (6 mg, 0.007 mmol) and K3P04 (92 mg, 0.434 mmol) were added and nitrogen was purged for 10 min. Then the reaction was shaken at 110 °C overnight. The reaction mixture was partitioned between water and EtOAc, organic phase was separated, dried and concentrated under reduced pressure. Crude material was purified by FC on silica gel (eluent: Cy to Cy/AcOEt 70/30) affording tert—butyl N-({1-[3-fluoro(3-fluorophenoxy)phenyl]hydroxypiperidin yl}methyl)carbamate (P31, 37 mg, y= 39 %), as yellow oil.
MS (ES) (m/z): 435.3 .
Example 14: 4-(aminomethyl)[3-fluoro(3-fluorophenoxy)phenyl]piperidinol (E14) TFA (0.2 mL) was added to a solution of utyl N-({1-[3-fluoro(3-fluorophenoxy)phenyl] hydroDeridinyl}methyl)carbamate (P31, 37 mg, 0.085 mmol) in DCM (3 mL). The mixture was stirred for 1 h at RT, and then the solvent was removed under reduced pressure. The residue was ation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] an Unmarked set by an [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan charged on SCX cartridge eluting with 1M NH3 in MeOH to afford 4-(aminomethyl)[3-fluoro(3- fluorophenoxy)phenyl]piperidinol (E14, 28 mg, y= 98%) as pale yellow oil.
MS (ES) (m/z): 335.2 [M+H]+ 1H NMR (CHLOROFORM-d): 6 ppm 7.36 - 7.26 (m, 1H), 6.89 - 6.79 (m, 2H), 6.75 (d, 1H), 6.47 - 6.37 (m, 2H), 6.16 (d, 1H), 3.48 (d, 2H), 3.24 (t, 2H), 2.70 (br. s., 2H), 1.74 - 1.54 (m, 4H) Preparation 32: utyl N-({1-[2,5-difluoro(3-fluorophenoxy)phenyl]hydroxypiperidin yl}methyl)carbamate (P32) H0 N)00 To a stirred on of tert—butyl N-[(4-hydroxypiperidinyl)methyl]carbamate (P28, 50 mg, 0.217 mmol) and 1-bromo-2,5-difluoro(3-fluorophenoxy)benzene (P5, 66 mg, 0.217 mmol) in DME (2 mL) at RT, DavePhos (8.5 mg, 0.0217 mmol), Pd2(dba)3 (6 mg, 0.007 mmol) and K3P04 (92 mg, 0.434 mmol) were added and en was purged for 10 min. The reaction mixture was shaken at 110 °C overnight.
The reaction mixture was partitioned between water and EtOAc, organic phase was separated, dried and concentrated under reduced pressure. Crude material was purified by FC on silica gel (e|uent: Cy to Cy 70/AcOEt 30) affording tert—butyl N-({1-[2,5-difluoro(3-fluorophenoxy)phenyl]hydroxypiperidin- 4-y|}methyl)carbamate (P32, 10 mg, y= 10%), as yellow oil.
MS (ES) (m/z): 453.3 [M+H]+.
Example 15: 4-(aminomethyl)[2,5-difluoro(3-fluorophenoxy)phenyl]piperidinol (E15) TFA (ODL) was added to a solution of tert—butyl N-({1-[2,5-difluoro(3-fluorophenoxy)phenyl] hydroxypiperidinyl}methy|)carbamate (P32, 10 mg, 0.022 mmol) in of DCM (3 mL). The mixture was [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan ionNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan stirred for 1h at RT, and then the solvent was removed under reduced pressure. The residue was charged on SCX cartridge eluting with 1M NH3 in MeOH to afford 4-(aminomethyl)[2,5-difluoro(3- fluorophenoxy)phenyl]piperidinol (E15, 7 mg, y= 90%) as colorless oil.
MS (ES) (m/z): 353.2 [M+H]+. 1H NMR (CHLOROFORM-d): 6 ppm 7.33 - 7.23 (m, 1H), 6.87 - 6.75 (m, 2H), 6.71 (d, 1H), 6.55 (br. s., 1H), 6.40 (br. s., 1H), 3.28 (br. s., 2H), 3.13 (br. s., 2H), 2.68 (br. s., 2H), 1.69 (br. s., 4H) Preparation 33: tert-butyl N-{[1-(2-fluorophenoxyphenyl)hydroxypiperidin yl]methy|}carbamate (P33) H0 N)00 To a stirred solution of utyl N-[(4-hydroxypiperidinyl)methyl]carbamate (P28, 50mg, 0.217mmol) and 1-bromofluorophenoxybenzene (P6, 58 mg, 0.217 mmol) in DME (2 mL) at RT, DavePhos (8.5 mg, 0.0217 mmol), Pd2(dba)3 (6 mg, 0.007 mmol) and K3P04 (92 mg, 0.434 mmol) were added and nitrogen was purged for 10 min. The reaction was then shaken at 110 °C overnight. The e was partitioned n water and EtOAc, c phase was separated, dried and concentrated under reduced pressure. The crude material was purified by FC on silica gel (eluent: Cy to Cy70/AcOEt 30) affording tert—butyl N-{[1-(2-fluorophenoxyphenyl)hydroxypiperidin yl]methy|}carbamate (P33, 30 mg, y= 33%), as yellow oil.
MS (ES) (m/z): 417.3 [M+H]+ Example 16: 4-(aminomethyl)(2-fluorophenoxyphenyl)piperidinol (E16) [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan ation] Mel.Chan Unmarked set by Mel.Chan TFA (0.3 mL) was added to a solution of tert—butyl N-{[1-(2-fluorophenoxyphenyl)hydroxypiperidin- 4-yl]methyl}carbamate (P33, 30 mg, 0.72 mmol) in DCM (3 mL). The mixture was stirred at RT for 1 h, and then the solvent was removed under reduced pressure. The residue was charged on SCX dge e|uting with 1M NH3 in MeOH to afford 4-(aminomethyl)(2-fluorophenoxyphenyl)piperidinol (E16, 18 mg, y= 80 %) as colorless oil.
MS (ES) (m/z): 317.2 [M+H]+ 1H NMR (CHLOROFORM-d): 6 ppm 7.34 (t, 2H), 7.09 (t, 1H), 7.01 (d, 3H), 6.84 (t, 1H), 6.70 (t, 1H), 3.30 (d, 2H), 3.23 - 3.08 (m, 2H), 2.70 (s, 2H), 1.78 - 1.64 (m, 4H) ation 34: utyl N-({1-[2-fluoro(3-fluorophenoxy)phenyl]hydroxypiperidin yl}methyl)carbamate (P34) N F To a d solution of tert—butyl N-[(4-hydroxypiperidinyl)methyl]carbamate (P28, 50 mg, 0.217 mmol) and 1-bromofluoro(3-fluorophenoxy)benzene (P7, 62 mg, 0.217 mmol) in DME (2 mL) at RT, DavePhos (8.5 mg, 0.0217 mmol), Pd2(dba)3 (6 mg, 0.007 mmol) and K3P04 (92 mg, 0.434 mmol) were added and nitrogen was purged for 10 min. The reaction was then shaken at 110 °C ght. The mixture was partitioned between water and EtOAc, organic phase was separated, dried and concentrated under reduced pressure. Crude material was purified by FC on silica gel (eluent: Cy to Cy 65/AcOEt 35) affording tert—butyl [2-fluoro(3-fluorophenoxy)phenyl]—4-hydroxypiperidin yl}methyl)carbamate (P34, 30 mg, y= 32%), as yellow oil.
MS (ES) (m/z): 435.3 [M+H]+.
Example 17: 4-(aminomethyl)[2-fluoro(3-fluorophenoxy)phenyl]piperidinol (E17) [Annotation] Mel.Chan None set by Mel.Chan ation] Mel.Chan ionNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan TFA (0.3 mL) was added to a solution of tert—butyl N-({1-[2-fluoro(3-fluorophenoxy)phenyl] hydroxypiperidinyl}methyl)carbamate (P34, 30 mg, 0.069 mmol) in of DCM (3 mL). The mixture was stirred for 1 h at RT, and then the solvent was removed under reduced pressure. The residue was charged on SCX cartridge e|uting with 1M NH3 in MeOH to afford nomethyl)[2-fluoro(3- fluorophenoxy)phenyl]piperidinol (E17, 18 mg, y= 78 %) as colourless oil.
MS (ES) (m/z): 335.2 [M+H]+. 1H NMR (CHLOROFORM-d): 6 ppm 7.29 - 7.23 (m, 1H), 7.09 - 7.00 (m, 1H), 6.87 (dd, 1H), 6.83 - 6.65 (m, 4H), 3.35 - 3.26 (m, 2H), 3.21 - 3.11 (m, 2H), 2.70 (br. s., 2H), 1.82 (t, 2H), 1.71 (br. s., 2H) Preparation 35 and 36: tert-butyl N-({1-[2,3-difluoro(3-fluorophenoxy)phenyl]hydroxypiperidin- 4-yl}methyl)carbamate (P35) and tert-butyl N-({1-[3,4-difluoro(3-fluorophenoxy)phenyl] hydroxypiperidinyl}methyl)carbamate (P36) HO Boc HEjN/BOCH if . 13L 0 F o F F o F F To a stirred solution of utyl hydroxypiperidinyl)methyl]carbamate (P28, 106 mg, 0.46mmol) and a mixture "1:1 of 1-bromo-2,3-difluoro(3-fluorophenoxy)benzene and 5-bromo-1,2- ro(3-fluorophenoxy)benzene (P4, 140 mg, 0.46 mmol) in DME (3 mL) at RT, DavePhos (18 mg, 0.046 mmol), Pd2(dba)3 (13 mg, 0.014 mmol) and K3P04 (195 mg, 0.92 mmol) were added, then nitrogen was purged for 10 min and the mixture heated to 100 °C and stirred at that temperature overnight. The on mixture was partitioned between water and EtOAc, organic phase was separated, dried and concentrated under reduced pressure. The crude material was ed by FC on silica gel (eluent: Cy to Cy/AcOEt 60/40) affording tert—butyl N-({1-[2,3-difluoro(3-fluorophenoxy)phenyl]hydroxypiperidin- 4-yl}methyl)carbamate (P35, 68mg, y=32%), as yellow solid and tert—butyl N-({1-[3,4-difluoro(3- fluorophenoxy)phenyl]hydroxypiperidinyl}methy|)carbamate (P36, 56mg, y= 26%) as yellow oil.
MS (ES) (m/z): 453.28 [M+H]+.
[Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan ation] Mel.Chan Unmarked set by Mel.Chan [Annotation] an None set by Mel.Chan [Annotation] an MigrationNone set by Mel.Chan ation] Mel.Chan Unmarked set by Mel.Chan Example 18: 4-(aminomethyl)[2,3-difluoro(3-fluorophenoxy)phenyl]piperidinol (E18) TFA (0.5 mL) was added to a solution of tert—butyl N-({1-[2,3-difluoro(3-fluorophenoxy)phenyl] hydroxypiperidinyl}methyl)carbamate (P35, 68 mg, 0.15 mmol) in DCM (3 mL) and the resulting mixture was stirred at RT for 1 h.
Solvent was removed in vacuum and the residue was charged on SCX cartridge eluting with MeOH and 1M NH3 in MeOH. After evaporation 4-(aminomethyl)[2,3-difluoro(3- fluorophenoxy)phenyl]piperidinol (E18, 50 mg, y= 94%) was obtained as yellow oil.
MS (ES) (m/z): 353.26 [M+H]+ 1H NMR (CHLOROFORM-d): 6 ppm 7.37 - 7.30 (m, 1H), 6.90 - 6.76 (m, 2H), 6.72 (d, 1H), 6.53 - 6.39 (m, 2H), 3.38 - 3.22 (m, 2H), 3.12 (br. s., 2H), 2.69 (br. s., 2H), 1.69 (br. s., 4H) e 19: 4-(aminomethyl)[3,4-difluoro(3-fluorophenoxy)phenyl]piperidinol (E19) TFA (0.5 mL) was added to a solution of tert—butyl N-({1-[3,4-difluoro(3-fluorophenoxy)phenyl] hydroxypiperidinyl}methyl)carbamate (P44, 56 mg, 0.15 mmol) in DCM (3 mL), the resulting mixture was stirred at RT for 1 h. Solvent was removed in vacuum and the residue was charged on SCX cartridge eluting with MeOH and 1M NH3 in MeOH. After evaporation 4-(aminomethyl)[3,4-difluoro(3- fluorophenoxy)phenyl]piperidinol (E19, 44 mg, y= quant) was obtained as yellow oil MS : 353.26 [M+H]+ 1H NMR (CHLOROFORM-d): 6 ppm 7.36 - 7.23 (m, 1H), 6.89 - 6.76 (m, 2H), 6.73 (d, 1H), 6.60 (dd, [Annotation] Mel.Chan None set by Mel.Chan ation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan ation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by an 1H), 6.44 (br. s., 1H), 3.36 (d, 2H), 3.15 (t, 2H), 2.67 (br. s., 2H), 1.73 - 1.58 (m, 4H) Preparation 37: (4-aminobenzylpiperidinyl)methanol (P37) LiAlH4 2M in THF (4.27 mL, 8.54 mmol) was added to a solution of 4-aminobenzylpiperidine carboxylic acid (500 mg, 2.13 mmol) in THF (12 mL) at 0 °C and then the mixture was refluxed for 2 hrs The stirred reaction mixture was cooled down to -10°C and NaZSO4*10HZO was carefully added portion- wise up to fizz end. The mixture was left stirring at RT for 30 min, then it was filtered; the solid was washed with DCM and the solvent concentrated under reduced pressure to give (4-amino benzylpiperidinyl)methanol (P37, 400 mg, y= 85%) that was used as such.
MS (ES) (m/z): 221.2 [M+H]+.
Preparation 38: utyl N-[1-benzyl(hydroxymethyl)piperidinyl]carbamate (P38) (4-aminobenzylpiperidinyl)methanol (P37, 400 mg, 1.81 mmol) was dissolved in DCM (10 mL), TEA (0.4 mL, 2.71 mmol) was added followed by a solution of Boczo (435 mg, 1.99 mmol) in DCM (5 mL).The resulting solution was stirred at RT for 2 hrs. NH4C| was added; the organic phase was separated, dried and concentrated. The residue was purified by FC on NH column (eluent: Cy to Ac 40/60) affording utyl N-[1-benzyl(hydroxymethyl)piperidinyl]carbamate (P38, 300 mg, y= 52%) as white solid.
MS (ES) (m/z): 321.2 [M+H]+.
[Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan Preparation 39: tert-butyl N-[4-(hydroxymethyl)piperidinyl]carbamate (P39) To a solution of tert—butyl N-[1-benzyl(hydroxymethyl)piperidinyl]carbamate (P38, 300 mg, 0.936 mmol) in MeOH (7 mL) ammonium formate (354 mg, 5.62 mmol) and 10% Pd/C (90 mg) were added at RT then the mixture was stirred under reflux for 1 h. The mixture was cooled down to RT and filtered h a pad of celite washing with MeOH. Solvent was eliminated under reduced re affording tert—butyl N-[4-(hydroxymethyl)piperidinyl]carbamate (P39, 200 mg, y= 93%) as white solid.
MS (ES) (m/z): 231.2 [M+H]+. ation 40: tert-butyl N-{1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin-Z-yl] (hydroxymethyl)piperidinyl}carbamate (P40) tert—butyl N-[4-(hydroxymethyl)piperidinyl]carbamate (P39, 75 mg, 0.326 mmol), 2-chloro(3- phenoxy)(trifluoromethyl)pyrimidine (P2, 95 mg, 0.326 mmol) and K2C03 (59 mg, 0.424 mmol) were mixed in dry DMSO (2 mL) and the mixture was shaken at 60 °C for 1 h. The mixture was cooled down, diluted with EtOAc and water. The organic phase was washed several times with brine, dried, filtered and evaporated. Crude material was purified by FC on silica gel (eluent: Cy to Ac 75/25) affording utyl N-{1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl] (hydroxymethyl)piperidinyl}carbamate (P40, 90 mg, y= 57%), as white solid.
MS (ES) (m/z): 487.3 [M+H]+.
[Annotation] Mel.Chan None set by Mel.Chan [Annotation] an ionNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by an [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan ionNone set by Mel.Chan ation] Mel.Chan Unmarked set by Mel.Chan Example 20: {4-amino[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidin yl}methanol (E20) Ho/Ej TFA (0.5 mL) was added to a solution of tert—butyl N-{1-[4-(3-fluorophenoxy) (trifluoromethyl)pyrimidinyl](hydroxymethyl)piperidinyl}carbamate (P40, 90 mg, 0.185 mmol) in 8 mL of DCM. The mixture was stirred at RT for 1 h, and then the solvent was removed under reduced pressure. The residue was charged on SCX cartridge eluting with 1M NH3 in MeOH to afford {4-amino [4-(3-fluorophenoxy)(trifluoromethyl)pyrimidiny|]piperidiny|}methano| (E20, 50 mg, y= 70%) MS (ES) (m/z): 387.2 [M+H]+ 1H NMR (DMSO-ds): 6 ppm 7.57 - 7.47 (m, 1H), 7.26 (td, 1H), 7.22 - 7.08 (m, 2H), 6.65 - 6.56 (m, 1H), 4.59 (br. s., 1H), 4.21 (br. s., 2H), 3.85 (br. s., 2H), 3.12 (br. s., 2H), 1.52 (br. s., 2H), 1.39 (br. s., 2H), 1.25 (br. s., 2H) Example 21: N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidin yl}methyl)methylpropanamide (E21) N N o F To a on of isobutyric acid (5 uL, 0.054 mmol) in DCM (2 mL) EDCOHCI (11 mg, 0.057 mmol), HOBt (14 mg, 0.103 mmol) and TEA (14 uL, 0.103 mmol) were added. After 10 min at RT, 4-(aminomethy|) [4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidinol (E12, 20 mg, 0.0517 mmol) was added. The resulting solution was stirred at RT for 4 hrs. Solvent was evaporated and the residue was purified by FC on Silica gel (eluent: Cy to Cy/AcOEt 20/80) affording N-({1-[4-(3-fluorophenoxy) (trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methyl)methy|propanamide (E21, 18.5 mg, y= 78%) as white solid MS (ES) (m/z): 457.16 [M+H]+ 1H NMDMSO-ds): 6ppm 7.65 (t, 1H), 7.57-7.47 (m, 1H), 7.25 (dd, 1H), 7.20-7.10 (m, 2H), 6.62 (s, 1H), 4.64 (s, 1H), 4.23 (br. s., 1H), 3.83 (br. s., 1H), 3.15 (br. s., 2H), 3.05 (d, 2H), 2.42 (dt, 1H), 1.36 [Annotation] an None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] an Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] an Unmarked set by Mel.Chan (br. s., 4H), 0.97 (d, 6H) Example 22: 2-cyclopropyl-N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl] hydroxypiperidinyl}methyl)acetamide (E22) N N o F To a solution of cyclopropylacetic acid (7.5 uL, 0.081 mmol) in DCM (2 mL) EDCOHCI (16.5 mg, 0.086 mmol), HOBt (21 mg, 0.156 mmol) and TEA (22 uL, 0.156 mmol) were added. After 10min at RT, 4- (aminomethyl)[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidinol (E12, 30 mg, 0.078 mmol) was added. The ing solution was stirred at RT for 4 hrs. Solvent was evaporated and the residue was purified by FC on Silica gel (eluent: Cy to Cy/AcOEt 20/80) affording 2-cyclopropyl-N-({1- [4-(3-fluorophenoxy)-6 (trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methyl)acetamide as white solid (E22, 7.5 mg, y= 21%) MS (ES) (m/z): 469.05 [M+H]+. 1H NMR OFORM-d): 6 ppm 7.46-7.34 (m, 1H), 7.06 -6.88 (m, 3H), 6.41 (br. s., 1H), 6.35 (s, 1H), 4.46 (br. s., 1H), 4.13 (br. s., 1H), 3.42 (br. s., 4H), 2.26 (br. s., 2H), 1.63 (br. s., 3H), 1.50 (br. s., 2H), 1.01 (br. s., 1H), 0.68 (br. s., 2H), 0.25 (br. s., 2H) Example 23: N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidin yl}methyl)(propanyloxy)acetamide (E23) N N O F To a Sign of isopropyloxyacetic acid (9.6 mg, 0.081 mmol) in DCM (2 mL) EDCOHCI (16.5 mg, 0.086 mmol), Bt (21 mg, 0.156 mmol) and TEA (22 uL, 0.156 mmol) were added. After 10 min at RT, 4- [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan ed set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] an Unmarked set by Mel.Chan (aminomethyl)[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidiny|]piperidinol (E11, 30 mg, 0.078 mmol) was added. The resulting solution was stirred at RT for 4 hrs. Solvent was evaporated and the residue was purified by FC on Silica gel (eluent: Cy to Cy/AcOEt 20/80) affording N-({1-[4-(3- fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methy|)(propan yloxy)acetamide as white solid (E23, 23.5 mg, y= 62%) MS (ES) (m/z): 487.07 [M+H]+ 1H NMR (CHLOROFORM-d): 6 ppm 7.44-7.31 (m, 1H), 7.06 -6.88 (m, 4H), 6.35 (s, 1H), 4.41 (br. s., 1H), 4.15 (d, 1H), 3.99 (s, 2H), 3.69 (spt, 1H), 3.34 (d, J=6.0 Hz, 4H), 1.63 (d, 2H), 1.49 (br. s., 2H), 1.28-1.15 (m, 6H) Example 24: N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidin yl}methyl)acetamide (E24) N N o F To a solution of acetic acid (4.7 (1L, 0.078 mmol) in DCM (2 mL) EDCOHCI (16.5 mg, 0.086 mmol), HOBt (21 mg, 0.156 mmol) and TEA (22 (1L, 0.156 mmol) were added. After 10 min at RT, nomethy|) [4-(3-fluorophenoxy)(trifluoromethy|)pyrimidinyl]piperidinol (E11, 30 mg, 0.078 mmol) was added. The resulting solution was d at RT for 4 hrs. Solvent was evaporated and the residue was purified by FC on Silica gel t: Cy to Cy/AcOEt/MeOH 0/90/10) affording N-({1-[4-(3- fluorophenoxy)(trifluoromethy|)pyrimidinyl]hydroxypiperidinyl}methy|)acetamide as white solid (E24, 26 mg, y= 77%) MS (ES) (m/z): 429.05 [M+H]+ 1H NMR (DMSO-ds): 6 ppm 7.74 (t, 1H), 7.47-7.58 (m, 1H), 7.22-7.31 (m, 1H), 7.09-7.22 (m, 2H), 6.62 (s, 1H), 4.61 (s, 1H), 4.24 (br. s., 1H), 3.87 (br. s., 1H), 3.19 (d, 2H), 3.06 (d, 3H), 1.84 (s, 3H), 1.39 (br. s., 4H) [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by an [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan ation 41: tert-butyl 3-[({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin-Z-yl] ypiperidinyl}methyl)carbamoyl]azetidinecarboxylate (P41) N N O F ll 10 l: H To a on of 1-Boc-azetidinecarboxylic acid (82 mg, 0.4 mmol) in DCM (6 mL) EDCOHCI (82 mg, 0.423 mmol), HOBt (105 mg, 0.776 mmol) and TEA (108 uL, 0.776 mmol) were added. After 10 min at RT, 4-(aminomethyl)[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidinol (E11, 150 mg, 0.388 mmol) was added. The resulting solution was d at RT for 12 hrs. Solvent was evaporated and the residue was purified by FC on Silica gel (eluent: Cy to AcOEt) affording tert—butyl 3-[({1-[4-(3- fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methyl)carbamoyl]azetidine- oxylate (P41, 90 mg, y= 40%) as white foam.
MS (ES) (m/z): 570.3 [M+H]+ Example 25: N-({1-[4-(3-f|uorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidin y|}methyl)azetidinecarboxamide (E25) N \O F?MO‘ QF To a solution of tert—butyl 3-[({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl] hydroxypiperidinyl}methyl)carbamoyl]azetidinecarboxylate (P41, 85 mg, 0.15 mmol) in DCM (5 mL). 0.8 mL of TFA was added and the solution stirred at RT for 1 h. Solvent and TFA excess was evaporated under reduced pressure and the residue was charged on SCX cartridge eluting with 1M NH3 in MeOH. After evaporation N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl] hydroxypiperidinyl}methyl)azetidinecarboxamide (E25, 70 mg, y= 99%) was obtained as white solid.
MS (Em/z): 470.06 [M+H]+ [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by an [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] an Unmarked set by an 1H NMR (DMSO-ds): 6 ppm 7.65 (t, 1H), 7.59-7.46 (m, 1H), 7.31-7.22 (m, 1H), 7.22-7.10 (m, 2H), 6.62 (s, 1H), 4.62 (s, 1H), 4.25 (br. s., 1H), 3.86 (br. s., 1H), 3.726-3.56 (m, 2H), 3.46-3.36 (m, 3H), 3.18 (br. s., 2H), 3.09 (d, 2H), 1.38 (br. s., 4H) Example 26: N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidin yl}methyl)benzamide (E26) N o F To a solution of benzoic acid (16 mg, 0.135 mmol) in DCM (2 mL) I (27 mg, 0.057 mmol), HOBt (35 mg, 0.258 mmol) and TEA (36 uL, 0.258 mmol) were added. After 20 min at RT, 4-(aminomethyl) [4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidinol (E11, 50 mg, 0.129 mmol) was added. The resulting solution was stirred at RT for 8 hrs. Solvent was ated and the residue was purified by FC on Silica gel (eluent: Cy to Cy/AcOEt 20/80) affording [4-(3-fluorophenoxy) (trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methy|)benzamide (E26, 50 mg, y= 79%) as white solid.
MS (ES) (m/z): 491.21 [M+H]+. 1H NMR (DMSO-ds): 6ppm 8.31 (t, 1H), 7.85 (d, 2H), 7.58-7.41 (m, 4H), 7.25 (dt, 1H), 7.20-7.08 (m, 2H), 6.61 (s, 1H), 4.76 (s, 1H), 4.29 (br. s., 1H), 3.90 (br. s., 1H), 3.30 (d, 2H), 3.16 (br. s., 2H), 1.45 (br. s., 4H) Example 27: N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidin yl}methyl)-1H-pyrazolecarboxamide (E27) To a solution of 1H-pyrazolecarboxylic acid (14.5 mg, 0.135 mmol) in DCM (2 mL) EDCOHCI (27 mg, 0.057 mmol), HOBt (35 mg, 0.258 mmol) and TEA (36 uL, 0.258 mmol) were added. After 20 min at RT, 4-(amigethyl)[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidinol (E11, 50 mg, 0.129 mmol) was added. The resulting solution was stirred at RT for 3 hrs. Solvent was evaporated and [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] an Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan the residue was ed by FC on Silica gel (eluent: Cy to AcOEt) affording [4-(3-fluorophenoxy) (trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methyl)-1H-pyrazolecarboxamide (E27, 30 mg, y= 48%) MS (ES) (m/z): 481 [M+H]+ 1H NMR (DMSO-ds): 6 ppm 13.11 (br. s., 1H), 8.21 (br. s., 1H), 7.94 (t, J=6.0 Hz, 2H), 7.57-7.45 (m, 1H), 7.26 (d, 1H), 720-7. 05 (m, 2H), 6.61 (s, 1H), 4.75 (s, 1H), 4.27 (br. s., 1H), 3.88 (br. s., 1H), 3.23 (d, 4H), 1.42 (br. s., 4H) Example 28: N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidin yl}methyl)pyrazinecarboxamide (E28) N N O F N H 10 To a solution of Pyrazinecarboxylic acid (17 mg, 0.135 mmol) in DCM (2 mL) EDCOHCI (27 mg, 0.057 mmol), HOBt (35 mg, 0.258 mmol) and TEA (36 (1L, 0.258 mmol) were added. After 20 min at RT, 4- (aminomethyl)[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidinol (E11, 50 mg, 0.129 mmol) was added. The resulting solution was stirred at RT for 3 hrs. Solvent was evaporated and the residue was purified by FC on Silica gel (eluent: Cy to AcOEt) affording N-({1-[4-(3-fluorophenoxy) (trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methy|)pyrazinecarboxamide (E28, 17 mg, y= MS (ES) (m/z) 493.02 [M+H]+ 1H NMR ds): 6 ppm 9.20 (d, 1H), 8.89 (d, 1H), 8.75 (s, 1H), 8.63 (t, 1H), 7.57-7.44 (m, 1H), 7.25 (d, 1H), 7.21-7.10 (m, 2H), 6.62 (s, 1H), 4.89 (s, 1H), 4.27 (br. s., 1H), 3.86 (br. s., 1H), 3.37 (br. s., 2H), 3.18 (br. s., 2H), 1.46 (br. s., 4H) Preparation 42: tert-butyl 1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl] hydroxypiperidinyl}methyl)carbamoyl]methyl}carbamate (P42) [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by an [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan To a solution of N-Boc-Gly (22.6 mg, 0.129 mmol) in DCM (2 mL) EDCOHCI (27 mg, 0.057 mmol), HOBt (35 mg, 0.258 mmol) and TEA (36 uL, 0.258 mmol) were added. After 20 min at RT, nomethyl)[4-(3- fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidinol (E11, 50 mg, 0.129 mmol) was added.
The ing solution was stirred at RT for 3 hrs. Solvent was evaporated and the residue was purified by FC on Silica gel (eluent: Cy to AcOEt) affording tert—butyl N-{[({1-[4-(3-fluorophenoxy) (trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methyl)carbamoyl]methyl}carbamate (P42, 26 mg, y= 37%) MS (ES) (m/z): 544.1 [M+H]+.
Example 29: 2-amino-N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin-Z-yl] hydroxypiperidinyl}methyl)acetamide (E29) N N o F H2N\/\ N To a solution of tert—butyl N-{[({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl] hydroxypiperidinyl}methyl)carbamoyl]methyl}carbamate (P42, 26 mg, 0.048 mmol) in DCM (2 mL) TFA was added and the solution was stirred at RT for 1 hr. Solvent and excess of TFA were removed under reduced pressure and the residue was dissolved in MeOH and loaded on a SCX cartridge g with MeOH and eluting with NH3 2M in MeOH. ing o-N-({1-[4-(3-fluorophenoxy) (trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methyl)acetamide (E29, 18 mg, y= 84%).
MS (ES) (m/z): 444.01 [M+H]+ 1H NMR (DMSO-ds):6 ppm 7.81 (br. s., 1 H) 7.58 - 7.45 (m, 1 H) 7.25 (t, 1 H) 7.27 (t, 1 H) 7.22 - 7.09 (m, 2 H) 6.62 (s, 1 H) 4.71 (s, 1 H) 4.21 (br. s., 2 H) 3.83 (br. s., 2 H), 3.17 -2.96 (m, 4 H) 1.99 (br. s., 2 H) 1.39 (br. s., 4 H) ation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] an Unmarked set by Mel.Chan Preparation 43: 5-benzyloxaazaspiro[2.4]heptane (P43) To an ice-cooled mixture of NaH 60% dispersion in mineral oil (0.297 g, 7.42 mmol.) and trimethylsulfoxonium iodide (1.38 g, 6.28 mmol) was added DMSO (5 mL) keeping the mixture at 10 °C.
After stirred for 10 min at 10 °C, it was allowed to reach RT and left stirring at that temperature for 1 h.
A solution of 1-benzylpyrrolidinone (0.92 mL, 5.71 mmol.) in DMSO (5 mL) was added via syringe. The mixture was stirred for 3 hrs at RT, diluted with EtZO and quenched by the addition of saturated aqueous NH4CI. Phases were ted and aqueous one was backextracted with EtZO. Combined organics were dried, filtered and concentrated under reduced pressure. Crude 5-benzyloxa azaspiro[2.4]heptane (P43, 850 mg, y= 79%) was used as such in next step.
MS (ES) (m/z): 427.2 [M+H]+.
Preparation 44: 1-benzyl[(cyclopropylamino)methyl]pyrrolidinol (P44) Ho NA To a stirred solution of 5-benzyloxaazaspiro[2.4]heptane (P43, 200 mg, 1.06 mmol) in MeOH (1 mL), at 0 °C, cyclopropylamine (0.15 mL, 2.11 mmol) was added dropwise. Once the addition was complete, the ice-bath was removed and the resulting reaction mixture was stirred at RT ght.
Then, reaction mixture was trated under d pressure, the residue was taken up with DCM, the s phase was extracted and then the ed organics were dried and concentrated under reduced pressure to afford 1-benzyl[(cyclopropylamino)methyl]pyrrolidinol (P44, 160 mg, y= 61%).
MS (ES) (m/z): 247.1 [M+H]+.
—D— [Annotation] Mel.Chan None set by Mel.Chan ation] Mel.Chan MigrationNone set by an ation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] an Unmarked set by Mel.Chan Preparation 45: tert-butyl N-[(1-benzylhydroxypyrrolidinyl)methyl]-N-cyclopropylcarbamate (P45) 1-benzyl[(cyclopropylamino)methyl]pyrrolidinol (P44, 160 mg, 0.649 mmol) was dissolved in DCM (2 mL), TEA (0.14 mL, 0.974 mmol) was added followed by a solution of Boczo (170 mg, 0.779 mmol) in DCM (1 mL).The resulting solution was stirred at RT for 2 hrs. NH4C| was added; the organic phase was separated, dried and concentrated. The residue was purified by FC on Silica gel t: Cy to Cy/AcOEt 70/30) affording tert—butyl N-[(1-benzylhydroxypyrrolidinyl)methyl]-N-cyclopropylcarbamate (P45, 110 mg, y= 50%) as colorless oil.
MS (ES) (m/z): 347.2 [M+H]+.
Preparation 46: tert-butyl N-cyclopropyl-N-[(3-hydroxypyrrolidinyl)methyl]carbamate (P46) To a on of tert—butyl N-[(1-benzylhydroxypyrrolidinyl)methyl]-N-cyclopropylcarbamate (P45, 110 mg, 0.317 mmol) in MeOH (3 mL) ammonium formate (120 mg, 1.90 mmol) and 10% Pd/C (32 mg) were added at RT, then the mixture was stirred under reflux for 1 h. The mixture was then cooled down to RT and filtered through a pad of celite washing with MeOH. Solvent was eliminated under reduced pressure affording tert—butyl N-cyclopropyl-N-[(3-hydroxypyrrolidinyl)methyl]carbamate (P46, 75 mg, y= 75V colourless oil.
MS (E m/z): 257.2 [M+H]+.
[Annotation] Mel.Chan None set by Mel.Chan [Annotation] an MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan ation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan ionNone set by an [Annotation] Mel.Chan Unmarked set by Mel.Chan Preparation 47: tert-butyl N-cyclopropyl-N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin yl]hydroxypyrrolidinyl}methyl)carbamate (P47) O 0 HO ;; 2-chloro(3-fluorophenoxy)(trifluoromethyl)pyrimidine (P2, 85 mg, 0.293 mmol), tert—butyl N- cyclopropyl-N-[(3-hydroxypyrrolidinyl)methyl]carbamate (P46, 75 mg, 0.293 mmol) and K2C03 (53 mg, 0.381 mmol) were mixed in dry DMSO (2 mL) and the mixture was shaken at 60 °C for 1 hr. The mixture was diluted with EtOAC and water. The organic phase was washed several times with brine, dried, filtered and evaporated. Crude material was purified by FC on NH column (eluent: Cy to Cy/AcOEt 85/15) ing tert—butyl N-cyclopropyl-N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]- 3-hydroxypyrrolidinyl}methyl)carbamate (P47, 80 mg, y= 53%).
MS (ES) (m/z): 513.2 [M+H]+.
Example 30: 3-[(cyclopropylamino)methy|][4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin yl]pyrrolidinol (E30) .0{EN/H"W cu=3 F TFA (0.3 mL) was added to a solution of tert—butyl N-cyclopropyl-N-({1-[4-(3-fluorophenoxy) (trifluoromethyl)pyrimidinyl]hydroxypyrrolidinyl}methyl)carbamate (P47, 60 mg, 0.117 mmol) in 3 mL 06M. The mixture was stirred at RT for 1 h, and then the solvent was removed under reduced pressu . he residue was charged on SCX cartridge eluting with 1M NH3 in MeOH to afford 3- [Annotation] Mel.Chan None set by an [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] an None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [(cyclopropylamino)methyl][4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin-Z-yl]pyrrolidinol (E30, 40 mg, y= 83%) as colorless oil.
|\/IS(ES)(m/2):413.18[|VI+I-Il+— 1H NMR (CHLOROFORM-d): 6 ppm 7.44- 7.33 (m, 1H), 7.05 -6.89 (m, 3H), 6.37 (d, 1H), 3.91- 3.66 (m, 2H), 3.60 -3.40 (m, 2H), 3.26 (d, 1H), 3.04- 2.86 (m, 2H), 2.34- 2.18(m,1H),2.02- 1.78 (m, 3H), 0.60- 0.35 (m, 4H) Examples 31 and 32: (35 or 3R)[(cyclopropylamino)methyl][4-(3-fluorophenoxy) (trifluoromethyl)pyrimidin-Z-yl]pyrrolidinol (E31) and (3R or 3S)[(cyclopropylamino)methyl] [4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]pyrrolidinol (E32) HO A A N How," N H H N N N O F N O F / / | | N\ N\ CF3 CF3 3-[(cyclopropylamino)methyl][4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]pyrrolidinol (E30, 30 mg) was submitted to chiral prep HPLC to separate single enantiomers.
Preparative HPLC conditions and results: Column pak AD-H (25 x 2.0 cm), 5 )1 Mobile phase n-Hexane/(Ethanol+0.1% isopropylamine) 75/25 % v/v Flow rate n) 14 mL/min DAD detection 220 nm Loop 2000 uL Total amount 30 mg Solubilization 30 mg in 3.5 mL(Ethanol/Methanol1/1)/n-Hex 70/30 % v/v = 8.6 mg/mL Injection 17 mg/injection Affording: (35 or 3R)[(cyclopropylamino)methyl][4—(3-fluorophenoxy)(trifluoromethyl)pyrimidin rnol (E31,single enantiomer: enantiomer 1, 8.4 mg, y=28% ) 100% ee [Annotation] Mel.Chan None set by an [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan ation] Mel.Chan Unmarked set by Mel.Chan (3R or 3S)[(cyclopropylamino)methyl][4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin yl]pyrrolidinol (E32, single enantiomer: omer 2, 7.3 mg, y=24%) 100%ee Preparation 48: 3-(aminomethyl)benzylpyrrolidinol (P48) HO§NW To a stirred solution of 5-benzyloxaazaspiro[2.4]heptane (P43, 850 mg, 4.49 mmol) in MeOH (5 mL), at 0 °C, 28% aq. NH4OH (10 mL) was added dropwise. Once the addition was complete, the ice-bath was removed and the resulting reaction mixture was stirred at RT overnight. Then, reaction mixture was concentrated under reduced pressure, the residue was taken up with DCM, aqueous phase was back extracted with DCM, combined organics were dried and concentrated under d pressure to obtain 3-(aminomethyl)benzylpyrrolidinol (P56, 900 mg, y= quant.).
MS (ES) (m/z): 207.1 [M+H]+.
Preparation 49: tert-butyl N-[(1-benzylhydroxypyrrolidinyl)methyl]carbamate (P49) HO N 3-(aminomethyl)benzylpyrrolidinol (P48, 900 mg, 4.49 mmol) was dissolved in DCM (10 mL), TEA (0.94 mL, 6.74 mmol) was added followed by a solution of Boczo (1.18 g, 5.39 mmol) in DCM (5 mL).The ing solution was stirred at RT for 2 hrs. NH4C| was added; the organic phase was separated, dried and concentrated. The residue was purified by FC on Silica gel (eluent: Cy to AcOEt) affording utyl benzylhydroxypyrrolidinyl)methyl]carbamate (P49, 470 mg, y= 34%) as colorless oil.
MS (ES) (m/z): 307.2 [M+H]+.
[Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan Preparation 50: tert-butyl N-[(3-hydroxypyrrolidinyl)methyl]carbamate (P50) HO Boo To a solution of tert—butyl N-[(1-benzylhydroxypyrrolidinyl)methyl]carbamate (P49, 470 mg, 1.53 mmol) in MeOH (10 mL) ammonium e (580 mg, 9.20 mmol) and 10% Pd/C (155 mg) were added at RT then the mixture was stirred under reflux for 3 hrs. The e was cooled down to RT and filtered through a pad of celite washing with MeOH. Solvent was eliminated under reduced pressure ing tert—butyl N-[(3-hydroxypyrrolidinyl)methyl]carbamate (P50, 350 mg, y= quant.), as colourless oil.
MS (ES) (m/z): 217.1 .
Preparation 51: tert-butyl N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin-Z-yl] hydroxypyrrolidinyl}methyl)carbamate (P51) HO N} 2-chloro(3-fluorophenoxy)(trifluoromethyl)pyrimidine (P2, 200 mg, 0.925 mmol), utyl N-[(3- hydroxypyrrolidinyl)methyl]carbamate (P50, 291 mg, 0.925 mmol) and K2C03 (166 mg, 1.203 mmol) were mixed in dry DMSO (4 mL) and the mixture was shaken at 60 °C for 2 hr. The mixture was diluted with EtOAC and water. The organic phase was washed several times with brine, dried, filtered and concentrated. Crude material was purified by FC on Silica gel (eluent: Cy to Cy/AcOEt 80/20) affording tert—butyl N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypyrrolidin yl}methyl)carbamate (P51, 200 mg, y= 46%), as white solid.
MS (ES) (m/z): 473.2 [M+H]+.
[Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan ed set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] an MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan Example 33: 3-(aminomethyl)[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin-Z-yl]pyrrolidinol (E33) TFA (0.32 mL) was added to a solution of tert—butyl N-({1-[4-(3-fluorophenoxy) (trifluoromethyl)pyrimidinyl]hydroxypyrrolidinyl}methyl)carbamate (P51, 200 mg, 0.423 mmol) in 8 mL of DCM. The mixture was stirred at RT for 1h, and then the solvent was removed under reduced pressure. The residue was charged on SCX cartridge eluting with 1M NH3 in MeOH to afford 3- (aminomethyl)[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]pyrrolidinol (E33, 160 mg, y= quant.) as ess oil.
MS (ES) (m/z): 373.2 [M+H]+. e 34: [4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypyrrolidin yl}methyl)methylpropanamide (E34) N N o F 0% NWQ To a solution of isobutyric acid (13 uL, 0.141 mmol) in DCM (4 mL) EDC HCI (30 mg, 0.155 mmol), HOBt (36 mg, 0.268 mmol) and TEA (37 uL, 0.268 mmol) were added. After 10 min at RT, 3-(aminomethyl) [4-(3-fluorophenoxy)(trifluoromethyl)pyrimidiny|]pyrro|idinol (E33, 50 mg, 0.134 mmol) was added. The resulting solution was stirred at RT for 4 hrs. Solvent was evaporated and the residue was purified by FC on Silica gel (eluent: Cy to Cy/AcOEt 30/70) affording N-({1-[4-(3-fluorophenoxy) (trifluoromethyl)pyrimidinyl]hydroxypyrrolidinyl}methyl)methy|propanamide (E34, 59 mg, y= 95%) as colourless oil.
MS (ES) (m/z): 443.24 [M+H]+. 1H NMR OFORM-d): 5 ppm 7.43- 7.33 (m, 1H), 7.04- 6.88 (m, 3H), 6.41 (s, 1H), 5.97 (br. s., 1H), 3.Dn, 7H), 2.64 (s, 1H), 2.44 (br. s., 1H), 1.98 (br. s., 2H), 1.26-1.12 (m, 6H) [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] an Unmarked set by an [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan Preparation 52: utyl 3-[({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin-Z-yl] hydroxypyrrolidinyl}methyl)carbamoyl]azetidinecarboxylate (P52) Boc CF3 ~60H N N o F To a solution of of 1-Boc-azetidinecarboxylic acid (28 mg, 0.141 mmol) in DCM (4 mL) EDC HCI (30 mg, 0.155 mmol), HOBt (36 mg, 0.268 mmol) and TEA (0.037 mL, 0.268 mmol) were added. After 10 min at RT, 3-(aminomethyl)[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]pyrrolidinol (E33, 50 mg, 0.134 mmol) was added. The resulting solution was stirred at the same temperature overnight.
Solvent was evaporated and the residue was purified by FC on Silica gel (eluent: Cy to AcOEt) affording utyl 3-[({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypyrrolidin yl}methyl)carbamoyl]azetidine-l—carboxylate (P52, 45 mg, y= 61%) as white solid.
MS (ES) (m/z): 556.10 [M+H]+ e 35: N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypyrrolidin y|}methyl)azetidinecarboxamide (E35) i N/ N/70H N N o F TFA (0.3 mL) was added to a solution of tert—butyl 3-[({1-[4-(3-fluorophenoxy) (trifluoromethyl)pyrimidinyl]hydroxypyrrolidinyl}methyl)carbamoyl]azetidinecarboxylate (P52, 45 mg, 0.081 mmol) in 3 mL of DCM. The mixture was stirred at RT for 1 h, and then the solvent was removed under reduced pressure. The residue was charged on SCX cartridge eluting with 1M NH3 in MeOH to afford [4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypyrrolidin yl}methyl)azetidinecarboxamide as white solid (E35, 36 mg, y= 98%).
MS (ES) (m/z): 456.21 [M+H]+ 1H NMR (DMSO-ds): 6 ppm 7.91 -7.80-(m, 1H), 7.57 -7.46 (m, 1H), 7.32 -7.20 (m, 1H), 7.20- 7.08 (m, 2H), 6.68- 6.59-(m, 1H), 5.04 (d, 1H), 3.69- 3.45 (m, 3H), 3.45-3.28 (m, 6H), 3.21-3.08 (m, 1H), 1.93- 1.68 (m, 2H) [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] an Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan Example 36: 4-(3-fluorophenoxy){3H,4H,5H,6H,7H-imidazo[4,5-c]pyridinyl} (trifluoromethyl)pyrimidine (E36) A mixture of 3H,4H,5H,6H,7H-imidazo[4,5-c]pyridine hydrochloride (50 mg, 0.31 mmol), 2-chloro(3- fluorophenoxy)(trifluoromethyl)pyrimidine (P2, 91 mg, 0.31 mmol) and K2C03 (98 mg, 0.713 mmol) in DMSO (0.5 mL) was heated at 100 °C for 1 h. After cooling at RT, EtOAc and water were added and the product was extracted in organic phase. The organic phase was dried and evaporated, and the residue was purified by FC on NH column (eluent: DCM to DCM/MeOH 90/10) affording 4-(3-fluorophenoxy) {3H,4H,5H,6H,7H-imidazo[4,5-c]pyridiny|}(trifluoromethyl)pyrimidine (E36, 18 mg, y= 15%) as a white solid.
MS (ES) (m/z): 380.11 [M+H]+ 1H NMR d5): 6 ppm 11.70 (br. s., 1H), 7.61-7.48 (m, 1H), 7.45 (s, 1H), 7.32-7.11 (m, 3H), 6.66 (s, 1H), 4.54 (br. s., 2H), 3.95 (br. s., 2H), 2.63 (br. s., 2H) Preparation 53: 1-benzyl[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]-decahydro-1,6- yridine (P53) 0347540 In a close vessel a mixture of 1-benzyl-decahydro-1,6-naphthyridine (51 mg, 0.22 mmol), 2-chloro(3- fluorophenoxy)(trifluoromethyl)pyrimidine (P2, 65 mg, 0.22 mmol) and K2C03 (39 mg, 0.29 mmol) in DMSO (0.9 mL) was heated at 90 °C and shaken 1.5 h at this temperature. After g at RT, EA and water were added, the c phase was washed with water, dried and evaporated; crude product was purified by FC on NH column (eluent: Cy to Cy/EA 90/10) ing 1-benzyl[4-(3-fluorophenoxy) (triflu ethyl)pyrimidiny|]-decahydro-1,6-naphthyridine (P53, 56 mg , y= 52%) [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by an [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan e 39: 6-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]-decahydro-1,6-naphthyridine hydrochloride (E39) 003 / QN O N H F Step a To a on of 1-benzyl[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]-decahydro-1,6- naphthyridine (P53, 56 mg, 0.11 mmol) in MeOH (3.5 mL), HCOONH4 (44 mg) and 10% Pd/C (15 mg) were added at RT then the mixture was stirred under reflux. After 1.5 h the reaction mixture was filtered on celite and the solvent removed under vacuum. The residue was dissolved in DCM, the organic solution washed with water twice, dried over NaZSO4 and the solvent removed under reduced pressure to give a crude material which was purified by FC on NH dge (eluent: Cy to Cy/EA 60/40) to give 6- [4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]-decahydro-1,6-naphthyridine (24 mg) Step b 6-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]-decahydro-1,6-naphthyridine (from step a, 24 mg, ) was dissolved in DCM (0.1 mL) and 2N HCI (0.031 mL) was added. The mixture was concentrated under reduced pressure, the e was triturated with ether and dried under vacuum to give 6-[4-(3- fluorophenoxy)(trifluoromethyl)pyrimidinyl]-decahydro-1,6-naphthyridine hydrochloride (E39, 24 mg, y= 46%) MS (ES) (m/z): 397.17 [M+H]+. 1H NMR ds): 6 ppm 9.29 (br. s., 1 H), 9.04 (br. s., 1 H), 7.59 - 7.43 (m, 1 H), 7.33 - 7.03 (m, 3 H), 6.76 - 6.64 (m, 1 H), 4.76 -3.15 (m, 6H), 3.10 -2.81 (m, 2 H), 2.17- 1.05 (m, 6 H) Biological Methods The ability of the compounds of formula Ito inhibit dopamine transporters may be ined using the ing biological assays: Measure of Affinit to the human trans orters DAT NET and SERT The affinities of the compounds of the invention for the human dopamine transporter (DAT), human nirine transporter (NET) and for the human serotonin transporter (SERT) may be determined by the assays described below. Affinity is expressed in terms of inhibition constant (Ki) of the [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by an compounds of the invention for DAT, NET and SERT, and it is typically calculated from the |C50 values obtained in competition experiments using Cheng and Prusoff on (Cheng and Prusoff, m. col. 22:3099, 1973). In the context of the t ion pKi values (corresponding to the antilogarithm of Ki) are used instead of Ki; pKi are only estimated to be accurate to about 0.3 log unit.
Scintillation Proximity Assay (SPA) for human DAT, NET and SERT binding a) Membrane preparation Chinese Hamster Ovary (CHO) cells stably expressing either human DAT (hDAT-CHO) or human NET (hNET-CHO) or human SERT (hSERT-CHO) are used for the membrane preparations for radioligand g assays using Scintillation proximity Assay (SPA) technique. Each cell line is cultured independently in F-12K Nutrient Mixture containing 10% of Fetal Bovine Serum (FBS) supplemented with 450ug/ml 6-418. When cells are at 70-80% of confluence 3mM Na Butyrate was added to the cell culture medium. After 24h of incubation, the e medium was removed and the cells detached with Versene (DAT) or by scraping (NET and SERT). Cell suspension is centrifuged at 41,000g for 10 minutes at 49C. The resultant pellets are re-suspended in 15 volumes of ld buffer (20mM HEPES, 145mM NaCl, SmM KCI, pH7.3), nized using an Ultra Turrax homogeniser and centrifuged as before. The resultant membrane s are re-suspended in up to 15 volume of ice-cold buffer, ted for 20 minutes at 379C and centrifuged as before at 41,000g. The final membrane pellets are re-suspended into 5-10 volumes of ice-cold buffer, dispensed into 0.5 ml aliquots and stored at -80° C until use.
Protein concentration for each preparation is determined using Bio-Rad Protein Assay kit. b Com etition Bindin Ex ts usin Scintillation Proximit Assa SPA for human DAT NET and The affinity of the compounds of the invention to the human DAT or NET or SERT orters is assessed by using the [3H]W|N-35,428 or [3H]nisoxetine or [3H]citalopram binding assays in recombinant human DAT, NET and SERT membranes with the SPA logy. The final assay volume is 50uL in 384 well plates.
Briefly, 0.5uL of test compound in neat DMSO or 0.5uL of DMSO for total binding (TB) or 0.5uL of indatraline 1mM (10 uM final tration) for non specific binding (NSB) are added to the assay plate. 50uL of the SPA mixture is added to each well, containing:, 30ug/mL or 10ug/mL or 25ug/mL DAT, NET, SERT membranes, respectively; 5nM [3H]W|N-35,428 or 5nM [3H]nisoxetine or 1nM [3H]citalopram, for DAT, NET, SERT assay, respectively; 2.5mg/mL or 1mg/mL or 4mg/mL WGA-PVT SPA beads (PerkinElmer RPNQCD, for DAT, NET, SERT assay, respectively. All components are added to Assay Buffer (20mM HEPES pH 7.4, 145mM NaCl, SmM KCI, 0.01% Pluronic F-127). 0.02% BSA was used for DAT binding only.
[Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan Plates are sealed with Topseal A and centrifuged 1min, 800rpm. Plates are loaded into a 1450 Microbeta TriLux (Perkin-Elmer) plate reader and the radioactivity counted after at least 4 hrs or ght incubation at room temperature. Curve fitting and IC50 estimations are performed using a four parameter model in XLfit (IDBS, Guilford, UK) for Microdoft Excel (Microsoft, Redmond, WA).
Uptake functional assay on hDAT-CHO cells The potency of the nds of the invention in blocking the DAT function is ed using an uptake assay in a recombinant CHO cell line expressing human DAT (hDAT-CHO). Potency is measured in terms of p|C50 by testing the compounds of invention for the inhibition of opamine uptake in DAT- CHO cells using a SPA technology in 384 well format.
Briefly, on the days of the experiment hDAT-CHO cells are ed using Versene and added (75,000 cells/mL) to the SPA Mixture, which contains the following components in Assay Buffer (20mM HEPES, 145mM NaCl, 5mM KCI, 2mM CaClz, 1mM MgClz and 1g/L glucose, pH 7.3): 0.02% w/v of Pluronic F127, 2mg/mL SPA Imaging beads (RPNQ0260, PerkinElmer), 10uM pargyline and 80nM of [3H]-dopamine. The SPA Mixture is added 50ul/well to 384 well plates ning 0.5uL/well of test compound in neat DMSO or 0.5uL of DMSO (control uptake) or 0.5uL of the rd inhibitor indatraline (at 10uM final in the assay). Plates are sealed with a Top-seal A and read using Viewlux ment (Perkin-Elmer) at 15-30 min time intervals. The first highest signal is used for data analysis.
Measure of the effect on hERG channel by tail current recording using in vitro Rapid ICETM The potency of the compounds of the invention in inhibiting human ERG potassium channel (hERG) tail current is assessed in a recombinant HEK293 cell line stably transfected with hERG cDNA using Rapid ICETM (Rapid Ion Channel Electrophysiology) assay. Rapid ICETM is an automated patch-clamp assay utilizing the ress 7000A system (Molecular Devices Corporation) or the QPatch HTX system on Bioscience A/S).
Briefly cells are cultivated for 24 to 72 hours before recordings in minimum essential medium supplemented with 10% FBS, 1% non-essential amino acids, 1% sodium te, 2mM L-glutamine. The day of the experiment cells are detached with TrprE and prepared to be loaded on the instrument. For ress cells are finally resuspended in 150 pl of ellular Buffer whereas for QPatch cells are ended in 7 ml Serum-Free Media containing 25 mM Hepes and Soybean trypsin inhibitor and immediately placed in the cell storage tank of the machine. The composition of the Extracellular Buffer ethanbis (mM : NaCl 137; KCI 4; CaCl2 1.8; MgCl2 1.0; D-glucose 10; N 2 hydroxyethylpiperazine-N’onic acid (HEPES) 10; pH 7.4 with 1 M NaOH. The composition of the pipette on is (mM): KCI 130; MgCl2 1.0; Ethylene glycol-bis(l3-aminoethyl ether)-N,N,N’,N’-tetraacetic acid (EGTA) 5; MgATP [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by an [Annotation] an ed set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan ation] Mel.Chan Unmarked set by Mel.Chan ; HEPES 10; pH 7.2 with 1 M KOH. The voltage protocol includes the following steps: step from -80 mV to —50 mV for 200 ms, +20 mV for 4.8 s, step to -50 mV for 5 s then step to the holding potential of -80 mV. Compounds of the ion are dissolved in DMSO and diluted in Extracellular Buffer to achieve final test concentrations (0.1, 1 and 10 uM) in 0.1% DMSO. The voltage protocol is run and recorded continuously during the ment. The vehicle, corresponding to 0.1% DMSO in Extracellular Buffer, is then applied for 3 min followed by the test substance in triplicate. The standard combined exposure time is 5min. The average of tail current amplitude values recorded from 4 sequential voltage pulses is used to calculate for each cell the effect of the test substance by calculating the residual current (% control) compared with vehicle pre-treatment. Data are reported as % inhibition for each concentration tested and |C50 values are estimated using DataXpress or QPatch software. At least two cells are tested, more if results diverge.
Representative compounds of the present invention were tested ing to the procedure described above, with results as listed in Table 1 below.
Table 1 [Annotation] Mel.Chan None set by Mel.Chan ation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by an [Annotation] Mel.Chan Unmarked set by Mel.Chan Example [Annotation] Mel.Chan None set by Mel.Chan ation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan ation] Mel.Chan Unmarked set by Mel.Chan While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the ion encompasses all of the usual variations, tions and/or modifications as come within the scope of the following claims.
[Annotation] Mel.Chan None set by Mel.Chan ation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] an ed set by Mel.Chan [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] an Unmarked set by Mel.Chan References 1 Wise RA, Annu Rev Neurosci. 1996; 19: 319-340 2 Cohen NJ et a|., Psychopharmacologia. 1971; 22(3): 282-294 3 Leibowitz SF et a|., Brain Res Bull. 1986; 17(5): 9. 4 Hartmann E et a|., Psychopharmacology (Berl). 1976 10; 50(2): 171-175 Lader MH, J Clin Psychiatry. 1996; 57 Suppl 2: 39-44 6 o-Gonzalez AL et a|., J Sex Marital Ther. 1997; 23(3): 176-194 7 Olfson M et a|., Arch Gen Psychiatry. 2006 Aug; 63(8): 865-872 8 n N, J Am Acad Child Adolesc Psychiatry. 2005; 44(6): 510 9 Denolle T et a|., Clin Pharmacol Ther. 1999; 66(3): 7 Nieoullon A, Prog Neurobiol. 2002; 67(1): 53-83 11 Cornish RS et a|., Pharm Res. 2005; 22(4): 603-612 12 Cook EH Jr et a|., Am J Hum Genet. 1995; 56(4): 993-998 13 Van Gaalen MM et a|., Biol Psychiatry. 2006; 60(1): 66-73 14 Yoon et a|., J Neurol Sci. 2007; 255(1-2): 50-56 Cheon et a|., Psychiatry Res. 2004; 130(1): 85-95 16 Kim CH et a|., EurJ Nucl Med Mol Imaging. 2003; : 1637-1643 17 Grigorenko EL et a|., Aggress Behav. 2010; 36(3): 158-176 18 Amsterdam et a|., J Affect Disord. 2012; 141(2-3): 425-431 19 Hsiao et a|., Psychiatry Res. 2013; 211(1): 72-77 Baldwin DS et a|., BrJ atry. 2013; 202: 396-397 21 Abler B et a|., Neuropsychopharmacology. 2011; 36(9): 1837-1847 22 Segman et a|., Mol Psychiatry. 2002; 7(8): 903-7 23 Devos D et a|., J Neurol Neurosurg Psychiatry. 2007; 78(5): 470-475 24 Espay et a|., Neurology. 2011; 76(14): 1256-1262 Auriel et a|., Clin Neuropharmacol. 2006; 29(1): 15-17 26 Baumann MH et a|.,J Pharmacol Exp Ther. 1994; 271(3): 1216-1222 27 Rothman RB et a|., Pharmacol Biochem Behav. 1991; 40(2): 387-397 28 Wang GJ et a|., Obesity (Silver Spring) 2011; 19(8): 1601-1608 29 Michaelides M et a|., Int Rev Psychiatry. 2012; 24(3): 211—218 Bello et a|., Brain Res Bull. 2006; 70(4-6): 422-429 31 Shir?ra M et a|.,J Psychiatry Neurosci. 2004; 29(2): 134-137 [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan ation] Mel.Chan Unmarked set by an [Annotation] Mel.Chan None set by Mel.Chan [Annotation] Mel.Chan MigrationNone set by Mel.Chan [Annotation] Mel.Chan Unmarked set by Mel.Chan 32 Slama et al., Diabete Metab. 1978; 4(3): 9 33 Remy P et al., Curr Opin Neurol. 2003; 16 Suppl 2: 537-41 34 Berrios GE, Compr Psychiatry 1990; 31(2): 140-151 Harris JD, Curr Opin Support Palliat Care 2008; 2(3): 180-186 36 Lacerda et al., J Cardiovasc Electrophysiol. 2010; 21(3): 301-310 37 Campbell VC et al., J Pharmacol Exp Ther. 2005; : 631-640 38 Zou MF et al.,J Med Chem. 2006; 49(21): 6391-6399 39 Li SM et al.,J Pharmacol Exp Ther. 2011; 336(2): 575-585

Claims (21)

1. A compound according to formula I, 5 I wherein: A is ed from phenyl and heteroaryl; B is selected from phenyl and heteroaryl; 10 L is a linker selected from alkylene and O; R1 is selected from alkyl, alkoxy, S-alkyl, S(O)qalkyl, COR5, 6, COOR5, CH2OH, OH, F and Cl; R2 is selected from NR7R8, CR11R12NR7R8, CONR7R8, (CR11R12)2NR7R8 and (CR11R12)3NR7R8, wherein R1 is alkyl, alkoxy, CH2OH, COR5, CONR5R6 or COOR5 when R2 is NR7R8; 15 R3 is selected from H and alkyl; R4, R5 and R6 are each independently selected from H and alkyl; R7 and R8 are independently selected from H, alkyl, cycloalkyl, heterocyclyl, and C(O)R10, wherein when R7 is 0, R8 is H or alkyl; or R7 and R8 may come together with the nitrogen atom to which they are attached to form heterocyclyl; 20 R9a, R9b, R9c, R9d, R9e and R9f are independently ed from H and alkyl; R10 is selected from alkyl, aryl, heterocyclyl and heteroaryl; - - - - is absent; 25 n is 1 and m is 0 or 1; q is 1 or 2; 1004852697 alkyl is a linear saturated hydrocarbon having up to 6 carbon atoms (C1-C6) or a branched saturated hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkyl may optionally be substituted with 1,2,3,4 or 5 substituents selected from S-alkyl, S(O)alkyl, S(O)2alkyl, cycloalkyl, heterocyclyl, , OH, -CN, CF3, COOR13, CONR13R14, F, Cl, NR13COR14 and NR13R14; cycloalkyl is a monocyclic saturated arbon of between 3 and 7 carbon atoms (C3-C7); cycloalkyl may optionally be substituted with 1, 2, 3, 4 or 5 substituents independently selected from S-alkyl, S(O)alkyl, S(O)2alkyl, alkyl, alkoxy, OH, -CN, CF3, COOR13, CONR13R14, F, Cl, and NR13R14; 10 phenyl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, OH, F, Cl, -CN, OCF3, CF3, NR13COR14 and alkylene is a bivalent C1-3 straight-chained alkyl radical or a bivalent C3-4 branched alkyl radical, wherein 15 alkylene may optionally be substituted with 1 or 2 substituents selected from S-alkyl, S(O)alkyl, S(O)2alkyl, heterocyclyl, alkoxy, OH, -CN, CF3, COOR13, R14, F, Cl, NR13COR14 and NR13R14; heterocyclyl is a monocyclic ring which is saturated or partially unsaturated, containing, where possible, 1 or 2 ring members ndently ed from N, S, O and NR13 and 2 to 5 carbon atoms; heterocyclyl 20 may optionally be substituted with 1, 2 or 3 substituents ndently selected from alkyl, cycloalkyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, oxo, OH, F, Cl, -CN, OCF3, CF3, NR13COR14 and NR13R14; heteroaryl is a 5 or 6 membered aromatic ring, containing, where possible, 1, 2 or 3 ring s ndently selected from N, NR13, S and O; heteroaryl may be optionally substituted with 1, 2 or 3 25 substituents independently selected from alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, OH, F, Cl, -CN, OCF3, CF3, NR13COR14 and 4; alkoxy is a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (C1-C6) or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms ); alkoxy may optionally be substituted with 1, 2, 3, 30 4 or 5 substituents independently selected from S-alkyl, kyl, S(O)2alkyl, alkyl, OH, -CN, CF3, COOR13, CONR13R14, F, Cl, NR13COR14 and NR13R14; R11, R12, R13 and R14 are ndently selected from H and alkyl; 1004852697 and ers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), pharmaceutically able salts and solvates thereof; provided that: 5 (a) the nd of formula I and tautomers, stereoisomers (including enantiomers, diastereoisomers and racemic and ic mixtures thereof), pharmaceutically able salts and solvates thereof is not selected from the group consisting of and ; and (b) the compound of formula I and tautomers, stereoisomers (including enantiomers, reoisomers 10 and racemic and scalemic mixtures thereof), pharmaceutically acceptable salts and solvates thereof is
2. The compound of claim 1 wherein R2 is selected from CR11R12NR7R8, CONR7R8, (CR11R12)2NR7R8 and 15 (CR11R12)3NR7R8.
3. The compound of claim 1 wherein R2 is CH2NR7R8.
4. The compound of any one of claims 1 to 3 wherein R9a, R9b, R9c, R9d, R9e, R9f, R11 and R12 are all H.
5. The compound of claim 1, according to formula IA, wherein: A is selected from phenyl and heteroaryl; B is selected from phenyl and heteroaryl; 1004852697 L is a linker selected from alkylene and O; R1 is selected from CH2OH, OH, F and Cl; 5 R7 and R8 are independently selected from H, alkyl, cycloalkyl, heterocyclyl, and C(O)R10, wherein when R7 is C(O)R10, R8 is H or alkyl; or R7 and R8 may come together with the nitrogen atom to which they are attached to form heterocyclyl; R10 is selected from alkyl, aryl, heterocyclyl and heteroaryl; m is 0 or 1; alkyl is a linear saturated hydrocarbon having up to 6 carbon atoms (C1-C6) or a branched saturated hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkyl may optionally be substituted with 1, 2, 3, 4 15 or 5 substituents selected from cycloalkyl, heterocyclyl, l, S(O)alkyl, S(O)2alkyl, , OH, -CN, CF3, COOR13, CONR13R14, F, Cl, NR13COR14 and NR13R14; cycloalkyl is a monocyclic saturated hydrocarbon of between 3 and 7 carbon atoms (C3-C7); cycloalkyl may optionally be substituted with 1, 2, 3, 4 or 5 substituents independently selected from S-alkyl, 20 S(O)alkyl, S(O)2alkyl, alkyl, alkoxy, OH, -CN, CF3, COOR13, CONR13R14, F, Cl, and NR13R14; phenyl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, OH, F, Cl, -CN, OCF3, CF3, NR13COR14 and NR13R14; heterocyclyl is a monocyclic ring which is saturated or partially unsaturated, containing, where possible, 1 or 2 ring s independently selected from N, S, O and NH and 2 to 5 carbon atoms; heterocyclyl may optionally be tuted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, alkoxy, S-alkyl, kyl, S(O)2alkyl, oxo, OH, F, Cl, -CN, OCF3, CF3, NR13COR14 and 4; aryl is a 5 or 6 membered aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, NR13, S and O; aryl may be ally substituted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, alkoxy, l, kyl, S(O)2alkyl, OH, F, Cl, -CN, OCF3, CF3, NR13COR14 and NR13R14; 1004852697 alkoxy is a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (C1-C6) or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkoxy may ally be substituted with 1, 2, 3, 4 or 5 substituents independently selected from l, S(O)alkyl, S(O)2alkyl, alkyl, OH, -CN, CF3, , 5 CONR13R14, F, Cl, NR13COR14 and NR13R14; R13 and R14 are independently selected from H and alkyl; and tautomers, stereoisomers (including enantiomers, diastereoisomers and c and scalemic 10 mixtures thereof), pharmaceutically acceptable salts and solvates thereof.
6. The compound of claim 5 wherein m is 1.
7. The compound of any one of claims 1 to 6 n R1 is OH.
8. The compound of any one of claims 1 to 7 wherein L is O.
9. The compound of any one of claims 1 to 8 wherein A is phenyl, pyridyl or pyrimidinyl, optionally 15 substituted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, heterocyclyl, alkoxy, l, S(O)alkyl, S(O)2alkyl, OH, F, Cl, -CN, OCF3, CF3, NR13COR14 and NR13R14.
10. The compound of any one of claims 1 to 8 wherein A is phenyl, 2-pyridyl or rimidinyl, optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, F, Cl, -CN and 20
11. The compound of any one of claims 1 to 8 wherein A is selected from the group consisting of: 1004852697 , , , , , , , , , , , , , 5 , , L-B F L-B F , F , and and .
12. The compound of any one of claims 1 to 11 wherein the compound according to formula I is: and wherein B, L, R1, R2, R3, R4, R9a to R9f, m and n are as defined in any one of claims 1 to 11.
13. The compound of any one of claims 1 to 12 wherein the compound ing to formula I is: 1004852697 N m N N L CF3 , and wherein B, L, R1, R7, R8 and m are as defined in any one of claims 1 to 12.
14. The compound of any one of claims 1 to 13 n B is phenyl, optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, 5 S(O)2alkyl, OH, F, Cl, -CN, OCF3, CF3, NR13COR14 and 4.
15. The compound of any one of claims 1 to 13 n B is selected from the group consisting of: , , , and . 10
16. A compound of claim 1 selected from: 4-[(dimethylamino)methyl][4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidinol; 1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl](pyrrolidinylmethyl)piperidinol; 4-[(cyclopropylamino)methyl][4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidinol; 4-{[cyclopropyl(methyl)amino]methyl}[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin 15 yl]piperidinol; 1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl][(methylamino)methyl]piperidinol; 1004852697 4-[(3,3-difluoropyrrolidinyl)methyl][4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin yl]piperidinol; 4-(1,4-diazepanylmethyl)[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidinol; 4-[(2,5-dimethylpyrrolidinyl)methyl][4-(3-fluorophenoxy)(trifluoromethyl)pyrimidin 5 yl]piperidinol; rt-butylamino)methyl][4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidinol; 1-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methyl)pyrrolidin- 2-one; nomethyl)[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidinol; 10 {4-fluoro[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidinyl}methanamine; 4-(aminomethyl)[3-fluoro(3-fluorophenoxy)phenyl]piperidinol; 4-(aminomethyl)[2,5-difluoro(3-fluorophenoxy)phenyl]piperidinol; 4-(aminomethyl)(2-fluorophenoxyphenyl)piperidinol; 4-(aminomethyl)[2-fluoro(3-fluorophenoxy)phenyl]piperidinol; 15 4-(aminomethyl)[2,3-difluoro(3-fluorophenoxy)phenyl]piperidinol; 4-(aminomethyl)[3,4-difluoro(3-fluorophenoxy)phenyl]piperidinol; no[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]piperidinyl}methanol; N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methyl) methylpropanamide; 20 2-cyclopropyl-N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidin yl}methyl)acetamide; N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methyl) (propanyloxy)acetamide; N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidin 25 yl}methyl)acetamide; N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methyl)azetidine- 3-carboxamide; N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidin yl}methyl)benzamide; 30 N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methyl)-1H- pyrazolecarboxamide; N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidinyl}methyl)pyrazine- 2-carboxamide; 1004852697 2-amino-N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypiperidin yl}methyl)acetamide; 3-[(cyclopropylamino)methyl][4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]pyrrolidinol; (3S)[(cyclopropylamino)methyl][4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]pyrrolidin- 5 3-ol; (3R)[(cyclopropylamino)methyl][4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]pyrrolidin- 3-ol; 3-(aminomethyl)[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]pyrrolidinol; N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypyrrolidinyl}methyl) 10 propanamide; N-({1-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]hydroxypyrrolidinyl}methyl)azetidine- 3-carboxamide; and pharmaceutically acceptable salts and solvates thereof.
17. A compound of claim 1 selected from: 15 4-(3-fluorophenoxy){3H,4H,5H,6H,7H-imidazo[4,5-c]pyridinyl}(trifluoromethyl)pyrimidine; 6-[4-(3-fluorophenoxy)(trifluoromethyl)pyrimidinyl]-decahydro-1,6-naphthyridine; and pharmaceutically acceptable salts and solvates thereof.
18. A ceutical composition comprising a compound of any one of claims 1 to 17 excluding proviso (b), and a pharmaceutically able ent. 20
19. Use of a compound of any one of claims 1 to 18 excluding proviso (b) for the manufacture of a medicament for the treatment or prevention of a condition, disease or er ameliorated by inhibition of a dopamine transporter.
20. Use of claim 19 excluding provisos (a) and (b) wherein said condition, disease or disorder is selected from sexual ction, affective ers, anxiety, depression, Tourette syndrome, Angelman 25 syndrome, attention t disorder (ADD), attention deficit hyperactivity er (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorder, substance abuse (including smoking cessation), eating disorders, chronic fatigue and impulse control disorder.
21. Use of claim 19 or 20 wherein said condition, e or disorder is selected from attention deficit 30 disorder (ADD), attention deficit hyperactivity disorder (ADHD), binge-eating disorder, and fatigue associated with a condition selected from the group consisting of chronic e syndrome, post-viral 1004852697 fatigue syndrome, HIV, multiple sclerosis, amyotrophic lateral sclerosis (ALS), myasthenia gravis, sarcoidosis, cancer, chemotherapy treatment, celiac e, irritable bowel syndrome, spondyloarthropathy, fibromyalgia, arthritis, infectious diseases, diabetes, eating ers, Parkinson's disease, sleep disorders, stroke, mood ers, drug abuse and alcohol abuse. 1004852697
NZ730702A 2015-09-14 N-(hetero)aryl-substituted heterocyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system NZ730702B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1416351.3A GB201416351D0 (en) 2014-09-16 2014-09-16 Heterocyclic derivatives
PCT/IB2015/057031 WO2016042453A1 (en) 2014-09-16 2015-09-14 N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system

Publications (2)

Publication Number Publication Date
NZ730702A NZ730702A (en) 2023-09-29
NZ730702B2 true NZ730702B2 (en) 2024-01-04

Family

ID=

Similar Documents

Publication Publication Date Title
RU2660897C2 (en) Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same
CA3079617A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
US9908897B2 (en) Spirocyclic derivatives
NO343182B1 (en) Pyrrolopyrimidine Compounds and Their Uses
HUE032847T2 (en) Compounds and Compositions as Protein Kinase Inhibitors
AU2015316470A1 (en) 2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of the human dopamine-active-transporter (DAT) protein for the treatment of e.g. attention deficit disorder (ADD)
JP2023012506A (en) N-(hetero)aryl-substituted heterocyclic derivatives useful for treatment of disease or condition related to central nervous system
KR102284205B1 (en) Pyrazole derivative compound and use thereof
EA007501B1 (en) Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
KR20180086258A (en) Sulfonamide derivatives and their preparation and application
JP2014530807A (en) Carbamate / urea derivatives containing piperidine and piperazine rings as H3 receptor inhibitors
WO2023093845A1 (en) Chimeric compound for targeted degradation of androgen receptor protein, preparation method therefor, and medical use thereof
JP4669479B2 (en) (4-Phenylpiperazin-1-yl) acylpiperidine derivatives, their preparation and their application in therapy
NZ730702B2 (en) N-(hetero)aryl-substituted heterocyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system
US20240182445A1 (en) Modulators of trek (twik related k+ channels) channel function
CN106573928A (en) 2-aminothiazole derivative or salt thereof